U.S. patent application number 12/191875 was filed with the patent office on 2009-05-07 for antibodies that specifically bind to neurokinin b.
This patent application is currently assigned to Human Genome Sciences, Inc.. Invention is credited to Craig A. Rosen, Steven M. Ruben.
Application Number | 20090117043 12/191875 |
Document ID | / |
Family ID | 29711948 |
Filed Date | 2009-05-07 |
United States Patent
Application |
20090117043 |
Kind Code |
A1 |
Rosen; Craig A. ; et
al. |
May 7, 2009 |
Antibodies That Specifically Bind to Neurokinin B
Abstract
The present invention relates to antibodies and related
molecules that specifically bind to neurokinin B. Such antibodies
have uses, for example, in the prevention and treatment of cancer
as well as immune system diseases and disorders including
pre-eclampsia, hypertension, inflammation, asthma, gastrointestinal
disorders, anxiety, depression, addiction, or pain. The invention
also relates to nucleic acid molecules encoding anti-neurokinin B
antibodies, vectors and host cells containing these nucleic acids,
and methods for producing the same. The present invention relates
to methods and compositions for preventing, detecting, diagnosing,
treating or ameliorating a disease or disorder, especially
pre-eclampsia, as well as hypertension, inflammation, asthma,
gastrointestinal disorders, anxiety, depression, addiction, or
pain, comprising administering to an animal, preferably a human, an
effective amount of one or more antibodies or fragments or variants
thereof, or related molecules, that specifically bind to neurokinin
B.
Inventors: |
Rosen; Craig A.;
(Laytonsville, MD) ; Ruben; Steven M.;
(Brookeville, MD) |
Correspondence
Address: |
HUMAN GENOME SCIENCES INC.;INTELLECTUAL PROPERTY DEPT.
14200 SHADY GROVE ROAD
ROCKVILLE
MD
20850
US
|
Assignee: |
Human Genome Sciences, Inc.
Rockville
MD
|
Family ID: |
29711948 |
Appl. No.: |
12/191875 |
Filed: |
August 14, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10981692 |
Nov 5, 2004 |
|
|
|
12191875 |
|
|
|
|
PCT/US03/16802 |
May 29, 2003 |
|
|
|
10981692 |
|
|
|
|
60383802 |
May 30, 2002 |
|
|
|
Current U.S.
Class: |
424/9.1 ;
424/172.1; 435/188; 435/320.1; 435/332; 435/7.1; 530/387.1;
530/387.3; 530/388.15; 530/388.2; 530/391.3; 530/391.7;
536/23.53 |
Current CPC
Class: |
Y10S 424/80 20130101;
A61K 2039/505 20130101; Y10S 435/975 20130101; C07K 2317/21
20130101; Y10S 424/806 20130101; Y10S 424/804 20130101; C07K 16/18
20130101; C07K 2317/622 20130101; Y10S 424/809 20130101 |
Class at
Publication: |
424/9.1 ;
530/387.1; 530/388.2; 530/388.15; 530/387.3; 530/391.3; 435/188;
530/391.7; 435/332; 424/172.1; 435/7.1; 536/23.53; 435/320.1 |
International
Class: |
A61K 49/00 20060101
A61K049/00; C07K 16/18 20060101 C07K016/18; C12N 9/96 20060101
C12N009/96; C12N 5/06 20060101 C12N005/06; C12N 15/00 20060101
C12N015/00; C12N 15/11 20060101 C12N015/11; A61K 39/395 20060101
A61K039/395; G01N 33/53 20060101 G01N033/53 |
Claims
1. An isolated antibody or fragment thereof comprising: (a) an
amino acid sequence that is at least 85% identical to a VH domain
of any one of the scFvs of SEQ ID NOs:22-40; (b) an amino acid
sequence that is at least 85% identical to a VL domain of any one
of the scFvs of SEQ ID NOs:22-40; or (c) both (a) and (b); wherein
said antibody or fragment thereof specifically binds neurokinin
B.
2. An isolated antibody or fragment thereof comprising the amino
acid sequence of the VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and
VLCDR3 of any one of the scFvs of SEQ ID NOs:22-40, wherein said
antibody or fragment thereof specifically binds neurokinin B.
3. The antibody or fragment thereof of claim 2 that binds
neurokinin B purified from a cell culture wherein said neurokinin B
is encoded by a polynucleotide encoding amino acids 1 to 121 of SEQ
ID NO:2.
4. The antibody or fragment thereof of claim 2 wherein the antibody
or fragment thereof is a whole immunoglobulin molecule, an scFv, a
Fab fragment, a Fab' fragment, a F(ab')2, an Fv, or a disulfide
linked Fv.
5. The antibody or fragment thereof of claim 2 wherein the antibody
or fragment thereof is monoclonal, human, chimeric, or
humanized.
6. The antibody or fragment thereof of claim 2 which comprises a
heavy chain immunoglobulin constant domain selected from the group
consisting of: (a) a human IgM constant domain; (b) a human IgG1
constant domain; (c) a human IgG2 constant domain; (d) a human IgG3
constant domain; (e) a human IgG4 constant domain; and (f) a human
IgA constant domain.
7. The antibody or fragment thereof of claim 2 which comprises a
light chain immunoglobulin constant domain selected from the group
consisting of: (a) a human Ig kappa constant domain; and (b) a
human Ig lambda constant domain.
8. The antibody or fragment thereof of claim 2 wherein the antibody
or fragment thereof has a dissociation constant (K.sub.D) of less
than or equal to 10.sup.-9M.
9. The antibody or fragment thereof of claim 2 wherein the antibody
or fragment thereof is conjugated to a detectable label.
10. The antibody or fragment thereof of claim 9, wherein the
detectable label is a radiolabel.
11. The antibody or fragment thereof of claim 10, wherein the
radiolabel is .sup.125I, .sup.131I, .sup.111In, .sup.90Y,
.sup.99Tc, .sup.177Lu, .sup.166Ho, or .sup.153Sm.
12. The antibody or fragment thereof of claim 9, wherein the
detectable label is an enzyme, a fluorescent label, a luminescent
label, or a bioluminescent label.
13. The antibody or fragment thereof of claim 2 wherein the
antibody or fragment thereof is biotinylated.
14. The antibody or fragment thereof of claim 2 wherein the
antibody or fragment thereof is conjugated to a therapeutic or
cytotoxic agent.
15. The antibody or fragment thereof of claim 14, wherein the
therapeutic or cytotoxic agent is an anti-metabolite, an alkylating
agent, an antibiotic, a growth factor, a cytokine, an
anti-angiogenic agent, an anti-mitotic agent, an anthracycline, a
toxin, or an apoptotic agent.
16. An isolated cell that produces the antibody or fragment thereof
of claim 2.
17. A method of treating, preventing, or ameliorating hypertension
or preeclampsia comprising administering to an animal the antibody
or fragment thereof of claim 2 or a composition containing said
antibody or fragment thereof.
18. A method of detecting neurokinin B in a biological sample
comprising: (a) contacting the biological sample with the antibody
or fragment thereof of claim 2; and (b) detecting said antibody
specifically bound to said neurokinin B.
19. A method for diagnosing or monitoring hypertension or
preeclampsia comprising: (a) administering to a subject an
effective amount of a labeled antibody of claim 9; (b) waiting for
a time interval following the administering for permitting the
antibody of claim 9 to preferentially concentrate at sites in the
subject where neurokinin B is expressed; (c) determining background
level; and (d) detecting the labeled antibody of claim 9 in the
subject, such that detection of labeled antibody above the
background level indicates that the subject has hypertension or
preeclampsia.
20. A kit comprising the antibody or fragment thereof of claim
2.
21. An isolated nucleic acid molecule encoding the antibody or
fragment thereof of claim 2.
22. A vector comprising the isolated nucleic acid molecule of claim
21.
23. A host cell comprising the vector of claim 22.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. application Ser.
No. 10/981,692, filed Nov. 5, 2004, which is a continuation-in-part
of International Application No. PCT/US03/16802, filed May 29,
2003, which claims benefit under 35 U.S.C. .sctn. 119(e) of U.S.
Provisional Application No. 60/383,802, filed May 30, 2002, each of
which is hereby incorporated by reference in its entirety.
REFERENCE TO SEQUENCE LISTING AS TEXT FILE
[0002] This application refers to a "Sequence Listing" listed
below, which is provided as a text file. The text file contains a
document entitled "PF590P1D1_SequenceListing.txt" (70,414 bytes,
created Aug. 4, 2008), which is incorporated by reference in its
entirety.
FIELD OF THE INVENTION
[0003] The present invention relates to antibodies and related
molecules that specifically bind to neurokinin B. Such antibodies
have uses, for example, in the diagnosis, prevention, and treatment
of pre-eclampsia, hypertension, inflammation, asthma,
gastrointestinal disorders, anxiety, depression, addiction, and/or
pain. The invention also relates to nucleic acid molecules encoding
anti-neurokinin B antibodies, vectors and host cells containing
these nucleic acids, and methods for producing the same. The
present invention relates to methods and compositions for
preventing, detecting, diagnosing, treating or ameliorating a
disease or disorder including pre-eclampsia, hypertension,
inflammation, asthma, gastrointestinal disorders, anxiety,
depression, addiction, and/or pain, comprising administering to an
animal, preferably a human, an effective amount of one or more
antibodies or fragments or variants thereof, or related molecules,
that specifically bind to neurokinin B.
BACKGROUND OF THE INVENTION
[0004] The tachykinins are an evolutionarily conserved family of
amidated peptides. The family name tachykinin refers to the ability
to induce fast, immediate contractile responses of smooth muscle
preparations (as opposed to bradykinin, which elicits a slow
contraction). The first family member to be isolated and
characterized was substance P (Von Euler and Gaddum, J. Physiology
London 72:74-86 (1931)), which caused peripheral vasodilation and
stimulated intestinal muscle contractions. Other members of the
tachykinin family include substance K (or neurokinin A; Nawa et
al., Life Sci. 34:1153-1160 (1984)) and neuromedin K (or neurokinin
B; Kangawa et al., Biophys. Res. Commun. 114:533-540 (1983)).
Neuropeptide K and neuropeptide .gamma., which are N-terminally
extended forms of neurokinin A, are also included in the family
(Tatemoto et al., Biophys. Res. Commun. 128:947-953 (1985); Kage et
al J. Neurochem. 50:1412-1417 (1988)). All tachykinin peptides
share the C-terminal pentapeptide--FXGLMa.
[0005] Substance P (SP), neurokinin A (NKA), and neurokinin B (NKB)
are derived from two precursor-encoding genes (Nawa et al, Nature
312:729-734 (1984); Kotani et al., Proc. Natl. Acad. Sci. USA
83:7074-7078 (1986)). Preprotachykinin A (PPTA) codes for SP and
NKA, while preprotachykinin B (PPTB) codes for NKB. As a
consequence of alternative splicing, three distinct mRNAs are
produced from the primary PPTA transcript (.alpha.-PPTA,
.beta.-PPTA, and .gamma.-PPTA), all of which code for SP (Nawa et
al, Nature 312:729-734 (1984)). Interestingly, .alpha.-PPTA does
not include the sixth exon that codes for NKA, .beta.-PPTA contains
all exons, and .gamma.-PPTA does not contain the fourth exon. As a
result, cells that exclusively express .alpha.-PPTA mRNA only
produce SP. When .beta.-PPTA is expressed, SP, NKA, or neuropeptide
K can be synthesized. .gamma.-PPTA gives rise to SP, NKA, or
neuropeptide .gamma.. This alternative RNA and polypeptide
precursor processing appears to be an important mechanism in
creating structural diversity and tissue-specific differences in
the expression of tachykinin neuropeptides. PPTB is cleaved at both
the N- and C-terminus to yield the mature form of neurokinin B
(amino acids 81 to 90 of SEQ ID NO:2).
[0006] The tachykinins exhibit a wide variety of functions. A
hallmark feature is their ability to induce contractile responses
in smooth muscle. Additional biologic roles include vasodilatation
in hypotension, mucous and pancreatic secretion, pain transmission,
neurogenic inflammation, and regulation of the immune system
(Longmore et al., Canadian J. Physiol Pharmacol. 75:612-621
(1997)). Tachykinins are normally restricted to the central nervous
system and exert their effects peripherally by their release from
nerve endings. Three membrane receptors that recognize the
tachykinins have been identified as NK1R, NK2R, and NK3R. Their
preferential endogenous ligands are substance P, neurokinin A, and
neurokinin B, respectively. Differences at the amino terminal end
of the tachykinins determine their receptor affinities. All three
receptors interact with G proteins and have a structure consisting
of seven hydrophobic transmembrane regions. Although many protease
enzymes are active in degrading tachykinins, the in vivo stability
is mainly regulated by angiotensin-converting enzyme (ACE) and
neutral endopeptidase 24.11 (NEP; Skidgel et al. Peptides 5:769-776
(1984)).
[0007] Tachykinins have a large number of in vivo functions, as
well as regulated expression patterns. Accordingly, promoting and
inhibiting such peptides has wide therapeutic application. There is
a clear need, therefore, for identification and characterization of
compositions, such as antibodies, that influence the biological
activity of tachykinins, both normally and in disease states. In
particular, there is a need to isolate and characterize antibodies
that modulate the biological activities of neurokinin B for the
treatment of pre-eclampsia, hypertension, inflammation, asthma,
gastrointestinal disorders, anxiety, depression, addiction, or
pain.
SUMMARY OF THE INVENTION
[0008] The present invention encompasses antibodies (including
molecules comprising, or alternatively consisting of, antibody
fragments or variants thereof) that specifically bind to neurokinin
B polypeptide (NKB; also known as neurokinin 3 (NK3), tachykinin 3
(TAC3), and neuromedin K; GenBank ID: AF216586; International
Publication No. WO 98/40483, which is hereby incorporated by
reference in its entirety) or a polypeptide fragment or variant of
neurokinin B. In particular, the invention encompasses antibodies
(including molecules comprising, or alternatively consisting of,
antibody fragments or variants thereof) that specifically bind to a
neurokinin B polypeptide (SEQ ID NO:2) or polypeptide fragment or
variant of human neurokinin B. In highly preferred embodiments,
antibodies of the invention bind a polypeptide consisting of amino
acids 81 to 90 of SEQ ID NO:2.
[0009] The present invention relates to methods and compositions
for preventing, treating or ameliorating a disease or disorder
comprising administering to an animal, preferably a human, an
effective amount of one or more antibodies or fragments or variants
thereof, or related molecules, that specifically bind to neurokinin
B or a fragment or variant thereof. In specific embodiments, the
present invention relates to methods and compositions for
preventing, treating or ameliorating a disease or disorder
associated with aberrant neurokinin B function or expression,
comprising administering to an animal, preferably a human, an
effective amount of one or more antibodies or fragments or variants
thereof, or related molecules, that specifically bind to neurokinin
B or a fragment or variant thereof.
[0010] In highly preferred embodiments, the present invention
encompasses methods for using the antibodies of the present
invention to treat, prevent, diagnose and/or prognose pre-eclampsia
and a symptom associated with pre-eclampsia including, but not
limited to, hypertension, proteinuria, coagulopathy, renal failure,
pulmonary edema, and cerebrovascular accident.
[0011] In additional preferred embodiments, the present invention
encompasses methods for using antibodies of the invention to treat,
prevent, diagnose and/or prognose an inflammatory disorder (e.g.,
inflammatory bowel syndrome, allergy, asthma, chronic cough,
inflammatory pain, and chronic obstructive pulmonary disease).
[0012] In further preferred embodiments, the present invention
relates to methods for using antibodies of the invention to
prevent, treat or ameliorate a gastrointestinal disorder (e.g.,
inflammatory bowel syndrome and irritable bowel syndrome).
[0013] In an additional preferred embodiment, the present invention
relates to methods for using antibodies of the invention to
prevent, treat or ameliorate a neurological disorder (e.g.,
anxiety, depression, and addiction).
[0014] In other highly preferred embodiments, the invention
encompasses methods for using the antibodies of the invention to
inhibit vasoconstriction. In specific embodiments, the invention
encompasses methods for using the antibodies of the present
invention to inhibit vasoconstriction of the mesenteric vascular
bed. In specific embodiments, the invention encompasses methods for
using the antibodies of the present invention to inhibit
vasoconstriction of the hepatic portal vein.
[0015] In other preferred embodiments, the invention encompasses
methods for using the antibodies of the invention to stimulate
vasoconstriction.
[0016] Another embodiment of the present invention includes the use
of the antibodies of the invention as a diagnostic tool to monitor
the expression of neurokinin B.
[0017] The present invention encompasses single chain Fv's (scFvs)
that specifically bind neurokinin B polypeptides (e.g., SEQ ID
NOs:22-40). Thus, in certain embodiments, the invention encompases
these scFvs, listed in Table 1.
[0018] Further, the present invention encompasses the
polynucleotides encoding the scFvs, as well as the amino acid
sequences of the scFvs. Molecules comprising, or alternatively
consisting of, fragments or variants of these scFvs (e.g., VH
domains, VH CDRs, VL domains, or VL CDRs having an amino acid
sequence of any one of the scFvs referred to in Table 1), that
specifically bind to neurokinin B or fragments or variants thereof
are also encompassed by the invention, as are nucleic acid
molecules that encode these antibodies and/or molecules.
[0019] The present invention also provides anti-neurokinin B
antibodies that are coupled to a detectable label, such as an
enzyme, a fluorescent label, a luminescent label, or a
bioluminescent label. The present invention also provides
anti-neurokinin B antibodies that are coupled to a therapeutic or
cytotoxic agent. The present invention also provides
anti-neurokinin B antibodies which are coupled to a radioactive
material.
[0020] The present invention also provides antibodies that bind
neurokinin B polypeptides and that act as either neurokinin B
agonists or neurokinin B antagonists. In preferred embodiments, the
antibodies of the invention act as neurokinin B antagonists. In
specific embodiments, the antibodies of the invention inhibit
neurokinin B binding to the neurokinin 3 receptor (NK3R; GenBank
ID: JQ1517). In other specific embodiments, the antibodies of the
invention inhibit neurokinin B binding to the neurokinin 2 receptor
(NK2R; GenBank ID:M57414) and/or the neurokinin 1 receptor (NK1R;
GenBank ID:M81797).
[0021] In further embodiments, the antibodies of the invention have
a dissociation constant (K.sub.D) of 10.sup.-7 M or less. In
preferred embodiments, the antibodies of the invention have a
dissociation constant (K.sub.D) of 10.sup.-9 M or less.
[0022] In further embodiments, antibodies of the invention have an
off rate (k.sub.off) of 10.sup.-3/sec or less. In preferred
embodiments, antibodies of the invention have an off rate
(k.sub.off) of 10.sup.-4/sec or less. In other preferred
embodiments, antibodies of the invention have an off rate
(k.sub.off) of 10.sup.-5/sec or less.
[0023] The present invention also provides panels of antibodies
(including molecules comprising, or alternatively consisting of,
antibody fragments or variants) wherein the panel members
correspond to one, two, three, four, five, ten, fifteen, twenty, or
more different antibodies of the invention (e.g., whole antibodies,
Fabs, F(ab').sub.2 fragments, Fd fragments, disulfide-linked Fvs
(sdFvs), anti-idiotypic (anti-Id) antibodies, and scFvs). The
present invention further provides mixtures of antibodies, wherein
the mixture corresponds to one, two, three, four, five, ten,
fifteen, twenty, or more different antibodies of the invention
(e.g., whole antibodies, Fabs, F(ab').sub.2 fragments, Fd
fragments, disulfide-linked Fvs (sdFvs), anti-idiotypic (anti-Id)
antibodies, and scFvs)). The present invention also provides for
compositions comprising, or alternatively consisting of, one, two,
three, four, five, ten, fifteen, twenty, or more antibodies of the
present invention (including molecules comprising, or alternatively
consisting of, antibody fragments or variants thereof). A
composition of the invention may comprise, or alternatively consist
of, one, two, three, four, five, ten, fifteen, twenty, or more
amino acid sequences of one or more antibodies or fragments or
variants thereof. Alternatively, a composition of the invention may
comprise, or alternatively consist of, nucleic acid molecules
encoding one or more antibodies of the invention.
[0024] The present invention also provides for fusion proteins
comprising an antibody (including molecules comprising, or
alternatively consisting of, antibody fragments or variants
thereof) of the invention, and a heterologous polypeptide (i.e., a
polypeptide unrelated to an antibody or antibody domain). Nucleic
acid molecules encoding these fusion proteins are also encompassed
by the invention. A composition of the present invention may
comprise, or alternatively consist of, one, two, three, four, five,
ten, fifteen, twenty or more fusion proteins of the invention.
Alternatively, a composition of the invention may comprise, or
alternatively consist of, nucleic acid molecules encoding one, two,
three, four, five, ten, fifteen, twenty or more fusion proteins of
the invention.
[0025] The present invention also provides for a nucleic acid
molecule(s), generally isolated, encoding an antibody (including
molecules, such as scFvs, VH domains, or VL domains, that comprise,
or alternatively consist of, an antibody fragment or variant
thereof) of the invention. The present invention also provides a
host cell transformed with a nucleic acid molecule of the invention
and progeny thereof. The present invention also provides a method
for the production of an antibody (including a molecule comprising,
or alternatively consisting of, an antibody fragment or variant
thereof) of the invention. The present invention further provides a
method of expressing an antibody (including a molecule comprising,
or alternatively consisting of, an antibody fragment or variant
thereof) of the invention from a nucleic acid molecule. These and
other aspects of the invention are described in further detail
below.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0026] The term "antibody," as used herein, refers to
immunoglobulin molecules and immunologically active portions of
immunoglobulin molecules, i.e., molecules that contain an antigen
binding site that specifically binds an antigen. As such, the term
antibody encompasses not only whole antibody molecules, but also
antibody multimers, antibody fragments as well as variants
(including derivatives) of antibodies, antibody multimers and
antibody fragments. Examples of molecules which are described by
the term "antibody" herein include, but are not limited to: single
chain Fvs (scFvs), Fab fragments, Fab' fragments, F(ab').sub.2,
disulfide linked Fvs (sdFvs), Fvs, and fragments comprising or
alternatively consisting of, either a VL or a VH domain. The term
"single chain Fv" or "scFv" as used herein refers to a polypeptide
comprising a VH domain of antibody linked to a VL domain of an
antibody. Antibodies that specifically bind to neurokinin B may
have cross-reactivity with other antigens. Preferably, antibodies
that specifically bind to neurokinin B do not cross-react with
other antigens (e.g., other members of the tachykinin family).
Antibodies that specifically bind to neurokinin B can be
identified, for example, by immunoassays or other techniques known
to those of skill in the art.
[0027] Antibodies of the invention include, but are not limited to,
monoclonal, multispecific, human or chimeric antibodies, single
chain antibodies, Fab fragments, F(ab') fragments, anti-idiotypic
(anti-Id) antibodies (including, e.g., anti-Id antibodies to
antibodies of the invention), intracellularly-made antibodies
(i.e., intrabodies), and epitope-binding fragments of any of the
above. The immunoglobulin molecules of the invention can be of any
type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g.,
IgG.sub.1, IgG.sub.2, IgG.sub.3, IgG.sub.4, IgA.sub.1 and
IgA.sub.2) or subclass of immunoglobulin molecule. Preferably, an
antibody of the invention comprises, or alternatively consists of,
a VH domain, VH CDR, VL domain, or VL CDR having an amino acid
sequence of any one of those referred to in Table 1, or a fragment
or variant thereof. In a preferred embodiment, the immunoglobulin
is an IgG1 isotype. In another preferred embodiment, the
immunoglobulin is an IgG4 isotype. Immunoglobulins may have both a
heavy and light chain. An array of IgG, IgE, IgM, IgD, IgA, and IgY
heavy chains may be paired with a light chain of the kappa or
lambda forms.
[0028] Antibodies of the invention may also include multimeric
forms of antibodies. For example, antibodies of the invention may
take the form of antibody dimers, trimers, or higher-order
multimers of monomeric immunoglobulin molecules. Dimers of whole
immunoglobulin molecules or of F(ab')2 fragments are tetravalent,
whereas dimers of Fab fragments or scFv molecules are bivalent.
Individual monomers withon an antibody multimer may be identical or
different, i.e., antibody multimers may be heteromeric or homomeric
antibody multimers. For example, individual antibodies within a
multimer may have the same or different binding specificities.
[0029] Multimerization of antibodies may be accomplished through
natural aggregation of antibodies or through chemical or
recombinant linking techniques known in the art. For example, some
percentage of purified antibody preparations (e.g., purified IgG1
molecules) spontaneously form protein aggregates containing
antibody homodimers, and other higher-order antibody multimers.
Alternatively, antibody homodimers may be formed through chemical
linkage techniques known in the art. For example,
heterobifunctional crosslinking agents including, but not limited
to, SMCC [succinimidyl
4-(maleimidomethyl)cyclohexane-1-carboxylate] and SATA
[N-succinimidyl S-acethylthio-acetate] (available, for example,
from Pierce Biotechnology, Inc. (Rockford, Ill.)) can be used to
form antibody multimers. An exemplary protocol for the formation of
antibody homodimers is given in Ghetie et al., Proceedings of the
National Academy of Sciences USA (1997) 94:7509-7514, which is
hereby incorporated by reference in its entirety. Antibody
homodimers can be converted to Fab'2 homodimers through digestion
with pepsin. Another way to form antibody homodimers is through the
use of the autophilic T15 peptide described in Zhao and Kohler, The
Journal of Immunology (2002) 25:396-404, which is hereby
incorporated by reference in its entirety.
[0030] Alternatively, antibodies can be made to multimerize through
recombinant DNA techniques. IgM and IgA naturally form antibody
multimers through the interaction with the J chain polypeptide.
Non-IgA or non-IgM molecules, such as IgG molecules, can be
engineered to contain the J chain interaction domain of IgA or IgM,
thereby conferring the ability to form higher order multimers on
the non-IgA or non-IgM molecules. (see, for example,
Chintalacharuvu et al., (2001) Clinical Immunology 101:21-31. and
Frigerio et al., (2000) Plant Physiology 123:1483-94., both of
which are hereby incorporated by reference in their entireties.)
ScFv dimers can also be formed through recombinant techniques known
in the art; an example of the construction of scFv dimers is given
in Goel et al., (2000) Cancer Research 60:6964-6971 which is hereby
incorporated by reference in its entirety. Antibody multimers may
be purified using any suitable method known in the art, including,
but not limited to, size exclusion chromatography.
[0031] By "isolated antibody" is intended an antibody removed from
its native environment. Thus, an antibody produced by, purified
from and/or contained within a hybridoma and/or a recombinant host
cell is considered isolated for purposes of the present
invention.
[0032] Unless otherwise defined in the specification, specific
binding or immunospecifc binding by an anti-neurokinin B antibody
means that the anti-neurokinin B antibody binds neurokinin B but
does not significantly bind to (i.e., cross-react with) proteins
other than neurokinin B, such as other proteins in the same family
of proteins). An antibody that binds neurokinin B protein and does
not cross-react with other proteins is not necessarily an antibody
that does not bind said other proteins in all conditions; rather,
the neurokinin B-specific antibody of the invention preferentially
binds neurokinin B compared to its ability to bind said other
proteins such that it will be suitable for use in at least one type
of assay or treatment, i.e., give low background levels or result
in no unreasonable adverse effects in treatment. It is well known
that the portion of a protein bound by an antibody is known as the
epitope. An epitope may either be linear (i.e., comprised of
sequential amino acids residues in a protein sequences) or
conformational (i.e., comprised of one or more amino acid residues
that are not contiguous in the primary structure of the protein but
that are brought together by the secondary, tertiary or quaternary
structure of a protein). Given that neurokinin B-specific
antibodies bind to epitopes of neurokinin B, an antibody that
specifically binds neurokinin B may or may not bind fragments of
neurokinin B and/or variants of neurokinin B (e.g., proteins that
are at least 90% identical to neurokinin B) depending on the
presence or absence of the epitope bound by a given neurokinin
B-specific antibody in the neurokinin B fragment or variant.
Likewise, neurokinin B-specific antibodies of the invention may
bind species orthologues of neurokinin B (including fragments
thereof) depending on the presence or absence of the epitope
recognized by the antibody in the orthologue. Additionally,
neurokinin B-specific antibodies of the invention may bind modified
forms of neurokinin B, for example, neurokinin B fusion proteins.
In such a case when antibodies of the invention bind neurokinin B
fusion proteins, the antibody must make binding contact with the
neurokinin B moiety of the fusion protein in order for the binding
to be specific. Antibodies that specifically bind to neurokinin B
can be identified, for example, by immunoassays or other techniques
known to those of skill in the art, e.g., the immunoassays
described in the Examples below.
[0033] The term "variant" as used herein refers to a polypeptide
that possesses a similar or identical amino acid sequence as a
neurokinin B polypeptide, a fragment of a neurokinin B polypeptide,
an anti-neurokinin B antibody or antibody fragment thereof. A
variant having a similar amino acid sequence refers to a
polypeptide that satisfies at least one of the following: (a) a
polypeptide comprising, or alternatively consisting of, an amino
acid sequence that is at least 30%, at least 35%, at least 40%, at
least 45%, at least 50%, at least 55%, at least 60%, at least 65%,
at least 70%, at least 75%, at least 80%, at least 85%, at least
90%, at least 95% or at least 99% identical to the amino acid
sequence of a neurokinin B polypeptide, a fragment thereof, an
anti-neurokinin B antibody or antibody fragment thereof (including
a VH domain, VHCDR, VL domain, or VLCDR having an amino acid
sequence of any one or more scFvs referred to in Table 1) described
herein; (b) a polypeptide encoded by a nucleotide sequence, the
complementary sequence of which hybridizes under stringent
conditions to a nucleotide sequence encoding a neurokinin B
polypeptide (e.g., SEQ ID NO:2), a fragment of a neurokinin B
polypeptide (e.g., the mature form of neurokinin B (amino acids 81
to 90 of SEQ ID NO:2)), an anti-neurokinin B antibody or antibody
fragment thereof (including a VH domain, VHCDR, VL domain, or VLCDR
having an amino acid sequence of any one of those referred to in
Table 1), described herein, of at least 5 amino acid residues, at
least 10 amino acid residues, at least 15 amino acid residues, at
least 20 amino acid residues, at least 25 amino acid residues, at
least 30 amino acid residues, at least 40 amino acid residues, at
least 50 amino acid residues, at least 60 amino residues, at least
70 amino acid residues, at least 80 amino acid residues, at least
90 amino acid residues, at least 100 amino acid residues, at least
125 amino acid residues, or at least 150 amino acid residues; and
(c) a polypeptide encoded by a nucleotide sequence that is at least
30%, at least 35%, at least 40%, at least 45%, at least 50%, at
least 55%, at least 60%, at least 65%, at least 70%, at least 75%,
at least 80%, at least 85%, at least 90%, at least 95% or at least
99%, identical to the nucleotide sequence encoding a neurokinin B
polypeptide, a fragment of a neurokinin B polypeptide, an
anti-neurokinin B antibody or antibody fragment thereof (including
a VH domain, VHCDR, VL domain, or VLCDR having an amino acid
sequence of any one or more scFvs referred to in Table 1),
described herein. A polypeptide with similar structure to a
neurokinin B polypeptide, a fragment of a neurokinin B polypeptide,
an anti-neurokinin B antibody or antibody fragment thereof,
described herein refers to a polypeptide that has a similar
secondary, tertiary or quaternary structure of a neurokinin B
polypeptide, a fragment of a neurokinin B polypeptide, an
anti-neurokinin B antibody, or antibody fragment thereof, described
herein. The structure of a polypeptide can determined by methods
known to those skilled in the art, including but not limited to,
X-ray crystallography, nuclear magnetic resonance, and
crystallographic electron microscopy. Preferably, a variant
neurokinin B polypeptide, a variant fragment of a neurokinin B
polypeptide, or a variant anti-neurokinin B antibody and/or
antibody fragment possesses similar or identical function and/or
structure as the reference neurokinin B polypeptide, the reference
fragment of a neurokinin B polypeptide, or the reference
anti-neurokinin B antibody and/or antibody fragment,
respectively.
[0034] To determine the percent identity of two amino acid
sequences or of two nucleic acid sequences, the sequences are
aligned for optimal comparison purposes (e.g., gaps can be
introduced in the sequence of a first amino acid or nucleic acid
sequence for optimal alignment with a second amino acid or nucleic
acid sequence). The amino acid residues or nucleotides at
corresponding amino acid positions or nucleotide positions are then
compared. When a position in the first sequence is occupied by the
same amino acid residue or nucleotide at the corresponding position
in the second sequence, then the molecules are identical at that
position. The percent identity between the two sequences is a
function of the number of identical positions shared by the
sequences (i.e., % identity=number of identical overlapping
positions/total number of positions.times.100%). In one embodiment,
the two sequences are the same length.
[0035] The determination of percent identity between two sequences
can be accomplished using a mathematical algorithm known to those
of skill in the art. An example of a mathematical algorithm for
comparing two sequences is the algorithm of Karlin and Altschul
Proc. Natl. Acad. Sci. USA 87:2264-2268 (1990), modified as in
Karlin and Altschul Proc. Natl. Acad. Sci. USA 90:5873-5877 (1993).
The BLASTn and BLASTx programs of Altschul, et al. J. Mol. Biol.
215:403-410 (1990) have incorporated such an algorithm. BLAST
nucleotide searches can be performed with the BLASTn program
(score=100, wordlength=12) to obtain nucleotide sequences
homologous to a nucleic acid molecules of the invention. BLAST
protein searches can be performed with the BLASTx program
(score=50, wordlength=3) to obtain amino acid sequences homologous
to a protein molecules of the invention. To obtain gapped
alignments for comparison purposes, Gapped BLAST can be utilized as
described in Altschul et al. Nucleic Acids Res. 25:3589-3402
(1997). Alternatively, PSI-BLAST can be used to perform an iterated
search which detects distant relationships between molecules (Id.).
When utilizing BLAST, Gapped BLAST, and PSI-BLAST programs, the
default parameters of the respective programs (e.g., BLASTx and
BLASTn) can be used.
[0036] Another example of a mathematical algorithm utilized for the
comparison of sequences is the algorithm of Myers and Miller,
CABIOS (1989). The ALIGN program (version 2.0) which is part of the
GCG sequence alignment software package has incorporated such an
algorithm. Other algorithms for sequence analysis known in the art
include ADVANCE and ADAM as described in Torellis and Robotti
Comput. Appl. Biosci., 10:3-5 (1994); and FASTA described in
Pearson and Lipman Proc. Natl. Acad. Sci. 85:2444-8 (1988). Within
FASTA, ktup is a control option that sets the sensitivity and speed
of the search.
[0037] The term "derivative" as used herein, refers to a variant
polypeptide of the invention that comprises, or alternatively
consists of, an amino acid sequence of a neurokinin B polypeptide,
a fragment of a neurokinin B polypeptide, or an antibody of the
invention that specifically binds to a neurokinin B polypeptide,
which has been altered by the introduction of amino acid residue
substitutions, deletions or additions. The term "derivative" as
used herein also refers to a neurokinin B polypeptide, a fragment
of a neurokinin B polypeptide, an antibody that specifically binds
to a neurokinin B polypeptide which has been modified, e.g., by the
covalent attachment of any type of molecule to the polypeptide. For
example, but not by way of limitation, a neurokinin B polypeptide,
a fragment of a neurokinin B polypeptide, or an anti-neurokinin B
antibody, may be modified, e.g., by glycosylation, acetylation,
pegylation, phosphorylation, amidation, derivatization by known
protecting/blocking groups, proteolytic cleavage, linkage to a
cellular ligand or other protein, etc. A derivative of a neurokinin
B polypeptide, a fragment of a neurokinin B polypeptide, or an
anti-neurokinin B antibody, may be modified by chemical
modifications using techniques known to those of skill in the art,
including, but not limited to, specific chemical cleavage,
acetylation, formylation, metabolic synthesis of tunicamycin, etc.
Further, a derivative of a neurokinin B polypeptide, a fragment of
a neurokinin B polypeptide, or an anti-neurokinin B antibody, may
contain one or more non-classical amino acids. A polypeptide
derivative possesses a similar or identical function as a
neurokinin B polypeptide, a fragment of a neurokinin B polypeptide,
or an anti-neurokinin B antibody, described herein.
[0038] The term "fragment" as used herein refers to a polypeptide
comprising an amino acid sequence of at least 5 amino acid
residues, at least 10 amino acid residues, at least 15 amino acid
residues, at least 20 amino acid residues, at least 25 amino acid
residues, at least 30 amino acid residues, at least 35 amino acid
residues, at least 40 amino acid residues, at least 45 amino acid
residues, at least 50 amino acid residues, at least 60 amino
residues, at least 70 amino acid residues, at least 80 amino acid
residues, at least 90 amino acid residues, at least 100 amino acid
residues, at least 110 amino acid residues, or at least 120 amino
acid residues of the amino acid sequence of neurokinin B, or an
anti-neurokinin B antibody (including molecules such as scFv's,
that comprise, or alternatively consist of, antibody fragments or
variants thereof) that specifically binds to neurokinin B.
[0039] The term "host cell" as used herein refers to the particular
subject cell transfected with a nucleic acid molecule and the
progeny or potential progeny of such a cell. Progeny may not be
identical to the parent cell transfected with the nucleic acid
molecule due to mutations or environmental influences that may
occur in succeeding generations or integration of the nucleic acid
molecule into the host cell genome.
Antibody Structure
[0040] The basic antibody structural unit is known to comprise a
tetramer. Each tetramer is composed of two identical pairs of
polypeptide chains, each pair having one "light" (about 25 kDa) and
one "heavy" chain (about 50-70 kDa). The amino-terminal portion of
each chain includes a variable region of about 100 to 110 or more
amino acids primarily responsible for antigen recognition. The
carboxy-terminal portion of each chain defines a constant region
primarily responsible for effector function. Human light chains are
classified as kappa and lambda light chains. Heavy chains are
classified as mu, delta, gamma, alpha, or epsilon, and define the
antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively.
See generally, Fundamental Immunology Ch. 7 (Paul, W., ed., 2nd ed.
Raven Press, N.Y. (1989), incorporated by reference in its entirety
for all purposes). The variable regions of each light/heavy chain
pair form the antibody binding site.
[0041] Thus, an intact IgG antibody has two binding sites. Except
in bifunctional or bispecific antibodies, the two binding sites are
the same.
[0042] The chains all exhibit the same general structure of
relatively conserved framework regions (FR) joined by three
hypervariable regions, also called complementarity determining
regions or CDRs. The CDRs from the heavy and the light chains of
each pair are aligned by the framework regions, enabling binding to
a specific epitope. From N-terminal to C-terminal, both light and
heavy chains comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3
and FR4. The assignment of amino acids to each domain is in
accordance with the definitions of Kabat Sequences of Proteins of
Immunological Interest (National Institutes of Health, Bethesda,
Md. (1987 and 1991)), or Chothia & Lesk J Mol. Biol.
196:901-917 (1987); Chothia et al. Nature 342:878-883 (1989).
[0043] A bispecific or bifunctional antibody is an artificial
hybrid antibody having two different heavy/light chain pairs and
two different binding sites. Bispecific antibodies can be produced
by a variety of methods including fusion of hybridomas or linking
of Fab' fragments. See, e.g., Songsivilai & Lachmann Clin. Exp.
Immunol. 79: 315-321 (1990), Kostelny et al. J Immunol. 148:1547
1553 (1992). In addition, bispecific antibodies may be formed as
"diabodies" (Holliger et al. "`Diabodies`: small bivalent and
bispecific antibody fragments" PNAS USA 90:6444-6448 (1993)) or
"Janusins" (Traunecker et al. "Bispecific single chain molecules
(Janusins) target cytotoxic lymphocytes on HIV infected cells" EMBO
J 10:3655-3659 (1991) and Traunecker et al. "Janusin: new molecular
design for bispecific reagents" Int. J. Cancer Suppl. 7:51-52
(1992)).
[0044] Production of bispecific antibodies can be a relatively
labor intensive process compared with production of conventional
antibodies and yields and degree of purity are generally lower for
bispecific antibodies. Bispecific antibodies do not exist in the
form of fragments having a single binding site (e.g., Fab, Fab',
and Fv).
Anti-Neurokinin B Antibodies
[0045] Using phage display technology, single chain antibody
molecules ("scFvs") have been identified that specifically bind to
neurokinin B (or fragments or variants thereof). Molecules
comprising, or alternatively consisting of, fragments or variants
of these scFvs (e.g., including VH domains, VH CDRs, VL domains, or
VL CDRs having an amino acid sequence of any one of those referred
to in Table 1), that specifically bind to neurokinin B (or
fragments or variants thereof) are also encompassed by the
invention, as are nucleic acid molecules that encode these scFvs,
and/or molecules.
[0046] In particular, the invention relates to scFvs comprising, or
alternatively consisting of the amino acid of SEQ ID NOs:22-40,
referred to in Table 1 below. Molecules comprising, or
alternatively consisting of, fragments or variants (e.g., including
VH domains, VH CDRs, VL domains, or VL CDRs identified in Table 1)
of the scFvs referred to in Table 1, that specifically bind to
neurokinin B are also encompassed by the invention, as are nucleic
acid molecules that encode these scFvs, and/or molecules (e.g., SEQ
ID NOs:3-21).
[0047] ScFvs corresponding to SEQ ID NOs: 22-40 were selected for
their ability to bind the mature form of the neurokinin B
polypeptide (amino acids 81 to 90 of SEQ ID NO:2).
[0048] The present invention provides antibodies (including
molecules comprising, or alternatively consisting of, antibody
fragments or variants thereof) that specifically bind to a
polypeptide or a polypeptide fragment of neurokinin B.
[0049] In particular, the invention provides antibodies
corresponding to the scFvs referred to in Table 1, such scFvs may
routinely be "converted" to immunoglobulin molecules by inserting,
for example, the nucleotide sequences encoding the VH and/or VL
domains of the scFv into an expression vector containing the
constant domain sequences and engineered to direct the expression
of the immunoglobulin molecule, as described in more detail in
Example 2 below.
[0050] Accordingly, in one embodiment, the invention provides
antibodies that comprise the VH and VL domains of scFvs of the
invention.
[0051] In a preferred embodiment, an antibody of the invention is
an antibody expressed by any one of the cell lines disclosed in
Table 1.
TABLE-US-00001 TABLE 1 scFvs that Specifically Bind to Neurokinin B
scFv scFv DNA Protein AAs of AAs of AAs of AAs of AAs of AAs of AAs
of AAs of SEQ ID SEQ ID VH VH VH VH VL VL VL VL scFv NO: NO: Domain
CDR1 CDR2 CDR3 Domain CDR1 CDR2 CDR3 N024C01 3 22 1-124 31-40 55-71
104-113 140-250 162-174 190-196 229-239 NO25B07 4 23 1-125 31-36
50-63 96-115 141-251 163-175 191-197 229-240 N015E08 5 24 1-116
31-35 50-66 99-105 132-242 154-166 182-188 221-231 NO15F10 6 25
1-121 31-35 50-66 99-110 138-248 160-172 188-194 227-237 NO24D01 7
26 1-118 31-35 50-66 99-107 134-244 155-168 184-190 223-233 NO15D08
8 27 1-121 31-35 50-66 99-110 137-247 159-171 187-193 226-236
NO24B07 9 28 1-121 31-35 50-66 99-110 138-248 160-172 188-194
227-237 NO24E07 10 29 1-117 31-35 50-66 99-106 133-243 155-167
183-189 222-232 NO23F05 11 30 1-128 31-35 50-66 99-117 145-255
167-179 195-201 234-244 NO24D08 12 31 1-119 31-35 50-66 99-108
135-245 157-169 185-191 224-234 NO23B03 13 32 1-122 31-35 50-66
99-111 139-248 161-174 190-196 229-237 NO23E01 14 33 1-117 31-35
50-66 99-106 133-243 155-167 183-189 222-232 NO24C05 15 34 1-125
31-37 52-70 103-114 141-251 163-176 192-198 231-240 NO25E05 16 35
1-119 31-35 50-66 99-108 136-245 158-170 186-192 225-234 NO25C01 17
36 1-119 31-35 50-66 99-108 135-245 157-169 185-191 224-234 NO24F09
18 37 1-121 31-35 50-66 99-110 137-247 159-171 187-193 226-236
NO24B01 19 38 1-118 31-35 50-66 99-107 135-246 158-170 186-192
225-235 NO24F07 20 39 1-122 31-35 50-66 99-111 138-248 160-172
188-194 227-237 NO15D10 21 40 1-116 31-35 50-66 99-105 132-242
154-166 182-188 221-231
[0052] The present invention encompasses antibodies (including
molecules comprising, or alternatively consisting of, antibody
fragments or variants thereof) that specifically bind to a
neurokinin B polypeptide or a fragment, variant, or fusion protein
thereof. A neurokinin B polypeptide includes, but is not limited
to, neurokinin B (SEQ ID NO:2) or the polypeptide encoded by the
cDNA contained in ATCC.TM. Deposit No. 97922 on Mar. 7, 1997 and/or
ATCC.TM. Deposit No. 97375 on Dec. 8, 1995. Neurokinin B may be
produced through recombinant expression of nucleic acids encoding
the polypeptides of SEQ ID NO:2 (e.g., the cDNA in ATCC.TM. Deposit
Number 97922 and/or ATCC.TM. Deposit No. 97375). Antibodies of the
invention may specifically bind neurokinin B as well as fragments
and variants thereof, and are described in more detail below.
Neurokinin B Polypeptides
[0053] In certain embodiments of the present invention, the
antibodies of the present invention bind a neurokinin B
polypeptide, or fragments or variants thereof. The following
section describes the neurokinin B polypeptides, fragments and
variants that may be bound by the antibodies of the invention in
more detail.
[0054] The antibodies of the present invention also include
antibodies that bind a polypeptide comprising, or alternatively,
consisting of the polypeptide encoded by the deposited cDNAs (the
deposit having ATCC.TM. Accession Number 97922 and/or ATCC.TM.
Deposit No. 97375); a polypeptide comprising, or alternatively,
consisting of the polypeptide of SEQ ID NO:2; a polypeptide
comprising, or alternatively, consisting of the precursor
polypeptide of SEQ ID NO:2 (predicted to constitute amino acid
residues from about 17 to about 121 in SEQ ID NO:2); a polypeptide
comprising, or alternatively, consisting of the mature polypeptide
of SEQ ID NO:2 (predicted to constitute amino acid residues from
about 81 to about 90 in SEQ ID NO:2); as well as polypeptides which
are at least 80% identical, more preferably at least 90% or 95%
identical, still more preferably at least 96%, 97%, 98% or 99%
identical to the polypeptides described above (e.g., the
polypeptide encoded by the deposited cDNA clones (the deposit
having ATCC.TM. Accession Number 97922 and/or ATCC.TM. Deposit No.
97375), the polypeptide of SEQ ID NO:2, and portions of such
polypeptides.
[0055] By a polypeptide having an amino acid sequence at least, for
example, 95% "identical" to a reference amino acid sequence of a
neurokinin B polypeptide is intended that the amino acid sequence
of the polypeptide is identical to the reference sequence except
that the polypeptide sequence may include up to one amino acid
alterations per each 20 amino acids of the reference amino acid of
the neurokinin B polypeptide. In other words, to obtain a
polypeptide having an amino acid sequence at least 95% identical to
a reference amino acid sequence, up to 5% of the amino acid
residues in the reference sequence may be deleted or substituted
with another amino acid, or a number of amino acids up to 5% of the
total amino acid residues in the reference sequence may be inserted
into the reference sequence. These alterations of the reference
sequence may occur at the amino or carboxy terminal positions of
the reference amino acid sequence or anywhere between those
terminal positions, interspersed either individually among residues
in the reference sequence or in one or more contiguous groups
within the reference sequence.
[0056] As a practical matter, whether any particular polypeptide is
at least 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance,
the amino acid sequence shown in SEQ ID NO:2 or to the amino acid
sequence encoded by deposited cDNA clones can be determined
conventionally using known computer programs such the Bestfit
program (Wisconsin Sequence Analysis Package, Version 8 for Unix,
Genetics Computer Group, University Research Park, 575 Science
Drive, Madison, Wis. 53711). When using Bestfit or any other
sequence alignment program to determine whether a particular
sequence is, for instance, 95% identical to a reference sequence
according to the present invention, the parameters are set, of
course, such that the percentage of identity is calculated over the
full length of the reference amino acid sequence and that gaps in
homology of up to 5% of the total number of amino acid residues in
the reference sequence are allowed.
[0057] In a specific embodiment, the identity between a reference
(query) sequence (a sequence of the present invention) and a
subject sequence, also referred to as a global sequence alignment,
is determined using the FASTDB computer program based on the
algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245 (1990)).
Preferred parameters used in a FASTDB amino acid alignment are:
Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20,
Randomization Group Length=0, Cutoff Score=1, Window Size=sequence
length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or
the length of the subject amino acid sequence, whichever is
shorter. According to this embodiment, if the subject sequence is
shorter than the query sequence due to N- or C-terminal deletions,
not because of internal deletions, a manual correction is made to
the results to take into consideration the fact that the FASTDB
program does not account for N- and C-terminal truncations of the
subject sequence when calculating global percent identity. For
subject sequences truncated at the N- and C-termini, relative to
the query sequence, the percent identity is corrected by
calculating the number of residues of the query sequence that are
N- and C-terminal of the subject sequence, which are not
matched/aligned with a corresponding subject residue, as a percent
of the total bases of the query sequence. A determination of
whether a residue is matched/aligned is determined by results of
the FASTDB sequence alignment. This percentage is then subtracted
from the percent identity, calculated by the above FASTDB program
using the specified parameters, to arrive at a final percent
identity score. This final percent identity score is what is used
for the purposes of this embodiment. Only residues to the N- and
C-termini of the subject sequence, which are not matched/aligned
with the query sequence, are considered for the purposes of
manually adjusting the percent identity score. That is, only query
residue positions outside the farthest N- and C-terminal residues
of the subject sequence. For example, a 90 amino acid residue
subject sequence is aligned with a 100 residue query sequence to
determine percent identity. The deletion occurs at the N-terminus
of the subject sequence and therefore, the FASTDB alignment does
not show a matching/alignment of the first 10 residues at the
N-terminus. The 10 unpaired residues represent 10% of the sequence
(number of residues at the N- and C-termini not matched/total
number of residues in the query sequence) so 10% is subtracted from
the percent identity score calculated by the FASTDB program. If the
remaining 90 residues were perfectly matched the final percent
identity would be 90%. In another example, a 90 residue subject
sequence is compared with a 100 residue query sequence. This time
the deletions are internal deletions so there are no residues at
the N- or C-termini of the subject sequence which are not
matched/aligned with the query. In this case the percent identity
calculated by FASTDB is not manually corrected. Once again, only
residue positions outside the N- and C-terminal ends of the subject
sequence, as displayed in the FASTDB alignment, which are not
matched/aligned with the query sequence are manually corrected for.
No other manual corrections are made for the purposes of this
embodiment.
[0058] In certain embodiments, the antibodies of the present
invention specifically bind neurokinin B polypeptide. An antibody
that specifically binds neurokinin B may, in some embodiments, bind
fragments, variants (including species orthologs and allelic
variants of neurokinin B), multimers, processed forms, subprocessed
forms, or modified forms of neurokinin B. For example, an antibody
specific for neurokinin B may bind the neurokinin B moiety of a
fusion protein comprising all or a portion of neurokinin B.
[0059] Neurokinin B proteins may be found as monomers or multimers
(i.e., dimers, trimers, tetramers, and higher multimers).
Accordingly, the present invention relates to antibodies that bind
neurokinin B proteins found as monomers or as part of multimers. In
specific embodiments, antibodies of the invention bind neurokinin B
monomers, dimers, trimers or tetramers. In additional embodiments,
antibodies of the invention bind at least dimers, at least trimers,
or at least tetramers containing one or more neurokinin B
polypeptides.
[0060] Antibodies of the invention may bind neurokinin B homomers
or heteromers. As used herein, the term homomer, refers to a
multimer containing only neurokinin B proteins of the invention
(including neurokinin B fragments, variants, and fusion proteins,
as described herein). These homomers may contain neurokinin B
proteins having identical or different polypeptide sequences. In a
specific embodiment, a homomer of the invention is a multimer
containing only neurokinin B proteins having an identical
polypeptide sequence. In another specific embodiment, antibodies of
the invention bind neurokinin B homomers containing neurokinin B
proteins having different polypeptide sequences. In specific
embodiments, antibodies of the invention bind a neurokinin B
homodimer (e.g., containing neurokinin B proteins having identical
or different polypeptide sequences) or a homotrimer (e.g.,
containing neurokinin B proteins having identical or different
polypeptide sequences). In additional embodiments, antibodies of
the invention bind at least a homodimer, at least a homotrimer, or
at least a homotetramer of neurokinin B.
[0061] As used herein, the term heteromer refers to a multimer
containing heterologous proteins (i.e., proteins containing
polypeptide sequences that do not correspond to a polypeptide
sequences encoded by a gene encoding neurokinin B) in addition to
the neurokinin B proteins of the invention. In a specific
embodiment, antibodies of the invention bind a heterodimer, a
heterotrimer, or a heterotetramer. In additional embodiments, the
antibodies of the invention bind at least a heterodimer, at least a
heterotrimer, or at least a heterotetramer containing one or more
neurokinin B polypeptides.
[0062] Antibodies of the invention bind neurokinin B multimers that
are the result of hydrophobic, hydrophilic, ionic and/or covalent
associations and/or may be indirectly linked, by for example,
liposome formation. Thus, in one embodiment, antibodies of the
invention may bind neurokinin B multimers, such as, for example,
homodimers or homotrimers, that are formed when neurokinin B
proteins contact one another in solution. In another embodiment,
antibodies of the invention may bind neurokinin B heteromultimers,
such as, for example, heterotrimers or heterotetramers, that are
formed when proteins of the invention contact antibodies to the
neurokinin B polypeptides (including antibodies to the heterologous
polypeptide sequence in a fusion protein) in solution. In other
embodiments, multimers that antibodies of the invention may bind
are formed by covalent associations with and/or between the
neurokinin B proteins of the invention. Such covalent associations
may involve one or more amino acid residues contained in the
polypeptide sequence of the protein (e.g., the polypeptide sequence
recited in SEQ ID NO:2 or the polypeptide encoded by the deposited
cDNA clone of ATCC.TM. Deposit 97922 and/or ATCC.TM. Deposit No.
97375). In one instance, the covalent associations are
cross-linking between cysteine residues located within the
polypeptide sequences of the proteins which interact in the native
(i.e., naturally occurring) polypeptide. In another instance, the
covalent associations are the consequence of chemical or
recombinant manipulation. Alternatively, such covalent associations
may involve one or more amino acid residues contained in the
heterologous polypeptide sequence in a neurokinin B fusion protein.
In one example, covalent associations are between the heterologous
sequence contained in a fusion protein (see, e.g., U.S. Pat. No.
5,478,925). In a specific example, the covalent associations are
between the heterologous sequence contained in a neurokinin B-Fc
fusion protein (as described herein). In another specific example,
covalent associations of fusion proteins are between heterologous
polypeptide sequences from another tachykinin family
ligand/receptor member, such as for example, substance P or
neurokinin A.
[0063] Antibodies of the invention may bind neurokinin B multimers
that were generated using chemical techniques known in the art. For
example, proteins desired to be contained in the multimers of the
invention may be chemically cross-linked using linker molecules and
linker molecule length optimization techniques known in the art
(see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated
by reference in its entirety). Additionally, multimers that may be
bound by one or more antibodies of the invention may be generated
using techniques known in the art to form one or more
inter-molecule cross-links between the cysteine residues located
within the polypeptide sequence of the proteins desired to be
contained in the multimer (see, e.g., U.S. Pat. No. 5,478,925,
which is herein incorporated by reference in its entirety).
Further, proteins that may be bound by one or more antibodies of
the invention may be routinely modified by the addition of cysteine
or biotin to the C terminus or N-terminus of the polypeptide
sequence of the protein and techniques known in the art may be
applied to generate multimers containing one or more of these
modified proteins (see, e.g., U.S. Pat. No. 5,478,925, which is
herein incorporated by reference in its entirety). Additionally,
techniques known in the art may be applied to generate liposomes
containing the protein components desired to be contained in the
multimer that antibodies of the invention may bind (see, e.g., U.S.
Pat. No. 5,478,925, which is herein incorporated by reference in
its entirety).
[0064] Alternatively, antibodies of the invention may bind
neurokinin B multimers that were generated using genetic
engineering techniques known in the art. In one embodiment,
proteins contained in multimers that may be bound by one or more
antibodies of the invention are produced recombinantly using fusion
protein technology described herein or otherwise known in the art
(see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated
by reference in its entirety). In a specific embodiment,
polynucleotides coding for a homodimer that may be bound by one or
more antibodies of the invention are generated by ligating a
polynucleotide sequence encoding a neurokinin B polypeptide to a
sequence encoding a linker polypeptide and then further to a
synthetic polynucleotide encoding the translated product of the
polypeptide in the reverse orientation from the original C-terminus
to the N-terminus (see, e.g., U.S. Pat. No. 5,478,925, which is
herein incorporated by reference in its entirety). In another
embodiment, recombinant techniques described herein or otherwise
known in the art are applied to generate recombinant neurokinin B
polypeptides which contain a transmembrane domain and which can be
incorporated by membrane reconstitution techniques into liposomes
(see, e.g., U.S. Pat. No. 5,478,925, which is herein incorporated
by reference in its entirety). In another embodiment, two or more
neurokinin B polypeptides are joined through synthetic linkers
(e.g., peptide, carbohydrate or soluble polymer linkers). Examples
include those peptide linkers described in U.S. Pat. No. 5,073,627
(hereby incorporated by reference). Proteins comprising multiple
neurokinin B polypeptides separated by peptide linkers may be
produced using conventional recombinant DNA technology. In specific
embodiments, antibodies of the invention bind proteins comprising
multiple neurokinin B polypeptides separated by peptide
linkers.
[0065] Another method for preparing multimer neurokinin B
polypeptides involves use of neurokinin B polypeptides fused to a
leucine zipper or isoleucine polypeptide sequence. Leucine zipper
domains and isoleucine zipper domains are polypeptides that promote
multimerization of the proteins in which they are found. Leucine
zippers were originally identified in several DNA-binding proteins
(Landschulz et al., Science 240:1759, (1988)), and have since been
found in a variety of different proteins. Among the known leucine
zippers are naturally occurring peptides and derivatives thereof
that dimerize or trimerize. Examples of leucine zipper domains
suitable for producing soluble multimeric neurokinin B proteins are
those described in PCT application WO 94/10308, hereby incorporated
by reference. Recombinant fusion proteins comprising a soluble
neurokinin B polypeptide fused to a peptide that dimerizes or
trimerizes in solution are expressed in suitable host cells, and
the resulting soluble multimeric neurokinin B is recovered from the
culture supernatant using techniques known in the art. In specific
embodiments, antibodies of the invention bind neurokinin B-leucine
zipper fusion protein monomers and/or neurokinin B-leucine zipper
fusion protein multimers.
[0066] Antibodies that bind neurokinin B may bind them as isolated
polypeptides or in their naturally occurring state. For, example
antibodies of the present invention may bind recombinantly produced
neurokinin B.
[0067] Antibodies that bind neurokinin B may bind selectively to
any of the processed forms of neurokinin B (e.g., neurokinin B
minus the signal sequence and the mature form of neurokinin B)
and/or may alter processing of the precursor protein (PPTB) to a
downstream form.
[0068] Antibodies of the present invention may also bind neurokinin
B purified from a cell culture, wherein the cells (e.g., CHO and
NSO) produce neurokinin B that is proteolytically and/or
preproteolytically processed.
[0069] In a specific embodiment, antibodies of the present
invention bind neurokinin B purified from a cell culture, wherein
the neurokinin B polypeptide is encoded by a polynucleotide
encoding amino acids 1 to 121 of SEQ ID NO:2 operably associated
with a regulatory sequence that controls expression of said
polynucleotide.
[0070] In a specific embodiment, antibodies of the present
invention bind neurokinin B peptide purified from a cell culture,
wherein the neurokinin B peptide is encoded by a polynucleotide
encoding amino acids 81 to 90 of SEQ ID NO:2 operably associated
with a regulatory sequence that controls expression of said
polynucleotide.
[0071] In certain embodiments, antibodies of the present invention
may also bind neurokinin B produced by chemical or semi-synthetic
methodologies known in the art (see, Kelley et al. in Genetic
Engineering Principles and Methods, Setlow, J. K., ed., Plenum
Press, NY., vol. 12, pp. 1-19 (1990); Stewart et al., Solid-Phase
Peptide Synthesis, W.H. Freeman Co., San Francisco (1989)). One
advantage of these methodologies is that they allow for the
incorporation of non-natural amino acid residues into the sequence
of neurokinin B.
[0072] Antibodies of the present invention may bind neurokinin B
polypeptide fragments comprising or alternatively, consisting of,
an amino acid sequence contained in SEQ ID NO:2, encoded by the
cDNA contained in ATCC.TM. deposit Number 97922 and/or ATCC.TM.
Deposit No. 97375, or encoded by nucleic acids which hybridize
(e.g., under stringent hybridization conditions) to the nucleotide
sequence contained in ATCC.TM. deposit Number 97922 and/or ATCC.TM.
Deposit No. 97375, or the complementary strand thereto. Protein
fragments may be "free-standing," or comprised within a larger
polypeptide of which the fragment forms a part or region, most
preferably as a single continuous region. Antibodies of the present
invention may bind polypeptide fragments, including, for example,
fragments that comprise or alternatively, consist of from about
amino acid residues: 1 to 16, 17 to 37, 38 to 58, 59 to 80, 81 to
90, 91 to 111 and/or 112 to 121 of SEQ ID NO:2. In this context
"about" includes the particularly recited value, larger or smaller
by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at
both extremes. Moreover, polypeptide fragments that antibodies of
the invention may bind can be at least about 5, 10, 20, 30, 40, 50,
60, 70, 80, 90, 100, or 110 amino acids in length. In this context
"about" includes the particularly recited value, larger or smaller
by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at
both extremes.
[0073] Preferably, antibodies of the present invention bind a
polypeptide comprising, or alternatively consisting of, a fragment
of the predicted mature neurokinin B polypeptide (predicted to
constitute amino acid residues from about 81 to about 90 in SEQ ID
NO:2), wherein the fragment has a neurokinin B functional activity
(e.g., antigenic activity or biological activity). Polynucleotides
encoding these polypeptides are also encompassed by the
invention.
[0074] In an additional embodiment, antibodies of the present
invention may bind a polypeptide comprising, or alternatively
consisting of, a fragment of the predicted neurokinin B precursor
polypeptide (predicted to constitute amino acid residues from about
17 to about 121 in SEQ ID NO:2). Polynucleotides encoding these
polypeptides are also encompassed by the invention. In a specific
embodiment, binding of an antibody to the neurokinin B precursor
polypeptide inhibits processing of the polypeptide to its mature
form.
[0075] In highly preferred embodiments, the antibodies of the
invention that bind neurokinin B prevent a neurokinin B receptor
(e.g., NK3R) from binding to neurokinin B. In other highly
preferred embodiments, the antibodies of the invention that bind
neurokinin B antagonize or neutralize neurokinin B. In other highly
preferred embodiments, the antibodies of the invention that bind
neurokinin B inhibit vasoconstriction (e.g., of the hepatic portal
vein, mesenteric vascular bed). In other embodiments, the
antibodies of the invention that bind neurokinin B stimulate
vasoconstriction (e.g., of the hepatic portal vein, mesenteric
vascular bed).
[0076] In another aspect, the invention provides an antibody that
binds a peptide or polypeptide comprising an epitope-bearing
portion of a polypeptide described herein. The epitope of this
polypeptide portion is an immunogenic or antigenic epitope of a
polypeptide of the invention. An "immunogenic epitope" is defined
as a part of a protein that elicits an antibody response when the
whole protein is the immunogen. On the other hand, a region of a
protein molecule to which an antibody can bind is defined as an
"antigenic epitope." The number of immunogenic epitopes of a
protein generally is less than the number of antigenic epitopes.
See, for instance, Geysen et al., Proc. Natl. Acad. Sci. USA
81:3998-4002 (1983).
[0077] As one of skill in the art will appreciate, neurokinin B
polypeptides and the epitope-bearing fragments thereof described
herein can be combined with parts of the constant domain of
immunoglobulins (IgG), resulting in chimeric polypeptides. These
fusion proteins facilitate purification and show an increased
half-life in vivo. This has been shown, e.g., for chimeric proteins
consisting of the first two domains of the human CD4-polypeptide
and various domains of the constant regions of the heavy or light
chains of mammalian immunoglobulins (EPA 394,827; Traunecker et
al., Nature 331:84-86 (1988)). Fusion proteins that have a
disulfide-linked dimeric structure due to the IgG part can also be
more efficient in binding and neutralizing other molecules than the
monomeric neurokinin B protein or protein fragment alone
(Fountoulakis et al., J Biochem 270:3958-3964 (1995)). Thus,
antibodies of the invention may bind fusion proteins that comprise
all or a portion of a neurokinin B polypeptide.
[0078] Recombinant DNA technology known to those skilled in the art
can be used to create novel mutant proteins or "muteins" including
single or multiple amino acid substitutions, deletions, additions
or fusion proteins. Such modified polypeptides can show, e.g.,
enhanced activity or increased stability. In addition, they may be
purified in higher yields and show better solubility than the
corresponding natural polypeptide, at least under certain
purification and storage conditions. Antibodies of the present
invention may also bind such modified neurokinin B polypeptides or
neurokinin B polypeptide fragments or variants.
[0079] For instance, for many proteins, including the extracellular
domain of a membrane associated protein or the mature form(s) of a
secreted protein, it is known in the art that one or more amino
acids may be deleted from the N-terminus or C-terminus without
substantial loss of biological function, or loss of the ability to
be bound by a specific antibody. For instance, Ron et al, J. Biol.
Chem., 268:2984-2988 (1993) reported modified KGF proteins that had
heparin binding activity even if 3, 8, or 27 amino-terminal amino
acid residues were missing
[0080] However, even if deletion of one or more amino acids from
the N-terminus of a protein results in modification or loss of one
or more biological functions of the protein, other functional
activities (e.g., biological activities, ability to bind a
neurokinin B receptor (e.g., NK3R)) may still be retained. For
example, the ability of shortened neurokinin B polypeptides to
induce and/or bind to antibodies which recognize the complete or
mature forms of the neurokinin B polypeptides generally will be
retained when less than the majority of the residues of the
complete or mature polypeptide are removed from the N-terminus.
Whether a particular polypeptide lacking N-terminal residues of a
complete polypeptide retains such immunologic activities can
readily be determined by routine methods described herein and
otherwise known in the art. It is not unlikely that a neurokinin B
polypeptide with deleted N-terminal amino acid residues may retain
some biological or immunogenic activities. In fact, peptides
composed of as few as six neurokinin B amino acid residues may
often evoke an immune response.
[0081] Accordingly, the present invention further provides
antibodies that bind polypeptides having one or more residues
deleted from the amino terminus of the neurokinin B amino acid
sequence of SEQ ID NO:2 up to the phenylalanine residue at position
number 85 and polynucleotides encoding such polypeptides. In
particular, the present invention provides antibodies that bind
polypeptides comprising, or alternatively consisting of, the amino
acid sequence of residues n.sup.1-90 of SEQ ID NO:2, where n.sup.1
is an integer from 1 to 85 corresponding to the position of the
amino acid residue in SEQ ID NO:2.
[0082] More in particular, the invention provides antibodies that
bind polypeptides comprising, or alternatively consisting of, the
amino acid sequence of residues of M-1 to M-90; R-2 to M-90; 1-3 to
M-90; M-4 to M-90; L-5 to M-90; L-6 to M-90; F-7 to M-90; T-8 to
M-90; A-9 to M-90; I-10 to M-90; L-11 to M-90; A-12 to M-90; F-13
to M-90; S-14 to M-90; L-15 to M-90; A-16 to M-90; Q-17 to M-90;
S-18 to M-90; F-19 to M-90; G-20 to M-90; A-21 to M-90; V-22 to
M-90; C-23 to M-90; K-24 to M-90; E-25 to M-90; P-26 to M-90; Q-27
to M-90; E-28 to M-90; E-29 to M-90; V-30 to M-90; V-31 to M-90;
P-32 to M-90; G-33 to M-90; G-34 to M-90; G-35 to M-90; R-36 to
M-90; S-37 to M-90; K-38 to M-90; R-39 to M-90; D-40 to M-90; P-41
to M-90; D-42 to M-90; L-43 to M-90; Y-44 to M-90; Q-45 to M-90;
L-46 to M-90; L-47 to M-90; Q-48 to M-90; R-49 to M-90; L-50 to
M-90; F-51 to M-90; K-52 to M-90; S-53 to M-90; H-54 to M-90; S-55
to M-90; S-56 to M-90; L-57 to M-90; E-58 to M-90; G-59 to M-90;
L-60 to M-90; L-61 to M-90; K-62 to M-90; A-63 to M-90; L-64 to
M-90; S-65 to M-90; Q-66 to M-90; A-67 to M-90; S-68 to M-90; T-69
to M-90; D-70 to M-90; P-71 to M-90; K-72 to M-90; E-73 to M-90;
S-74 to M-90; T-75 to M-90; S-76 to M-90; P-77 to M-90; E-78 to
M-90; K-79 to M-90; R-80 to M-90; D-81 to M-90; M-82 to M-90; H-83
to M-90; D-84 to M-90; F-85 to M-90 of the neurokinin B sequence of
SEQ ID NO:2.
[0083] As mentioned above, even if deletion of one or more amino
acids from the C-terminus of a protein results in modification or
loss of one or more biological functions of the protein, other
functional activities (e.g., biological activities, ability to bind
a neurokinin B receptor (e.g., NK3R)) may still be retained. For
example the ability of the shortened neurokinin B polypeptide to
induce and/or bind to antibodies which recognize the complete or
mature forms of the neurokinin B polypeptide generally will be
retained when less than the majority of the residues of the
complete or mature polypeptide are removed from the C-terminus.
Whether a particular polypeptide lacking C-terminal residues of a
complete polypeptide retains such immunologic activities can
readily be determined by routine methods described herein and
otherwise known in the art. It is not unlikely that a neurokinin B
polypeptide with a large number of deleted C-terminal amino acid
residues may retain some biological or immunogenic activities. In
fact, peptides composed of as few as six neurokinin B amino acid
residues may often evoke an immune response.
[0084] In another embodiment, antibodies of the invention bind
C-terminal deletions of the mature neurokinin B polypeptide that
can be described by the general formula 81-m.sup.1 where m.sup.1 is
a number from 86 to 89 corresponding to the amino acid sequence
identified of SEQ ID NO:2. In specific embodiments, the invention
provides antibodies that bind neurokinin B polypeptides comprising,
or alternatively consisting of, the amino acid sequence of
residues: D-81 to L-89; D-81 to G-88; D-81 to V-87; D-81 to F-86 of
the neurokinin B sequence of SEQ ID NO:2.
[0085] In another embodiment, antibodies of the invention bind
C-terminal deletions of the neurokinin B polypeptide that can be
described by the general formula 1-m.sup.2 where m.sup.2 is a
number from 6 to 120 corresponding to the amino acid sequence
identified of SEQ ID NO:2. In specific embodiments, the invention
provides antibodies that bind neurokinin B polypeptides comprising,
or alternatively consisting of, the amino acid sequence of
residues: M-1 to A-120; M-1 to R-119; M-1 to P-118; M-1 to P-117;
M-1 to Y-116; M-1 to K-115; M-1 to L-114; M-1 to 1-113; M-1 to
G-112; M-1 to F-111; M-1 to S-110; M-1 to P-109; M-1 to V-108; M-1
to N-107; M-1 to E-106; M-1 to Q-105; M-1 to N-104; M-1 to V-103;
M-1 to D-102; M-1 to T-101; M-1 to P-100; M-1 to S-99; M-1 to D-98;
M-1 to P-97; M-1 to Q-96; M-1 to V-95; M-1 to S-94; M-1 to R-93;
M-1 to K-92; M-1 to G-91; M-1 to M-90; M-1 to L-89; M-1 to G-88;
M-1 to V-87; M-1 to F-86; M-1 to F-85; M-1 to D-84; M-1 to H-83;
M-1 to M-82; M-1 to D-81; M-1 to R-80; M-1 to K-79; M-1 to E-78;
M-1 to P-77; M-1 to S-76; M-1 to T-75; M-1 to S-74; M-1 to E-73;
M-1 to K-72; M-1 to P-71; M-1 to D-70; M-1 to T-69; M-1 to S-68;
M-1 to A-67; M-1 to Q-66; M-1 to S-65; M-1 to L-64; M-1 to A-63;
M-1 to K-62; M-1 to L-61; M-1 to L-60; M-1 to G-59; M-1 to E-58;
M-1 to L-57; M-1 to S-56; M-1 to S-55; M-1 to H-54; M-1 to S-53;
M-1 to K-52; M-1 to F-51; M-1 to L-50; M-1 to R-49; M-1 to Q-48;
M-1 to L-47; M-1 to L-46; M-1 to Q-45; M-1 to Y-44; M-1 to L-43;
M-1 to D-42; M-1 to P-41; M-1 to D-40; M-1 to R-39; M-1 to K-38;
M-1 to S-37; M-1 to R-36; M-1 to G-35; M-1 to G-34; M-1 to G-33;
M-1 to P-32; M-1 to V-31; M-1 to V-30; M-1 to E-29; M-1 to E-28;
M-1 to Q-27; M-1 to P-26; M-1 to E-25; M-1 to K-24; M-1 to C-23;
M-1 to V-22; M-1 to A-21; M-1 to G-20; M-1 to F-19; M-1 to S-18;
M-1 to Q-17; M-1 to A-16; M-1 to L-15; M-1 to S-14; M-1 to F-13;
M-1 to A-12; M-1 to L-11; M-1 to 1-10; M-1 to A-9; M-1 to T-8; M-1
to F-7; M-1 to L-6 of the neurokinin B sequence of SEQ ID NO:2.
[0086] The invention also provides antibodies that bind
polypeptides having one or more amino acids deleted from both the
amino and the carboxyl termini of a neurokinin B polypeptide, which
may be described generally as having residues n.sup.1-m.sup.1 or
n.sup.1-m.sup.2 of SEQ ID NO:2, where n.sup.1, m.sup.1, and m.sup.2
are integers as described above.
[0087] The present application is also directed to antibodies that
bind proteins containing polypeptides at least 90%, 95%, 96%, 97%,
98% or 99% identical to the neurokinin B polypeptide sequence set
forth herein as n.sup.1-m.sup.1 or n.sup.1-m.sup.2. In preferred
embodiments, the present invention encompasses antibodies that bind
proteins containing polypeptides at least 90%, 95%, 96%, 97%, 98%
or 99% identical to polypeptides having the amino acid sequence of
the specific neurokinin B N- and/or C-terminal deletions recited
herein.
[0088] In certain preferred embodiments, antibodies of the
invention bind neurokinin B fusion proteins as described above
wherein the neurokinin B portion of the fusion protein are those
described as n.sup.1-m.sup.1 or n.sup.1-m.sup.2 herein.
[0089] Preferably, antibodies of the present invention bind
fragments of neurokinin B comprising, or alternatively consisting
of, the mature protein; i.e., residues 81-90 of SEQ ID NO:2.
[0090] It will be recognized in the art that some amino acid
sequence of neurokinin B can be varied without significant effect
of the structure or function of the protein. If such differences in
sequence are contemplated, it should be remembered that there will
be critical areas on the protein, which determine activity. Such
areas will usually comprise residues which make up the ligand
binding site or which form tertiary structures which affect these
domains.
[0091] Thus, the invention further includes antibodies that bind
variations of the neurokinin B protein which show substantial
neurokinin B protein activity or which include regions of
neurokinin B such as the protein fragments discussed below. Such
mutants include deletions, insertions, inversions, repeats, and
type substitution. Guidance concerning which amino acid changes are
likely to be phenotypically silent can be found in Bowie, J. U. et
al., Science 247:1306-1310 (1990).
[0092] Thus, antibodies of the present invention may bind a
fragment, derivative, or analog of the polypeptide of SEQ ID NO:2,
or that encoded by the cDNA in ATCC.TM. deposit 97922 and/or
ATCC.TM. Deposit No. 97375. Such fragments, variants or derivatives
may be (i) one in which at least one or more of the amino acid
residues are substituted with a conserved or non-conserved amino
acid residue (preferably a conserved amino acid residue(s), and
more preferably at least one but less than ten conserved amino acid
residues) and such substituted amino acid residue may or may not be
one encoded by the genetic code, or (ii) one in which one or more
of the amino acid residues includes a substituent group, or (iii)
one in which the mature polypeptide is fused with another compound,
such as a compound to increase the half-life of the polypeptide
(for example, polyethylene glycol), or (iv) one in which the
additional amino acids are fused to the mature polypeptide, such as
an IgG Fc fusion region peptide or leader or secretory sequence or
a sequence which is employed for purification of the mature
polypeptide or a proprotein sequence. Such fragments, derivatives
and analogs are deemed to be within the scope of those skilled in
the art from the teachings herein.
[0093] Of particular interest are substitutions of charged amino
acids with another charged amino acid and with neutral or
negatively charged amino acids. The latter results in proteins with
reduced positive charge to improve the characteristics of the
neurokinin B protein. The prevention of aggregation is highly
desirable. Aggregation of proteins not only results in a loss of
activity but can also be problematic when preparing pharmaceutical
formulations, because they can be immunogenic. (Pinckard et al.,
Clin Exp. Immunol 2:331-340 (1967); Robbins et al., Diabetes
36:838-845 (1987); Cleland et al. Crit. Rev. Therapeutic Drug
Carrier Systems 10:307-377 (1993)).
[0094] The replacement of amino acids can also change the
selectivity of binding to cell surface receptors. Ostade et al.,
Nature 361:266-268 (1993) describes certain mutations resulting in
selective binding of TNF-alpha to only one of the two known types
of TNF receptors. Thus, the antibodies of the present invention may
bind a neurokinin B polypeptide that contains one or more amino
acid substitutions, deletions or additions, either from natural
mutations or human manipulation.
[0095] As indicated, changes are preferably of a minor nature, such
as conservative amino acid substitutions that do not significantly
affect the folding or activity of the protein (see Table 2).
TABLE-US-00002 TABLE 2 Conservative Amino Acid Substitutions.
Aromatic Phenylalanine Tryptophan Tyrosine Hydrophobic Leucine
Isoleucine Valine Polar Glutamine Asparagine Basic Arginine Lysine
Histidine Acidic Aspartic Acid Glutamic Acid Small Alanine Serine
Threonine Methionine Glycine
[0096] In specific embodiments, the number of substitutions,
additions or deletions in the amino acid sequence of SEQ ID NO:2
and/or any of the polypeptide fragments described herein is 1-10,
5-10, 1-5, 1-3 or 1-2.
[0097] In specific embodiments, the antibodies of the invention
bind neurokinin B polypeptides or fragments or variants thereof
(especially a fragment comprising or alternatively consisting of,
the mature form of neurokinin B), that contains any one or more of
the following conservative mutations in neurokinin B: M1 replaced
with A, G, I, L, S, T, or V; R2 replaced with H, or K; I3 replaced
with A, G, L, S, T, M, or V; M4 replaced with A, G, I, L, S, T, or
V; L5 replaced with A, G, I, S, T, M, or V; L6 replaced with A, G,
I, S, T, M, or V; F7 replaced with W, or Y; T8 replaced with A, G,
I, L, S, M, or V; A9 replaced with G, I, L, S, T, M, or V; I10
replaced with A, G, L, S, T, M, or V; L11 replaced with A, G, I, S,
T, M, or V; A12 replaced with G, I, L, S, T, M, or V; F13 replaced
with W, or Y; S14 replaced with A, G, I, L, T, M, or V; L15
replaced with A, G, I, S, T, M, or V; A16 replaced with G, I, L, S,
T, M, or V; Q17 replaced with N; S18 replaced with A, G, I, L, T,
M, or V; F19 replaced with W, or Y; G20 replaced with A, I, L, S,
T, M, or V; A21 replaced with G, I, L, S, T, M, or V; V22 replaced
with A, G, I, L, S, T, or M; K24 replaced with H, or R; E25
replaced with D; Q27 replaced with N; E28 replaced with D; E29
replaced with D; V30 replaced with A, G, I, L, S, T, or M; V31
replaced with A, G, I, L, S, T, or M; G33 replaced with A, I, L, S,
T, M, or V; G34 replaced with A, I, L, S, T, M, or V; G35 replaced
with A, I, L, S, T, M, or V; R36 replaced with H, or K; S37
replaced with A, G, I, L, T, M, or V; K38 replaced with H, or R;
R39 replaced with H, or K; D40 replaced with E; D42 replaced with
E; L43 replaced with A, G, I, S, T, M, or V; Y44 replaced with F,
or W; Q45 replaced with N; L46 replaced with A, G, I, S, T, M, or
V; L47 replaced with A, G, I, S, T, M, or V; Q48 replaced with N;
R49 replaced with H, or K; L50 replaced with A, G, I, S, T, M, or
V; F51 replaced with W, or Y; K52 replaced with H, or R; S53
replaced with A, G, I, L, T, M, or V; H54 replaced with K, or R;
S55 replaced with A, G, I, L, T, M, or V; S56 replaced with A, G,
I, L, T, M, or V; L57 replaced with A, G, I, S, T, M, or V; E58
replaced with D; G59 replaced with A, I, L, S, T, M, or V; L60
replaced with A, G, I, S, T, M, or V; L61 replaced with A, G, I, S,
T, M, or V; K62 replaced with H, or R; A63 replaced with G, I, L,
S, T, M, or V; L64 replaced with A, G, I, S, T, M, or V; S65
replaced with A, G, I, L, T, M, or V; Q66 replaced with N; A67
replaced with G, I, L, S, T, M, or V; S68 replaced with A, G, I, L,
T, M, or V; T69 replaced with A, G, I, L, S, M, or V; D70 replaced
with E; K72 replaced with H, or R; E73 replaced with D; S74
replaced with A, G, I, L, T, M, or V; T75 replaced with A, G, I, L,
S, M, or V; S76 replaced with A, G, I, L, T, M, or V; E78 replaced
with D; K79 replaced with H, or R; R80 replaced with H, or K; D81
replaced with E; M82 replaced with A, G, I, L, S, T, or V; H83
replaced with K, or R; D84 replaced with E; F85 replaced with W, or
Y; F86 replaced with W, or Y; V87 replaced with A, G, I, L, S, T,
or M; G88 replaced with A, I, L, S, T, M, or V; L89 replaced with
A, G, I, S, T, M, or V; M90 replaced with A, G, I, L, S, T, or V;
G91 replaced with A, I, L, S, T, M, or V; K92 replaced with H, or
R; R93 replaced with H, or K; S94 replaced with A, G, I, L, T, M,
or V; V95 replaced with A, G, I, L, S, T, or M; Q96 replaced with
N; D98 replaced with E; S99 replaced with A, G, I, L, T, M, or V;
T101 replaced with A, G, I, L, S, M, or V; D102 replaced with E;
V103 replaced with A, G, I, L, S, T, or M; N104 replaced with Q;
Q105 replaced with N; E106 replaced with D; N107 replaced with Q;
V108 replaced with A, G, I, L, S, T, or M; S110 replaced with A, G,
I, L, T, M, or V; F111 replaced with W, or Y; G112 replaced with A,
I, L, S, T, M, or V; I113 replaced with A, G, L, S, T, M, or V;
L114 replaced with A, G, I, S, T, M, or V; K115 replaced with H, or
R; Y116 replaced with F, or W; R119 replaced with H, or K; A120
replaced with G, I, L, S, T, M, or V; E121 replaced with D of SEQ
ID NO:2.
[0098] In specific embodiments, the antibodies of the invention
bind neurokinin B polypeptides or fragments or variants thereof
(especially a fragment comprising or alternatively consisting of,
the mature form of neurokinin B), that contains any one or more of
the following non-conservative mutations in neurokinin B: M1
replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; R2 replaced
with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; I3
replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; M4 replaced
with D, E, H, K, R, N, Q, F, W, Y, P, or C; L5 replaced with D, E,
H, K, R, N, Q, F, W, Y, P, or C; L6 replaced with D, E, H, K, R, N,
Q, F, W, Y, P, or C; F7 replaced with D, E, H, K, R, N, Q, A, G, I,
L, S, T, M, V, P, or C; T8 replaced with D, E, H, K, R, N, Q, F, W,
Y, P, or C; A9 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C;
I10 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L11
replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; A12 replaced
with D, E, H, K, R, N, Q, F, W, Y, P, or C; F13 replaced with D, E,
H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C; S14 replaced with
D, E, H, K, R, N, Q, F, W, Y, P, or C; L15 replaced with D, E, H,
K, R, N, Q, F, W, Y, P, or C; A16 replaced with D, E, H, K, R, N,
Q, F, W, Y, P, or C; Q17 replaced with D, E, H, K, R, A, G, I, L,
S, T, M, V, F, W, Y, P, or C; S18 replaced with D, E, H, K, R, N,
Q, F, W, Y, P, or C; F19 replaced with D, E, H, K, R, N, Q, A, G,
I, L, S, T, M, V, P, or C; G20 replaced with D, E, H, K, R, N, Q,
F, W, Y, P, or C; A21 replaced with D, E, H, K, R, N, Q, F, W, Y,
P, or C; V22 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C;
C23 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F,
W, Y, or P; K24 replaced with D, E, A, G, I, L, S, T, M, V, N, Q,
F, W, Y, P, or C; E25 replaced with H, K, R, A, G, I, L, S, T, M,
V, N, Q, F, W, Y, P, or C; P26 replaced with D, E, H, K, R, A, G,
I, L, S, T, M, V, N, Q, F, W, Y, or C; Q27 replaced with D, E, H,
K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; E28 replaced with
H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; E29
replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or
C; V30 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; V31
replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; P32 replaced
with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C;
G33 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G34
replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G35 replaced
with D, E, H, K, R, N, Q, F, W, Y, P, or C; R36 replaced with D, E,
A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S37 replaced with
D, E, H, K, R, N, Q, F, W, Y, P, or C; K38 replaced with D, E, A,
G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; R39 replaced with D,
E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D40 replaced
with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; P41
replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y,
or C; D42 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F,
W, Y, P, or C; L43 replaced with D, E, H, K, R, N, Q, F, W, Y, P,
or C; Y44 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M,
V, P, or C; Q45 replaced with D, E, H, K, R, A, G, I, L, S, T, M,
V, F, W, Y, P, or C; L46 replaced with D, E, H, K, R, N, Q, F, W,
Y, P, or C; L47 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or
C; Q48 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W,
Y, P, or C; R49 replaced with D, E, A, G, I, L, S, T, M, V, N, Q,
F, W, Y, P, or C; L50 replaced with D, E, H, K, R, N, Q, F, W, Y,
P, or C; F51 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T,
M, V, P, or C; K52 replaced with D, E, A, G, I, L, S, T, M, V, N,
Q, F, W, Y, P, or C; S53 replaced with D, E, H, K, R, N, Q, F, W,
Y, P, or C; H54 replaced with D, E, A, G, I, L, S, T, M, V, N, Q,
F, W, Y, P, or C; S55 replaced with D, E, H, K, R, N, Q, F, W, Y,
P, or C; S56 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C;
L57 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; E58
replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or
C; G59 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L60
replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L61 replaced
with D, E, H, K, R, N, Q, F, W, Y, P, or C; K62 replaced with D, E,
A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; A63 replaced with
D, E, H, K, R, N, Q, F, W, Y, P, or C; L64 replaced with D, E, H,
K, R, N, Q, F, W, Y, P, or C; S65 replaced with D, E, H, K, R, N,
Q, F, W, Y, P, or C; Q66 replaced with D, E, H, K, R, A, G, I, L,
S, T, M, V, F, W, Y, P, or C; A67 replaced with D, E, H, K, R, N,
Q, F, W, Y, P, or C; S68 replaced with D, E, H, K, R, N, Q, F, W,
Y, P, or C; T69 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or
C; D70 replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W,
Y, P, or C; P71 replaced with D, E, H, K, R, A, G, I, L, S, T, M,
V, N, Q, F, W, Y, or C; K72 replaced with D, E, A, G, I, L, S, T,
M, V, N, Q, F, W, Y, P, or C; E73 replaced with H, K, R, A, G, I,
L, S, T, M, V, N, Q, F, W, Y, P, or C; S74 replaced with D, E, H,
K, R, N, Q, F, W, Y, P, or C; T75 replaced with D, E, H, K, R, N,
Q, F, W, Y, P, or C; S76 replaced with D, E, H, K, R, N, Q, F, W,
Y, P, or C; P77 replaced with D, E, H, K, R, A, G, I, L, S, T, M,
V, N, Q, F, W, Y, or C; E78 replaced with H, K, R, A, G, I, L, S,
T, M, V, N, Q, F, W, Y, P, or C; K79 replaced with D, E, A, G, I,
L, S, T, M, V, N, Q, F, W, Y, P, or C; R80 replaced with D, E, A,
G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D81 replaced with H,
K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; M82 replaced
with D, E, H, K, R, N, Q, F, W, Y, P, or C; H83 replaced with D, E,
A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; D84 replaced with
H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; F85
replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C;
F86 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P,
or C; V87 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; G88
replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L89 replaced
with D, E, H, K, R, N, Q, F, W, Y, P, or C; M90 replaced with D, E,
H, K, R, N, Q, F, W, Y, P, or C; G91 replaced with D, E, H, K, R,
N, Q, F, W, Y, P, or C; K92 replaced with D, E, A, G, I, L, S, T,
M, V, N, Q, F, W, Y, P, or C; R93 replaced with D, E, A, G, I, L,
S, T, M, V, N, Q, F, W, Y, P, or C; S94 replaced with D, E, H, K,
R, N, Q, F, W, Y, P, or C; V95 replaced with D, E, H, K, R, N, Q,
F, W, Y, P, or C; Q96 replaced with D, E, H, K, R, A, G, I, L, S,
T, M, V, F, W, Y, P, or C; P97 replaced with D, E, H, K, R, A, G,
I, L, S, T, M, V, N, Q, F, W, Y, or C; D98 replaced with H, K, R,
A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; S99 replaced with
D, E, H, K, R, N, Q, F, W, Y, P, or C; P100 replaced with D, E, H,
K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, or C; T101 replaced
with D, E, H, K, R, N, Q, F, W, Y, P, or C; D102 replaced with H,
K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; V103 replaced
with D, E, H, K, R, N, Q, F, W, Y, P, or C; N104 replaced with D,
E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; Q105 replaced
with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W, Y, P, or C; E106
replaced with H, K, R, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or
C; N107 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, F, W,
Y, P, or C; V108 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or
C; P109 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q,
F, W, Y, or C; S110 replaced with D, E, H, K, R, N, Q, F, W, Y, P,
or C; F111 replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M,
V, P, or C; G112 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or
C; I113 replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; L114
replaced with D, E, H, K, R, N, Q, F, W, Y, P, or C; K115 replaced
with D, E, A, G, I, L, S, T, M, V, N, Q, F, W, Y, P, or C; Y116
replaced with D, E, H, K, R, N, Q, A, G, I, L, S, T, M, V, P, or C;
P117 replaced with D, E, H, K, R, A, G, I, L, S, T, M, V, N, Q, F,
W, Y, or C; P118 replaced with D, E, H, K, R, A, G, I, L, S, T, M,
V, N, Q, F, W, Y, or C; R119 replaced with D, E, A, G, I, L, S, T,
M, V, N, Q, F, W, Y, P, or C; A120 replaced with D, E, H, K, R, N,
Q, F, W, Y, P, or C; E121 replaced with H, K, R, A, G, I, L, S, T,
M, V, N, Q, F, W, Y, P, or C of SEQ ID NO:2.
[0099] Amino acids in the neurokinin B protein of the present
invention that are essential for function can be identified by
methods known in the art, such as site-directed mutagenesis or
alanine-scanning mutagenesis (Cunningham and Wells, Science
244:1081-1085 (1989)). The latter procedure introduces single
alanine mutations at every residue in the molecule. The resulting
mutant molecules are then tested for biological activity such as
receptor binding. Sites that are critical for ligand-receptor
binding can also be determined by structural analysis such as
crystallization, nuclear magnetic resonance or photoaffinity
labeling (Smith et al., J. Mol. Biol. 224:899-904 (1992) and de Vos
et al. Science 255:306-312 (1992)). In preferred embodiments,
antibodies of the present invention bind regions of neurokinin B
that are essential for neurokinin B function. In other preferred
embodiments, antibodies of the present invention bind regions of
neurokinin B that are essential for neurokinin B function and
inhibit or abolish neurokinin B function. In other preferred
embodiments, antibodies of the present invention bind regions of
neurokinin B that are essential for neurokinin B function and
enhance neurokinin B function.
[0100] Additionally, protein engineering may be employed to improve
or alter the characteristics of neurokinin B polypeptides.
Recombinant DNA technology known to those skilled in the art can be
used to create novel mutant proteins or muteins including single or
multiple amino acid substitutions, deletions, additions or fusion
proteins. Such modified polypeptides can show, e.g., enhanced
activity or increased stability. In addition, they may be purified
in higher yields and show better solubility than the corresponding
natural polypeptide, at least under certain purification and
storage conditions. Antibodies of the present invention may bind
such modified neurokinin B polypeptides.
[0101] Non-naturally occurring variants of neurokinin B may be
produced using art-known mutagenesis techniques, which include, but
are not limited to oligonucleotide mediated mutagenesis, alanine
scanning, PCR mutagenesis, site directed mutagenesis (see e.g.,
Carter et al., Nucl. Acids Res. 13:4331 (1986); and Zoller et al.,
Nucl. Acids Res. 10:6487 (1982)), cassette mutagenesis (see e.g.,
Wells et al., Gene 34:315 (1985)), restriction selection
mutagenesis (see e.g., Wells et al, Philos. Trans. R. Soc. London
SerA 317:415 (1986)).
[0102] Thus, the invention also encompasses antibodies that bind
neurokinin B derivatives and analogs that have one or more amino
acid residues deleted, added, and/or substituted to generate
neurokinin B polypeptides that have better binding activity, better
therapeutic activity, are expressed better, or are better suited to
scale up, etc., in the host cells chosen. For example, cysteine
residues can be deleted or substituted with another amino acid
residue in order to eliminate disulfide bridges; N-linked
glycosylation sites can be altered or eliminated to achieve, for
example, expression of a homogeneous product that is more easily
recovered and purified from yeast hosts which are known to
hyperglycosylate N-linked sites. To this end, a variety of amino
acid substitutions at one or both of the first or third amino acid
positions on any one or more of the glycosylation recognition
sequences in the neurokinin B polypeptides and/or an amino acid
deletion at the second position of any one or more such recognition
sequences will prevent glycosylation of the neurokinin B at the
modified tripeptide sequence (see, e.g., Miyajimo et al., EMBO J
5(6): 1193-1197). Additionally, one or more of the amino acid
residues of neurokinin B polypeptides (e.g., arginine and lysine
residues) may be deleted or substituted with another residue to
eliminate undesired processing by proteases such as, for example,
furins or kexins.
Antibodies of the Invention May Bind Modified Neurokinin B
Polypeptides
[0103] It is specifically contemplated that antibodies of the
present invention may bind modified forms of neurokinin B
protein.
[0104] In specific embodiments, antibodies of the present invention
bind neurokinin B polypeptides (such as those described above)
including, but not limited to naturally purified neurokinin B
polypeptides, neurokinin B polypeptides produced by chemical
synthetic procedures, and neurokinin B polypeptides produced by
recombinant techniques from a prokaryotic or eukaryotic host,
including, for example, bacterial, yeast, higher plant, insect and
mammalian cells using, for example, the recombinant compositions
and methods described above. Depending upon the host employed in a
recombinant production procedure, the polypeptides may be
glycosylated or non-glycosylated. In addition, neurokinin B
polypeptides may also include an initial modified methionine
residue, in some cases as a result of host-mediated processes.
[0105] In addition, neurokinin B proteins that antibodies of the
present invention may bind can be chemically synthesized using
techniques known in the art (e.g., see Creighton, Proteins:
Structures and Molecular Principles, W.H. Freeman & Co., N.Y.
(1983), and Hunkapiller, et al., Nature 310:105-111 (1984)). For
example, a peptide corresponding to a fragment of a neurokinin B
polypeptide can be synthesized by use of a peptide synthesizer.
Furthermore, if desired, nonclassical amino acids or chemical amino
acid analogs can be introduced as a substitution or addition into
the neurokinin B polypeptide sequence. Non-classical amino acids
include, but are not limited to, to the D-isomers of the common
amino acids, 2,4-diaminobutyric acid, a-amino isobutyric acid,
4-aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx,
6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino
propionic acid, ornithine, norleucine, norvaline, hydroxyproline,
sarcosine, citrulline, homocitrulline, cysteic acid,
t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,
b-alanine, fluoro-amino acids, designer amino acids such as
b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids,
and amino acid analogs in general. Furthermore, the amino acid can
be D (dextrorotary) or L (levorotary).
[0106] The invention additionally, encompasses antibodies that bind
neurokinin B polypeptides which are differentially modified during
or after translation, e.g., by glycosylation, acetylation,
phosphorylation, amidation, derivatization by known
protecting/blocking groups, proteolytic cleavage, linkage to an
antibody molecule or other cellular ligand, etc. Any of numerous
chemical modifications may be carried out by known techniques,
including but not limited to, specific chemical cleavage by
cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease,
NaBH.sub.4, acetylation, formylation, oxidation, reduction,
metabolic synthesis in the presence of tunicamycin; etc.
[0107] Additional post-translational modifications to neurokinin B
polypeptides include, for example, e.g., N-linked or O-linked
carbohydrate chains, processing of N-terminal or C-terminal ends),
attachment of chemical moieties to the amino acid backbone,
chemical modifications of N-linked or O-linked carbohydrate chains,
and addition or deletion of an N-terminal methionine residue as a
result of procaryotic host cell expression. The polypeptides may
also be modified with a detectable label, such as an enzymatic,
fluorescent, isotopic or affinity label to allow for detection and
isolation of the protein.
[0108] Also provided by the invention are antibodies that bind
chemically modified derivatives of neurokinin B polypeptide which
may provide additional advantages such as increased solubility,
stability and circulating time of the polypeptide, or decreased
immunogenicity (see U.S. Pat. No. 4,179,337). The chemical moieties
for derivitization may be selected from water soluble polymers such
as polyethylene glycol, ethylene glycol/propylene glycol
copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and
the like. The polypeptides may be modified at random positions
within the molecule, or at predetermined positions within the
molecule and may include one, two, three or more attached chemical
moieties.
[0109] The polymer may be of any molecular weight, and may be
branched or unbranched. For polyethylene glycol, the preferred
molecular weight is between about 1 kDa and about 100 kDa (the term
"about" indicating that in preparations of polyethylene glycol,
some molecules will weigh more, some less, than the stated
molecular weight) for ease in handling and manufacturing. Other
sizes may be used, depending on the desired therapeutic profile
(e.g., the duration of sustained release desired, the effects, if
any on biological activity, the ease in handling, the degree or
lack of antigenicity and other known effects of the polyethylene
glycol to a therapeutic protein or analog). For example, the
polyethylene glycol may have an average molecular weight of about
200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000,
5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000,
10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000,
14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000,
18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000,
50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000,
90,000, 95,000, or 100,000 kDa.
[0110] As noted above, the polyethylene glycol may have a branched
structure. Branched polyethylene glycols are described, for
example, in U.S. Pat. No. 5,643,575; Morpurgo et al., Appl.
Biochem. Biotechnol. 56:59-72 (1996); Vorobjev et al., Nucleosides
Nucleotides 18:2745-2750 (1999); and Caliceti et al, Bioconjug.
Chem. 10:638-646 (1999), the disclosures of each of which are
incorporated herein by reference.
[0111] The polyethylene glycol molecules (or other chemical
moieties) should be attached to the protein with consideration of
effects on functional or antigenic domains of the protein. There
are a number of attachment methods available to those skilled in
the art, e.g., EP 0 401 384, herein incorporated by reference
(coupling PEG to G-CSF), see also Malik et al., Exp. Hematol.
20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl
chloride). For example, polyethylene glycol may be covalently bound
through amino acid residues via a reactive group, such as, a free
amino or carboxyl group. Reactive groups are those to which an
activated polyethylene glycol molecule may be bound. The amino acid
residues having a free amino group may include lysine residues and
the N-terminal amino acid residues; those having a free carboxyl
group may include aspartic acid residues, glutamic acid residues
and the C-terminal amino acid residue. Sulfhydryl groups may also
be used as a reactive group for attaching the polyethylene glycol
molecules. Preferred for therapeutic purposes is attachment at an
amino group, such as attachment at the N-terminus or lysine
group.
[0112] As suggested above, polyethylene glycol may be attached to
proteins via linkage to any of a number of amino acid residues. For
example, polyethylene glycol can be linked to a proteins via
covalent bonds to lysine, histidine, aspartic acid, glutamic acid,
or cysteine residues. One or more reaction chemistries may be
employed to attach polyethylene glycol to specific amino acid
residues (e.g., lysine, histidine, aspartic acid, glutamic acid, or
cysteine) of the protein or to more than one type of amino acid
residue (e.g., lysine, histidine, aspartic acid, glutamic acid,
cysteine and combinations thereof) of the protein.
[0113] One may specifically desire proteins chemically modified at
the N-terminus. Using polyethylene glycol as an illustration of the
present composition, one may select from a variety of polyethylene
glycol molecules (by molecular weight, branching, etc.), the
proportion of polyethylene glycol molecules to protein (or peptide)
molecules in the reaction mix, the type of pegylation reaction to
be performed, and the method of obtaining the selected N-terminally
pegylated protein. The method of obtaining the N-terminally
pegylated preparation (i.e., separating this moiety from other
monopegylated moieties if necessary) may be by purification of the
N-terminally pegylated material from a population of pegylated
protein molecules. Selective proteins chemically modified at the
N-terminus modification may be accomplished by reductive
alkylation, which exploits differential reactivity of different
types of primary amino groups (lysine versus the N-terminal)
available for derivatization in a particular protein. Under the
appropriate reaction conditions, substantially selective
derivatization of the protein at the N-terminus with a carbonyl
group containing polymer is achieved.
[0114] As indicated above, pegylation of the proteins of the
invention may be accomplished by any number of means. For example,
polyethylene glycol may be attached to the protein either directly
or by an intervening linker. Linkerless systems for attaching
polyethylene glycol to proteins are described in Delgado et al,
Crit. Rev. Thera. Drug Carrier Sys. 9:249-304 (1992); Francis et
al., Intern. J. of Hematol. 68:1-18 (1998); U.S. Pat. No.
4,002,531; U.S. Pat. No. 5,349,052; WO 95/06058; and WO 98/32466,
the disclosures of each of which are incorporated herein by
reference.
[0115] One system for attaching polyethylene glycol directly to
amino acid residues of proteins without an intervening linker
employs tresylated MPEG, which is produced by the modification of
monmethoxy polyethylene glycol (MPEG) using tresylchloride
(ClSO.sub.2CH.sub.2CF.sub.3). Upon reaction of protein with
tresylated MPEG, polyethylene glycol is directly attached to amine
groups of the protein. Thus, the invention includes
protein-polyethylene glycol conjugates produced by reacting
proteins of the invention with a polyethylene glycol molecule
having a 2,2,2-trifluoreothane sulphonyl group.
[0116] Polyethylene glycol can also be attached to proteins using a
number of different intervening linkers. For example, U.S. Pat. No.
5,612,460, the entire disclosure of which is incorporated herein by
reference, discloses urethane linkers for connecting polyethylene
glycol to proteins. Protein-polyethylene glycol conjugates wherein
the polyethylene glycol is attached to the protein by a linker can
also be produced by reaction of proteins with compounds such as
MPEG-succinimidylsuccinate, MPEG activated with
1,1'-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate,
MPEG-p-nitrophenolcarbonate, and various MPEG-succinate
derivatives. A number additional polyethylene glycol derivatives
and reaction chemistries for attaching polyethylene glycol to
proteins are described in WO 98/32466, the entire disclosure of
which is incorporated herein by reference. Pegylated protein
products produced using the reaction chemistries set out herein are
included within the scope of the invention.
[0117] The number of polyethylene glycol moieties attached to each
neurokinin B polypeptide (i.e., the degree of substitution) may
also vary. For example, the pegylated proteins of the invention may
be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15,
17, 20, or more polyethylene glycol molecules. Similarly, the
average degree of substitution within ranges such as 1-3, 2-4, 3-5,
4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16,
15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per
protein molecule. Methods for determining the degree of
substitution are discussed, for example, in Delgado et al., Crit.
Rev. Thera. Drug Carrier Sys. 9:249-304 (1992).
[0118] As mentioned the antibodies of the present invention may
bind neurokinin B polypeptides that are modified by either natural
processes, such as posttranslational processing, or by chemical
modification techniques, which are well known in the art. It will
be appreciated that the same type of modification may be present in
the same or varying degrees at several sites in a given neurokinin
B polypeptide. neurokinin B polypeptides may be branched, for
example, as a result of ubiquitination, and they may be cyclic,
with or without branching. Cyclic, branched, and branched cyclic
neurokinin B polypeptides may result from posttranslation natural
processes or may be made by synthetic methods. Modifications
include acetylation, acylation, ADP-ribosylation, amidation,
covalent attachment of flavin, covalent attachment of a heme
moiety, covalent attachment of a nucleotide or nucleotide
derivative, covalent attachment of a lipid or lipid derivative,
covalent attachment of phosphotidylinositol, cross-linking,
cyclization, disulfide bond formation, demethylation, formation of
covalent cross-links, formation of cysteine, formation of
pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI
anchor formation, hydroxylation, iodination, methylation,
myristoylation, oxidation, pegylation, proteolytic processing,
phosphorylation, prenylation, racemization, selenoylation,
sulfation, transfer-RNA mediated addition of amino acids to
proteins such as arginylation, and ubiquitination. (See, for
instance, PROTEINS--STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T.
E. Creighton, W. H. Freeman and Company, New York (1993);
POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson,
Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al.,
Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci
663:48-62 (1992)).
Antibodies that Specifically Bind Neurokinin B
[0119] In one embodiment, the invention provides antibodies (e.g.,
anti-neurokinin B antibodies comprising two heavy chains and two
light chains linked together by disulfide bridges) that
specifically bind a neurokinin B polypeptide (e.g., SEQ ID NO:2) or
fragments or variants thereof, wherein the amino acid sequence of
the heavy chain and the amino acid sequence of the light chain are
the same as the amino acid sequence of a heavy chain and a light
chain of an antibody expressed by one or more cell lines referred
to in Table 1. In another embodiment, the invention provides
antibodies (each consisting of two heavy chains and two light
chains linked together by disulfide bridges to form an antibody)
that specifically bind a neurokinin B polypeptide (e.g., SEQ ID
NO:2) or fragments or variants thereof, wherein the amino acid
sequence of the heavy chain or the amino acid sequence of the light
chain are the same as the amino acid sequence of a heavy chain or a
light chain of an antibody expressed by one or more cell lines
referred to in Table 1. Specific binding to neurokinin B
polypeptides may be determined by immunoassays known in the art or
described herein for assaying specific antibody-antigen binding.
Molecules comprising, or alternatively consisting of, fragments or
variants of these antibodies that specifically bind to neurokinin B
are also encompassed by the invention, as are nucleic acid
molecules encoding these antibodies molecules, fragments and/or
variants (e.g., SEQ ID NOs:3-21).
[0120] In one embodiment of the present invention, antibodies that
specifically bind to neurokinin B or a fragment or variant thereof,
comprise a polypeptide having the amino acid sequence a heavy chain
of an antibody expressed by at least one of the cell lines referred
to in Table 1 and/or a light chain of an antibody expressed by at
least one of the cell lines referred to in Table 1.
[0121] In another embodiment of the present invention, antibodies
that specifically bind to neurokinin B or a fragment or variant
thereof, comprise a polypeptide having the amino acid sequence of
any one of the VH domains of at least one of the scFvs referred to
in Table 1 and/or any one of the VL domains of at least one of the
scFvs referred to in Table 1. In preferred embodiments, antibodies
of the present invention comprise the amino acid sequence of a VH
domain and VL domain of the scFvs referred to in Table 1. Molecules
comprising, or alternatively consisting of, antibody fragments or
variants of the VH and/or VL domains of at least one of the scFvs
referred to in Table 1 that specifically bind to neurokinin B are
also encompassed by the invention, as are nucleic acid molecules
encoding these VH and VL domains, molecules, fragments and/or
variants.
[0122] The present invention also provides antibodies that
specifically bind to a polypeptide, or polypeptide fragment or
variant of neurokinin B, wherein said antibodies comprise, or
alternatively consist of, a polypeptide having an amino acid
sequence of any one, two, three, or more of the VH CDRs contained
in a VH domain of one or more scFvs referred to in Table 1. In
particular, the invention provides antibodies that specifically
bind neurokinin B, comprising, or alternatively consisting of, a
polypeptide having the amino acid sequence of a VH CDR1 contained
in a VH domain of one or more scFvs referred to in Table 1. In
another embodiment, antibodies that specifically bind neurokinin B,
comprise, or alternatively consist of, a polypeptide having the
amino acid sequence of a VH CDR2 contained in a VH domain of one or
more scFvs referred to in Table 1. In a preferred embodiment,
antibodies that specifically bind neurokinin B, comprise, or
alternatively consist of a polypeptide having the amino acid
sequence of a VH CDR3 contained in a VH domain of one or more scFvs
referred to in Table 1. Molecules comprising, or alternatively
consisting of, these antibodies, or antibody fragments or variants
thereof, that specifically bind to neurokinin B or a neurokinin B
fragment or variant thereof are also encompassed by the invention,
as are nucleic acid molecules encoding these antibodies, molecules,
fragments and/or variants (e.g., SEQ ID NOs:3-21).
[0123] The present invention also provides antibodies that
specifically bind to a polypeptide, or polypeptide fragment or
variant of neurokinin B, wherein said antibodies comprise, or
alternatively consist of, a polypeptide having an amino acid
sequence of any one, two, three, or more of the VL CDRs contained
in a VL domain of one or more scFvs referred to in Table 1. In
particular, the invention provides antibodies that specifically
bind neurokinin B, comprising, or alternatively consisting of, a
polypeptide having the amino acid sequence of a VL CDR1 contained
in a VL domain of one or more scFvs referred to in Table 1. In
another embodiment, antibodies that specifically bind neurokinin B,
comprise, or alternatively consist of, a polypeptide having the
amino acid sequence of a VL CDR2 contained in a VL domain of one or
more scFvs referred to in Table 1. In a preferred embodiment,
antibodies that specifically bind neurokinin B, comprise, or
alternatively consist of a polypeptide having the amino acid
sequence of a VL CDR3 contained in a VL domain of one or more scFvs
referred to in Table 1. Molecules comprising, or alternatively
consisting of, these antibodies, or antibody fragments or variants
thereof, that specifically bind to neurokinin B or a neurokinin B
fragment or variant thereof are also encompassed by the invention,
as are nucleic acid molecules encoding these antibodies, molecules,
fragments and/or variants (e.g., SEQ ID NOs:3-21).
[0124] The present invention also provides antibodies (including
molecules comprising, or alternatively consisting of, antibody
fragments or variants) that specifically bind to a neurokinin B
polypeptide or polypeptide fragment or variant of neurokinin B,
wherein said antibodies comprise, or alternatively consist of, one,
two, three, or more VH CDRs and one, two, three or more VL CDRs, as
contained in a VH domain or VL domain of one or more scFvs referred
to in Table 1. In particular, the invention provides for antibodies
that specifically bind to a polypeptide or polypeptide fragment or
variant of neurokinin B, wherein said antibodies comprise, or
alternatively consist of, a VH CDR1 and a VL CDR1, a VH CDR1 and a
VL CDR2, a VH CDR1 and a VL CDR3, a VH CDR2 and a VL CDR1, VH CDR2
and VL CDR2, a VH CDR2 and a VL CDR3, a VH CDR3 and a VH CDR1, a VH
CDR3 and a VL CDR2, a VH CDR3 and a VL CDR3, or any combination
thereof, of the VH CDRs and VL CDRs contained in a VH domain or VL
domain of one or more scFvs referred to in Table 1. In a preferred
embodiment, one or more of these combinations are from the same
scFv as disclosed in Table 1. Molecules comprising, or
alternatively consisting of, fragments or variants of these
antibodies, that specifically bind to neurokinin B are also
encompassed by the invention, as are nucleic acid molecules
encoding these antibodies, molecules, fragments or variants (e.g.,
SEQ ID NOs:3-21).
[0125] In other preferred embodiments, the invention provides
antibodies that competitively inhibit binding of an antibody
comprising a fragment (e.g., VH domain, VL domain, VHCDR1, VHCDR2,
VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or variant of an scFv referred
to in Table 1 to a neurokinin B polypeptide. In preferred
embodiments, the invention provides antibodies that which reduce
the binding of an antibody comprising a fragment (e.g., VH domain,
VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, or VLCDR3) or
variant of an scFv referred to in Table 1 to a Neurokinin B
polypeptide by between 1% and 10% in a competitive inhibition
assay. In preferred embodiments, the invention provides antibodies
that which reduce the binding of an antibody comprising a fragment
(e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1,
VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to
a neurokinin B polypeptide by between 1% and 10% in a competitive
inhibition assay.
[0126] In preferred embodiments, the invention provides antibodies
that which reduce the binding of an antibody comprising a fragment
(e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1,
VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to
a neurokinin B polypeptide by at least 10% and up to 20% in a
competitive inhibition assay.
[0127] In preferred embodiments, the invention provides antibodies
that which reduce the binding of an antibody comprising a fragment
(e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1,
VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to
a neurokinin B polypeptide by at least 20% and up to 30% in a
competitive inhibition assay.
[0128] In preferred embodiments, the invention provides antibodies
that which reduce the binding of an antibody comprising a fragment
(e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1,
VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to
a neurokinin B polypeptide by at least 30% and up to 40% in a
competitive inhibition assay.
[0129] In preferred embodiments, the invention provides antibodies
that which reduce the binding of an antibody comprising a fragment
(e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1,
VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to
a neurokinin B polypeptide by at least 40% and up to 50% in a
competitive inhibition assay.
[0130] In preferred embodiments, the invention provides antibodies
that which reduce the binding of an antibody comprising a fragment
(e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1,
VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to
a neurokinin B polypeptide by at least 50% and up to 60% in a
competitive inhibition assay.
[0131] In preferred embodiments, the invention provides antibodies
that which reduce the binding of an antibody comprising a fragment
(e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1,
VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to
a neurokinin B polypeptide by at least 60% and up to 70% in a
competitive inhibition assay.
[0132] In preferred embodiments, the invention provides antibodies
that which reduce the binding of an antibody comprising a fragment
(e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1,
VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to
a neurokinin B polypeptide by at least 70% and up to 80% in a
competitive inhibition assay.
[0133] In preferred embodiments, the invention provides antibodies
that which reduce the binding of an antibody comprising a fragment
(e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1,
VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to
a neurokinin B polypeptide by at least 80% and up to 90% in a
competitive inhibition assay.
[0134] In preferred embodiments, the invention provides antibodies
that which reduce the binding of an antibody comprising a fragment
(e.g., VH domain, VL domain, VHCDR1, VHCDR2, VHCDR3, VLCDR1,
VLCDR2, or VLCDR3) or variant of an scFv referred to in Table 1 to
a neurokinin B polypeptide by at least 90% and up to 100% in a
competitive inhibition assay.
Nucleic Acid Molecules Encoding Anti-Neurokinin B Antibodies
[0135] The present invention also provides for nucleic acid
molecules, generally isolated, encoding an antibody of the
invention (including molecules comprising, or alternatively
consisting of, antibody fragments or variants thereof). In specific
embodiments, the nucleic acid molecules encoding an antibody of the
invention comprise, or alternatively consist of SEQ ID NOs:3-21 or
fragments or variants thereof.
[0136] In a specific embodiment, a nucleic acid molecule of the
invention encodes an antibody (including molecules comprising, or
alternatively consisting of, antibody fragments or variants
thereof), comprising, or alternatively consisting of, a VH domain
having an amino acid sequence of any one of the VH domains of at
least one of the scFvs referred to in Table 1 and a VL domain
having an amino acid sequence of VL domain of at least one of the
scFvs referred to in Table 1. In another embodiment, a nucleic acid
molecule of the invention encodes an antibody (including molecules
comprising, or alternatively consisting of, antibody fragments or
variants thereof), comprising, or alternatively consisting of, a VH
domain having an amino acid sequence of any one of the VH domains
of at least one of the scFvs referred to in Table 1 or a VL domain
having an amino acid sequence of a VL domain of at least one of the
scFvs referred to in Table 1.
[0137] The present invention also provides antibodies that
comprise, or alternatively consist of, variants (including
derivatives) of the antibody molecules (e.g., the VH domains and/or
VL domains) described herein, which antibodies specifically bind to
neurokinin B or fragment or variant. Standard techniques known to
those of skill in the art can be used to introduce mutations in the
nucleotide sequence encoding a molecule of the invention,
including, for example, site-directed mutagenesis and PCR-mediated
mutagenesis which result in amino acid substitutions. Preferably,
the variants (including derivatives) encode less than 50 amino acid
substitutions, less than 40 amino acid substitutions, less than 30
amino acid substitutions, less than 25 amino acid substitutions,
less than 20 amino acid substitutions, less than 15 amino acid
substitutions, less than 10 amino acid substitutions, less than 5
amino acid substitutions, less than 4 amino acid substitutions,
less than 3 amino acid substitutions, or less than 2 amino acid
substitutions relative to the reference VH domain, VHCDR1, VHCDR2,
VHCDR3, VL domain, VLCDR1, VLCDR2, or VLCDR3. A "conservative amino
acid substitution" is one in which the amino acid residue is
replaced with an amino acid residue having a side chain with a
similar charge. Families of amino acid residues having side chains
with similar charges have been defined in the art. These families
include amino acids with basic side chains (e.g., lysine, arginine,
histidine), acidic side chains (e.g., aspartic acid, glutamic
acid), uncharged polar side chains (e.g., glycine, asparagine,
glutamine, serine, threonine, tyrosine, cysteine), nonpolar side
chains (e.g., alanine, valine, leucine, isoleucine, proline,
phenylalanine, methionine, tryptophan), beta-branched side chains
(e.g., threonine, valine, isoleucine) and aromatic side chains
(e.g., tyrosine, phenylalanine, tryptophan, histidine).
Alternatively, mutations can be introduced randomly along all or
part of the coding sequence, such as by saturation mutagenesis, and
the resultant mutants can be screened for biological activity to
identify mutants that retain activity (e.g., the ability to bind a
neurokinin B receptor).
[0138] For example, it is possible to introduce mutations only in
framework regions or only in CDR regions of an antibody molecule.
Introduced mutations may be silent or neutral missense mutations,
i.e., have no, or little, effect on an antibody's ability to bind
antigen. These types of mutations may be useful to optimize codon
usage, or improve a hybridoma's antibody production. Alternatively,
non-neutral missense mutations may alter an antibody's ability to
bind antigen. The location of most silent and neutral missense
mutations is likely to be in the framework regions, while the
location of most non-neutral missense mutations is likely to be in
CDR, though this is not an absolute requirement. One of skill in
the art would be able to design and test mutant molecules with
desired properties such as no alteration in antigen binding
activity or alteration in binding activity (e.g., improvements in
antigen binding activity or change in antibody specificity).
Following mutagenesis, the encoded protein may routinely be
expressed and the functional and/or biological activity of the
encoded protein, (e.g., ability to specifically bind a neurokinin B
receptor) can be determined using techniques described herein or by
routinely modifying techniques known in the art.
[0139] In a specific embodiment, an antibody of the invention
(including a molecule comprising, or alternatively consisting of,
an antibody fragment or variant thereof), that specifically binds
neurokinin B polypeptides or fragments or variants thereof,
comprises, or alternatively consists of, an amino acid sequence
encoded by a nucleotide sequence that hybridizes to a nucleotide
sequence that is complementary to that encoding one of the VH or VL
domains of one or more scFvs referred to in Table 1 under stringent
conditions, e.g., hybridization to filter-bound DNA in 6.times.
sodium chloride/sodium citrate (SSC) at about 45.degree. C.
followed by one or more washes in 0.2.times.SSC/0.1% SDS at about
50-65.degree. C., under highly stringent conditions, e.g.,
hybridization to filter-bound nucleic acid in 6.times.SSC at about
45.degree. C. followed by one or more washes in 0.1.times.SSC/0.2%
SDS at about 68.degree. C., or under other stringent hybridization
conditions which are known to those of skill in the art (see, for
example, Ausubel, F. M. et al., eds., 1989, Current Protocols in
Molecular Biology, Vol. I, Green Publishing Associates, Inc. and
John Wiley & Sons, Inc., New York at pages 6.3.1-6.3.6 and
2.10.3). Nucleic acid molecules encoding these antibodies are also
encompassed by the invention.
[0140] It is well known within the art that polypeptides, or
fragments or variants thereof, with similar amino acid sequences
often have similar structure and many of the same biological
activities. Thus, in one embodiment, an antibody (including a
molecule comprising, or alternatively consisting of, an antibody
fragment or variant thereof), that specifically binds to a
neurokinin B polypeptide or fragments or variants of a neurokinin B
polypeptide, comprises, or alternatively consists of, a VH domain
having an amino acid sequence that is at least 35%, at least 40%,
at least 45%, at least 50%, at least 55%, at least 60%, at least
65%, at least 70%, at least 75%, at least 80%, at least 85%, at
least 90%, at least 95%, or at least 99% identical, to the amino
acid sequence of a VH domain of at least one of the scFvs referred
to in Table 1.
[0141] In another embodiment, an antibody (including a molecule
comprising, or alternatively consisting of, an antibody fragment or
variant thereof), that specifically binds to a neurokinin B
polypeptide or fragments or variants of a neurokinin B polypeptide,
comprises, or alternatively consists of, a VL domain having an
amino acid sequence that is at least 35%, at least 40%, at least
45%, at least 50%, at least 55%, at least 60%, at least 65%, at
least 70%, at least 75%, at least 80%, at least 85%, at least 90%,
at least 95%, or at least 99% identical, to the amino acid sequence
of a VL domain of at least one of the scFvs referred to in Table
1.
Methods of Producing Antibodies
[0142] Antibodies in accordance with the invention are preferably
prepared utilizing a phage scFv display library. Technologies
utilized for achieving the same are disclosed in the patents,
applications, and references disclosed herein.
[0143] In phage display methods, functional antibody domains are
displayed on the surface of phage particles, which carry the
polynucleotide sequences encoding them. In particular, DNA
sequences encoding VH and VL domains are amplified from animal cDNA
libraries (e.g., human or murine cDNA libraries of lymphoid
tissues) or synthetic cDNA libraries. The DNA encoding the VH and
VL domains are joined together by an scFv linker by PCR and cloned
into a phagemid vector (e.g., p CANTAB 6 or pComb 3 HSS). The
vector is electroporated in E. coli and the E. coli is infected
with helper phage. Phage used in these methods are typically
filamentous phage including fd and M13 and the VH and VL domains
are usually recombinantly fused to either the phage gene III or
gene VIII. Phage expressing an antigen binding domain that binds to
an antigen of interest (i.e., a neurokinin B polypeptide or a
fragment thereof) can be selected or identified with antigen, e.g.,
using labeled antigen or antigen bound or captured to a solid
surface or bead. Examples of phage display methods that can be used
to make the antibodies of the present invention include, but are
not limited to, those disclosed in Brinkman et al., J. Immunol.
Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods
184:177-186 (1995); Kettleborough et al., Eur. J. Immunol.
24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et
al., Advances in Immunology 57:191-280 (1994); PCT application No.
PCT/GB91/O1 134; PCT publications WO 90/02809; WO 91/10737; WO
92/01047; WO 92/18719; WO 93/11236; WO 95/15982; WO 95/20401;
WO97/13844; and U.S. Pat. Nos. 5,698,426; 5,223,409; 5,403,484;
5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908;
5,516,717; 5,780,225; 5,658,727; 5,735,743 and 5,969,108; each of
which is incorporated herein by reference in its entirety.
[0144] For some uses, such as for in vitro affinity maturation of
an antibody of the invention, it may be useful to express the VH
and VL domains of one or more scFvs referred to in Table 1 as
single chain antibodies or Fab fragments in a phage display
library. For example, the cDNAs encoding the VH and VL domains of
the scFvs referred to in Table 1 may be expressed in all possible
combinations using a phage display library, allowing for the
selection of VH/VL combinations that bind neurokinin B polypeptides
with preferred binding characteristics such as improved affinity or
improved off rates. Additionally, VH and VL domains--the CDR
regions of the VH and VL domains of the scFvs referred to in Table
1, in particular, may be mutated in vitro. Expression of VH and VL
domains with "mutant" CDRs in a phage display library allows for
the selection of VH/VL combinations that bind neurokinin B
polypeptides with preferred binding characteristics such as
improved affinity or improved off rates.
Additional Methods of Producing Antibodies
[0145] Antibodies of the invention (including antibody fragments or
variants) can be produced by any method known in the art. For
example, it will be appreciated that antibodies in accordance with
the present invention can be expressed in cell lines including, but
not limited to, myeloma cell lines and hybridoma cell lines.
Sequences encoding the cDNAs or genomic clones for the particular
antibodies can be used for transformation of a suitable mammalian
or nonmammalian host cells or to generate phage display libraries,
for example. Additionally, polypeptide antibodies of the invention
may be chemically synthesized or produced through the use of
recombinant expression systems.
[0146] One way to produce the antibodies of the invention would be
to clone the VH and/or VL domains of the scFvs referred to in Table
1. In order to isolate the VH and VL domains from bacteria
transfected with a vector containing the scFv, PCR primers
complementary to VH or VL nucleotide sequences (See Example 2), may
be used to amplify the VH and VL sequences. The PCR products may
then be cloned using vectors, for example, which have a PCR product
cloning site consisting of a 5' and 3' single T nucleotide
overhang, that is complementary to the overhanging single adenine
nucleotide added onto the 5' and 3' end of PCR products by many DNA
polymerases used for PCR reactions. The VH and VL domains can then
be sequenced using conventional methods known in the art.
Alternatively, the VH and VL domains may be amplified using vector
specific primers designed to amplify the entire scFv, (i.e., the VH
domain, linker and VL domain.)
[0147] The cloned VH and VL genes may be placed into one or more
suitable expression vectors. By way of non-limiting example, PCR
primers including VH or VL nucleotide sequences, a restriction
site, and a flanking sequence to protect the restriction site may
be used to amplify the VH or VL sequences. Utilizing cloning
techniques known to those of skill in the art, the PCR amplified VH
or VL domains may be cloned into vectors expressing the appropriate
immunoglobulin constant region, e.g., the human IgG1 or IgG4
constant region for VH domains, and the human kappa or lambda
constant regions for kappa and lambda VL domains, respectively.
Preferably, the vectors for expressing the VH or VL domains
comprise a promoter suitable to direct expression of the heavy and
light chains in the chosen expression system, a secretion signal, a
cloning site for the immunoglobulin variable domain, immunoglobulin
constant domains, and a selection marker such as neomycin. The VH
and VL domains may also be cloned into a single vector expressing
the necessary constant regions. The heavy chain conversion vectors
and light chain conversion vectors are then co-transfected into
cell lines to generate stable or transient cell lines that express
full-length antibodies, e.g., IgG, using techniques known to those
of skill in the art (See, for example, Guo et al., J. Clin.
Endocrinol. Metab. 82:925-31 (1997), and Ames et al., J. Immunol.
Methods 184:177-86 (1995), which are herein incorporated in their
entireties by reference).
[0148] The invention provides polynucleotides comprising, or
alternatively consisting of, a nucleotide sequence encoding an
antibody of the invention (including molecules comprising, or
alternatively consisting of, antibody fragments or variants
thereof). The invention also encompasses polynucleotides that
hybridize under high stringency, or alternatively, under
intermediate or lower stringency hybridization conditions, e.g., as
defined supra, to polynucleotides complementary to nucleic acids
having a polynucleotide sequence that encodes an antibody of the
invention or a fragment or variant thereof.
[0149] The polynucleotides may be obtained, and the nucleotide
sequence of the polynucleotides determined, by any method known in
the art. If the amino acid sequences of the VH domains, VL domains
and CDRs thereof, are known, nucleotide sequences encoding these
antibodies can be determined using methods well known in the art,
i.e., the nucleotide codons known to encode the particular amino
acids are assembled in such a way to generate a nucleic acid that
encodes the antibody, of the invention. Such a polynucleotide
encoding the antibody may be assembled from chemically synthesized
oligonucleotides (e.g., as described in Kutmeier et al.,
BioTechniques 17:242 (1994)), which, briefly, involves the
synthesis of overlapping oligonucleotides containing portions of
the sequence encoding the antibody, annealing and ligating of those
oligonucleotides, and then amplification of the ligated
oligonucleotides by PCR.
[0150] Alternatively, a polynucleotide encoding an antibody
(including molecules comprising, or alternatively consisting of,
antibody fragments or variants thereof) may be generated from
nucleic acid from a suitable source. If a clone containing a
nucleic acid encoding a particular antibody is not available, but
the sequence of the antibody molecule is known, a nucleic acid
encoding the immunoglobulin may be chemically synthesized or
obtained from a suitable source (e.g., an antibody cDNA library, or
a cDNA library generated from, or nucleic acid, preferably poly
A.sup.+ RNA, isolated from, any tissue or cells expressing the
antibody, such as hybridoma cells or Epstein Barr virus transformed
B cell lines that express an antibody of the invention) by PCR
amplification using synthetic primers hybridizable to the 3' and 5'
ends of the sequence or by cloning using an oligonucleotide probe
specific for the particular gene sequence to identify, e.g., a cDNA
clone from a cDNA library that encodes the antibody. Amplified
nucleic acids generated by PCR may then be cloned into replicable
cloning vectors using any method well known in the art.
[0151] Once the nucleotide sequence of the antibody (including
molecules comprising, or alternatively consisting of, antibody
fragments or variants thereof) is determined, the nucleotide
sequence of the antibody may be manipulated using methods well
known in the art for the manipulation of nucleotide sequences,
e.g., recombinant DNA techniques, site directed mutagenesis, PCR,
etc. (see, for example, the techniques described in Sambrook et
al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold
Spring Harbor Laboratory, Cold Spring Harbor, N.Y. and Ausubel et
al., eds., 1998, Current Protocols in Molecular Biology, John Wiley
& Sons, NY, which are both incorporated by reference herein in
their entireties), to generate antibodies having a different amino
acid sequence, for example to create amino acid substitutions,
deletions, and/or insertions.
[0152] In a specific embodiment, VH and VL domains of one or more
scFvs referred to in Table 1, or fragments or variants thereof, are
inserted within antibody framework regions using recombinant DNA
techniques known in the art. In a specific embodiment, one, two,
three, four, five, six, or more of the CDRs of VH and/or VL domains
of one or more scFvs referred to in Table 1, or fragments or
variants thereof, is inserted within antibody framework regions
using recombinant DNA techniques known in the art. The antibody
framework regions may be naturally occurring or consensus antibody
framework regions, and preferably human antibody framework regions
(see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a
listing of human antibody framework regions, the contents of which
are hereby incorporated by reference in its entirety). Preferably,
the polynucleotides generated by the combination of the antibody
framework regions and CDRs encode an antibody (including molecules
comprising, or alternatively consisting of, antibody fragments or
variants thereof) that specifically binds to neurokinin B.
Preferably, as discussed supra, polynucleotides encoding variants
of antibodies or antibody fragments having one or more amino acid
substitutions may be made within the framework regions, and,
preferably, the amino acid substitutions do not significantly alter
binding of the antibody to its antigen. Additionally, such methods
may be used to make amino acid substitutions or deletions of one or
more variable region cysteine residues participating in an
intrachain disulfide bond to generate antibody molecules, or
antibody fragments or variants, lacking one or more intrachain
disulfide bonds. Other alterations to the polynucleotide are
encompassed by the present invention and fall within the ordinary
skill of the art.
Xenomouse.TM. Technology
[0153] The ability to clone and reconstruct megabase-sized human
loci in YACs and to introduce them into the mouse germline provides
a powerful approach to elucidating the functional components of
very large or crudely mapped loci as well as generating useful
models of human disease. Furthermore, the utilization of such
technology for substitution of mouse loci with their human
equivalents could provide unique insights into the expression and
regulation of human gene products during development, their
communication with other systems, and their involvement in disease
induction and progression.
[0154] An important practical application of such a strategy is the
"humanization" of the mouse humoral immune system. Introduction of
human immunoglobulin (Ig) loci into mice in which the endogenous Ig
genes have been inactivated offers the opportunity to study the
mechanisms underlying programmed expression and assembly of
antibodies as well as their role in B cell development.
Furthermore, such a strategy could provide an ideal source for
production of fully human monoclonal antibodies (Mabs) an important
milestone towards fulfilling the promise of antibody therapy in
human disease.
[0155] Fully human antibodies are expected to minimize the
immunogenic and allergic responses intrinsic to mouse or
mouse-derivatized Monoclonal antibodies and thus to increase the
efficacy and safety of the administered antibodies. The use of
fully human antibodies can be expected to provide a substantial
advantage in the treatment of chronic and recurring human diseases,
such as cancer, which require repeated antibody
administrations.
[0156] One approach towards this goal was to engineer mouse strains
deficient in mouse antibody production with large fragments of the
human Ig loci in anticipation that such mice would produce a large
repertoire of human antibodies in the absence of mouse antibodies.
Large human Ig fragments would preserve the large variable gene
diversity as well as the proper regulation of antibody production
and expression. By exploiting the mouse machinery for antibody
diversification and selection and the lack of immunological
tolerance to human proteins, the reproduced human antibody
repertoire in these mouse strains should yield high affinity
antibodies against any antigen of interest, including human
antigens. Using the hybridoma technology, antigen-specific human
Monoclonal antibodies with the desired specificity could be readily
produced and selected.
[0157] This general strategy was demonstrated in connection with
the generation of the first XenoMouse.TM. strains as published in
1994. See Green et al. Nature Genetics 7:13-21 (1994). The
XenoMouse.TM. strains were engineered with yeast artificial
chromosomes (YACS) containing 245 kb and 10 190 kb-sized germline
configuration fragments of the human heavy chain locus and kappa
light chain locus, respectively, which contained core variable and
constant region sequences. Id. The human Ig containing YACs proved
to be compatible with the mouse system for both rearrangement and
expression of antibodies and were capable of substituting for the
inactivated mouse Ig genes. This was demonstrated by their ability
to induce B-cell development, to produce an adult-like human
repertoire of fully human antibodies, and to generate
antigen-specific human monoclonal antibodies. These results also
suggested that introduction of larger portions of the human Ig loci
containing greater numbers of V genes, additional regulatory
elements, and human Ig constant regions might recapitulate
substantially the full repertoire that is characteristic of the
human humoral response to infection and immunization. The work of
Green et al. was recently extended to the introduction of greater
than approximately 80% of the human antibody repertoire through
introduction of megabase sized, germline configuration YAC
fragments of the human heavy chain loci and kappa light chain loci,
respectively, to produce XenoMouse.TM. mice. See Mendez et al.
Nature Genetics 15:146-156 (1997), Green and Jakobovits J Exp. Med.
188:483-495 (1998), Green, Journal of Immunological Methods
231:11-23 (1999) and U.S. patent application Ser. No. 08/759,620,
filed Dec. 3, 1996, the disclosures of which are hereby
incorporated by reference.
[0158] Such approach is further discussed and delineated in U.S.
patent application Ser. No. 07/466,008, filed Jan. 12, 1990, Ser.
No. 07/710,515, filed Nov. 8, 1990, Ser. No. 07/919,297, filed Jul.
24, 1992, Ser. No. 07/922,649, filed Jul. 30, 1992, filed Ser. No.
08/031,801, filed Mar. 15, 1993, Ser. No. 08/112,848, filed Aug.
27, 1993, Ser. No. 08/234,145, filed Apr. 28, 1994, Ser. No.
08/376,279, filed Jan. 20, 1995, Ser. No. 08/430,938, Apr. 27,
1995, Ser. No. 08/464,584, filed Jun. 5, 1995, Ser. No. 08/464,582,
filed Jun. 5, 1995, Ser. No. 08/471,191, filed Jun. 5, 1995, Ser.
No. 08/462,837, filed Jun. 5, 1995, Ser. No. 08/486,853, filed Jun.
5, 1995, Ser. No. 08/486,857, filed Jun. 5, 1995, Ser. No.
08/486,859, filed Jun. 5, 1995, Ser. No. 08/462,513, filed Jun. 5,
1995, Ser. No. 08/724,752, filed Oct. 2, 1996, and Ser. No.
08/759,620, filed Dec. 3, 1996. See also Mendez et al. Nature
Genetics 15:146-156 (1997) and Green and Jakobovits J Exp. Med.
188:483 495 (1998). See also European Patent No., EP 0 463 151 B1,
grant published Jun. 12, 1996, International Patent Application
No., WO 94/02602, published Feb. 3, 1994, International Patent
Application No., WO 96/34096, published Oct. 31, 1996, and WO
98/24893, published Jun. 11, 1998. The disclosures of each of the
above-cited patents, applications, and references are hereby
incorporated by reference in their entirety.
[0159] Human anti-mouse antibody (HAMA) responses have led the
industry to prepare chimeric or otherwise humanized antibodies.
While chimeric antibodies have a human constant region and a murine
variable region, it is expected that certain human anti-chimeric
antibody (HACA) responses will be observed, particularly in chronic
or multi-dose utilizations of the antibody. Thus, it would be
desirable to provide fully human antibodies against neurokinin B
polypeptides in order to vitiate concerns and/or effects of HAMA or
HACA responses.
[0160] Monoclonal antibodies specific for neurokinin B polypeptides
may be prepared using hybridoma technology. (Kohler et al., Nature
256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976);
Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al.,
in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y.,
pp. 571-681 (1981)). Briefly, XenoMouse.TM. mice may be immunized
with neurokinin B polypeptides. After immunization, the splenocytes
of such mice may be extracted and fused with a suitable myeloma
cell line. Any suitable myeloma cell line may be employed in
accordance with the present invention; however, it is preferable to
employ the parent myeloma cell line (SP2O), available from the
ATCC.TM.. After fusion, the resulting hybridoma cells are
selectively maintained in HAT medium, and then cloned by limiting
dilution as described by Wands et al. (Gastroenterology 80:225-232
(1981)). The hybridoma cells obtained through such a selection are
then assayed to identify clones, which secrete antibodies capable
of binding the neurokinin B polypeptides.
[0161] For some uses, including in vivo use of antibodies in humans
and in vitro detection assays, it may be preferable to use human or
chimeric antibodies. Completely human antibodies are particularly
desirable for therapeutic treatment of human patients. See also,
U.S. Pat. Nos. 4,444,887 and 4,716,111; and PCT publications WO
98/46645, WO 98/50435, WO 98/24893, WO98/16654, WO 96/34096, WO
96/35735, and WO 91/10741, each of which is incorporated herein by
reference in its entirety. In a specific embodiment, antibodies of
the present invention comprise one or more VH and VL domains of the
invention and constant regions from another immunoglobulin
molecule, preferably a human immunoglobulin molecule. In a specific
embodiment, antibodies of the present invention comprise one or
more CDRs corresponding to the VH and VL domains of the invention
and framework regions from another immunoglobulin molecule,
preferably a human immunoglobulin molecule. In other embodiments,
an antibody of the present invention comprises one, two, three,
four, five, six or more VL CDRs or VH CDRs corresponding to one or
more of the VH or VL domains of one or more scFvs referred to in
Table 1, or fragments or variants thereof, and framework regions
(and, optionally one or more CDRs not present in the antibodies
expressed by scFvs referred to in Table 1) from a human
immunoglobulin molecule. In a preferred embodiment, an antibody of
the present invention comprises a VH CDR3, VL CDR3, or both,
corresponding to the same scFv, or different scFvs selected from
the scFvs referred to in Table 1, or fragments or variants thereof,
and framework regions from a human immunoglobulin.
[0162] A chimeric antibody is a molecule in which different
portions of the antibody are derived from different immunoglobulin
molecules such as antibodies having a human variable region and a
non-human (e.g., murine) immunoglobulin constant region or vice
versa. Methods for producing chimeric antibodies are known in the
art. See e.g., Morrison, Science 229:1202 (1985); Oi et al.,
BioTechniques 4:214 (1986); Gillies et al., J. Immunol. Methods
125:191-202 (1989); U.S. Pat. Nos. 5,807,715; 4,816,567; and
4,816,397, which are incorporated herein by reference in their
entirety. Chimeric antibodies comprising one or more CDRs from
human species and framework regions from a non-human immunoglobulin
molecule (e.g., framework regions from a murine, canine or feline
immunoglobulin molecule) (or vice versa) can be produced using a
variety of techniques known in the art including, for example,
CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Pat.
Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing
(EP 592,106; EP 519,596; Padlan, Molecular Immunology
28(4/5):489-498 (1991); Studnicka et al., Protein Engineering
7(6):805-814 (1994); Roguska et al., PNAS 91:969-973 (1994)), and
chain shuffling (U.S. Pat. No. 5,565,352). In a preferred
embodiment, chimeric antibodies comprise a human CDR3 having an
amino acid sequence of any one of the VH CDR3s or VL CDR3s of a VH
or VL domain of one or more of the scFvs referred to in Table 1, or
a variant thereof, and non-human framework regions or human
framework regions different from those of the frameworks in the
corresponding scFv disclosed in Table 1. Often, framework residues
in the framework regions will be substituted with the corresponding
residue from the CDR donor antibody to alter, preferably improve,
antigen binding. These framework substitutions are identified by
methods well known in the art, e.g., by modeling of the
interactions of the CDR and framework residues to identify
framework residues important for antigen binding and sequence
comparison to identify unusual framework residues at particular
positions. (See, e.g., Queen et al., U.S. Pat. No. 5,585,089;
Riechmann et al., Nature 352:323 (1988), which are incorporated
herein by reference in their entireties.)
[0163] Intrabodies are antibodies, often scFvs, that are expressed
from a recombinant nucleic acid molecule and engineered to be
retained intracellularly (e.g., retained in the cytoplasm,
endoplasmic reticulum, or periplasm). Intrabodies may be used, for
example, to ablate the function of a protein to which the intrabody
binds. The expression of intrabodies may also be regulated through
the use of inducible promoters in the nucleic acid expression
vector comprising the intrabody. Intrabodies of the invention can
be produced using methods known in the art, such as those disclosed
and reviewed in Chen et al., Hum. Gene Ther. 5:595-601 (1994);
Marasco, W. A., Gene Ther. 4:11-15 (1997); Rondon and Marasco,
Annu. Rev. Microbiol. 51:257-283 (1997); Proba et al., J. Mol.
Biol. 275:245-253 (1998); Cohen et al, Oncogene 17:2445-2456
(1998); Ohage and Steipe, J. Mol. Biol. 291:1119-1128 (1999); Ohage
et al., J. Mol. Biol. 291:1129-1134 (1999); Wirtz and Steipe,
Protein Sci. 8:2245-2250 (1999); Zhu et al., J. Immunol. Methods
231:207-222 (1999); and references cited therein.
[0164] Recombinant expression of an antibody of the invention
(including antibody fragments or variants thereof (e.g., a heavy or
light chain of an antibody of the invention), requires construction
of an expression vector(s) containing a polynucleotide that encodes
the antibody. Once a polynucleotide encoding an antibody molecule
(e.g., a whole antibody, a heavy or light chain of an antibody, or
portion thereof (preferably, but not necessarily, containing the
heavy or light chain variable domain)), of the invention has been
obtained, the vector(s) for the production of the antibody molecule
may be produced by recombinant DNA technology using techniques well
known in the art. Thus, methods for preparing a protein by
expressing a polynucleotide containing an antibody encoding
nucleotide sequence are described herein. Methods, which are well
known to those skilled in the art, can be used to construct
expression vectors containing antibody coding sequences and
appropriate transcriptional and translational control signals.
These methods include, for example, in vitro recombinant DNA
techniques, synthetic techniques, and in vivo genetic
recombination. The invention, thus, provides replicable vectors
comprising a nucleotide sequence encoding an antibody molecule of
the invention (e.g., a whole antibody, a heavy or light chain of an
antibody, a heavy or light chain variable domain of an antibody, or
a portion thereof, or a heavy or light chain CDR, a single chain
Fv, or fragments or variants thereof), operably linked to a
promoter. Such vectors may include the nucleotide sequence encoding
the constant region of the antibody molecule (see, e.g., PCT
Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Pat.
No. 5,122,464, the contents of each of which are hereby
incorporated by reference in its entirety) and the variable domain
of the antibody may be cloned into such a vector for expression of
the entire heavy chain, the entire light chain, or both the entire
heavy and light chains.
[0165] The expression vector(s) is(are) transferred to a host cell
by conventional techniques and the transfected cells are then
cultured by conventional techniques to produce an antibody of the
invention. Thus, the invention includes host cells containing
polynucleotide(s) encoding an antibody of the invention (e.g.,
whole antibody, a heavy or light chain thereof, or portion thereof,
or a single chain antibody, or a fragment or variant thereof),
operably linked to a heterologous promoter. In preferred
embodiments, for the expression of entire antibody molecules,
vectors encoding both the heavy and light chains may be
co-expressed in the host cell for expression of the entire
immunoglobulin molecule, as detailed below.
[0166] A variety of host-expression vector systems may be utilized
to express the antibody molecules of the invention. Such
host-expression systems represent vehicles by which the coding
sequences of interest may be produced and subsequently purified,
but also represent cells which may, when transformed or transfected
with the appropriate nucleotide coding sequences, express an
antibody molecule of the invention in situ. These include, but are
not limited to, bacteriophage particles engineered to express
antibody fragments or variants thereof (single chain antibodies),
microorganisms such as bacteria (e.g., E. coli, B. subtilis)
transformed with recombinant bacteriophage DNA, plasmid DNA or
cosmid DNA expression vectors containing antibody coding sequences;
yeast (e.g., Saccharomyces, Pichia) transformed with recombinant
yeast expression vectors containing antibody coding sequences;
insect cell systems infected with recombinant virus expression
vectors (e.g., baculovirus) containing antibody coding sequences;
plant cell systems infected with recombinant virus expression
vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic
virus, TMV) or transformed with recombinant plasmid expression
vectors (e.g., Ti plasmid) containing antibody coding sequences; or
mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3, NS0 cells)
harboring recombinant expression constructs containing promoters
derived from the genome of mammalian cells (e.g., metallothionein
promoter) or from mammalian viruses (e.g., the adenovirus late
promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial
cells such as Escherichia coli, and more preferably, eukaryotic
cells, especially for the expression of whole recombinant antibody
molecule, are used for the expression of a recombinant antibody
molecule. For example, mammalian cells such as Chinese hamster
ovary cells (CHO), in conjunction with a vector such as the major
intermediate early gene promoter element from human cytomegalovirus
is an effective expression system for antibodies (Foecking et al.,
Gene 45:101 (1986); Cockett et al., Bio/Technology 8:2 (1990);
Bebbington et al., Bio/Techniques 10:169 (1992); Keen and Hale,
Cytotechnology 18:207 (1996)). These references are incorporated in
their entireties by reference herein.
[0167] In bacterial systems, a number of expression vectors may be
advantageously selected depending upon the use intended for the
antibody molecule being expressed. For example, when a large
quantity of such a protein is to be produced, for the generation of
pharmaceutical compositions of an antibody molecule, vectors, which
direct the expression of high levels of fusion protein products
that are readily purified, may be desirable. Such vectors include,
but are not limited to, the E. coli expression vector pUR278
(Ruther et al., EMBO 1. 2:1791 (1983)), in which the antibody
coding sequence may be ligated individually into the vector in
frame with the lac Z coding region so that a fusion protein is
produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res.
13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem.
24:5503-5509 (1989)); and the like. pGEX vectors may also be used
to express foreign polypeptides as fusion proteins with glutathione
5-transferase (GST). In general, such fusion proteins are soluble
and can easily be purified from lysed cells by adsorption and
binding to matrix glutathione agarose beads followed by elution in
the presence of free glutathione. The pGEX vectors are designed to
include thrombin or factor Xa protease cleavage sites so that the
cloned target gene product can be released from the GST moiety.
[0168] In an insect system, Autographa californica nuclear
polyhedrosis virus (AcNPV) may be used as a vector to express
foreign genes. The virus grows in Spodoptera frugiperda cells.
Antibody coding sequences may be cloned individually into
non-essential regions (for example, the polyhedrin gene) of the
virus and placed under control of an AcNPV promoter (for example,
the polyhedrin promoter).
[0169] In mammalian host cells, a number of viral-based expression
systems may be utilized. In cases where an adenovirus is used as an
expression vector, the antibody coding sequence of interest may be
ligated to an adenovirus transcription/translation control complex,
e.g., the late promoter and tripartite leader sequence. This
chimeric gene may then be inserted in the adenovirus genome by in
vitro or in vivo recombination. Insertion in a non-essential region
of the viral genome (e.g., region E1 or E3) will result in a
recombinant virus that is viable and capable of expressing the
antibody molecule in infected hosts (e.g., see Logan & Shenk,
Proc. Natl. Acad. Sci. USA 8 1:355-359 (1984)). Specific initiation
signals may also be required for efficient translation of inserted
antibody coding sequences. These signals include the ATG initiation
codon and adjacent sequences. Furthermore, the initiation codon
must be in phase with the reading frame of the desired coding
sequence to ensure translation of the entire insert. These
exogenous translational control signals and initiation codons can
be of a variety of origins, both natural and synthetic. The
efficiency of expression may be enhanced by the inclusion of
appropriate transcription enhancer elements, transcription
terminators, etc. (see, e.g., Bittner et al., Methods in Enzymol.
153:51-544 (1987)).
[0170] In addition, a host cell strain may be chosen which
modulates the expression of the inserted sequences, or modifies and
processes the gene product in the specific fashion desired. Such
modifications (e.g., glycosylation) and processing (e.g., cleavage)
of protein products may be important for the function of the
protein. Different host cells have characteristic and specific
mechanisms for the post-translational processing and modification
of proteins and gene products. Appropriate cell lines or host
systems can be chosen to ensure the correct modification and
processing of the foreign protein expressed. To this end,
eukaryotic host cells that possess the cellular machinery for
proper processing of the primary transcript, glycosylation, and
phosphorylation of the gene product may be used. Such mammalian
host cells include, but are not limited to, CHO, VERY, BHK, Hela,
COS, NSO, MDCK, 293, 3T3, W138, and in particular, breast cancer
cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and
T47D, and normal mammary gland cell line such as, for example,
CRL7O3O and HsS78Bst.
[0171] For long-term, high-yield production of recombinant
proteins, stable expression is preferred. For example, cell lines,
which stably express the antibody, may be engineered. Rather than
using expression vectors that contain viral origins of replication,
host cells can be transformed with DNA controlled by appropriate
expression control elements (e.g., promoter, enhancer, sequences,
transcription terminators, polyadenylation sites, etc.), and a
selectable marker. Following the introduction of the foreign DNA,
engineered cells may be allowed to grow for 1-2 days in an enriched
media, and then are switched to a selective media. The selectable
marker in the recombinant plasmid confers resistance to the
selection and allows cells to stably integrate the plasmid into
their chromosomes and grow to form foci that in turn can be cloned
and expanded into cell lines. This method may advantageously be
used to engineer cell lines that express the antibody molecule.
Such engineered cell lines may be particularly useful in screening
and evaluation of compositions that interact directly or indirectly
with the antibody molecule.
[0172] A number of selection systems may be used, including but not
limited to, the herpes simplex virus thymidine kinase (Wigler et
al., Cell 11:223 (1977)), hypoxanthine-guanine
phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl.
Acad. Sci. USA 48:202 (1992)), and adenine
phosphoribosyltransferase (Lowy et al., Cell 22:8 17 (1980)) genes
can be employed in tk-, hgprt- or aprt- cells, respectively. Also,
antimetabolite resistance can be used as the basis of selection for
the following genes: dhfr, which confers resistance to methotrexate
(Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al.,
Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers
resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl.
Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to
the aminoglycoside G-418 (Clinical Pharmacy 12:488-505; Wu and Wu,
Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol.
Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993);
and Morgan and Anderson, Ann. Rev. Biochem. 62: 191-217 (1993); TIB
TECH 11(5):155-2 15 (May, 1993)); and hygro, which confers
resistance to hygromycin (Santerre et al., Gene 30:147 (1984)).
Methods commonly known in the art of recombinant DNA technology may
be routinely applied to select the desired recombinant clone, and
such methods are described, for example, in Ausubel et al. (eds.),
Current Protocols in Molecular Biology, John Wiley & Sons, NY
(1993); Kriegler, Gene Transfer and Expression, A Laboratory
Manual, Stockton Press, NY (1990); and in Chapters 12 and 13,
Dracopoli et al. (eds), Current Protocols in Human Genetics, John
Wiley & Sons, NY (1994); Colberre-Garapin et al., J. Mol. Biol.
150:1 (1981), which are incorporated by reference herein in their
entireties.
[0173] The expression levels of an antibody molecule can be
increased by vector amplification (for a review, see Bebbington and
Hentschel, "The use of vectors based on gene amplification for the
expression of cloned genes in mammalian cells" in DNA Cloning, Vol.
3. (Academic Press, New York, 1987)). When a marker in the vector
system expressing antibody is amplifiable, increase in the level of
inhibitor present in culture of host cell will increase the number
of copies of the marker gene. Since the amplified region is
associated with the coding sequence of the antibody, production of
the antibody will also increase (Crouse et al., Mol. Cell. Biol.
3:257 (1983)).
[0174] Vectors which use glutamine synthase (GS) or DHFR as the
selectable markers can be amplified in the presence of the drugs
methionine sulphoximine or methotrexate, respectively. An advantage
of glutamine synthase based vectors is the availability of cell
lines (e.g., the murine myeloma cell line, NS0) that are glutamine
synthase negative. Glutamine synthase expression systems can also
function in glutamine synthase expressing cells (e.g., Chinese
Hamster Ovary (CHO) cells) by providing additional inhibitor to
prevent the functioning of the endogenous gene. A glutamine
synthase expression system and components thereof are detailed in
PCT publications: WO87/04462; WO86/05807; WO89/01036; WO89/10404;
and WO91/06657, which are incorporated in their entireties by
reference herein. Additionally, glutamine synthase expression
vectors that may be used according to the present invention are
commercially available from suppliers, including, for example Lonza
Biologics, Inc. (Portsmouth, N.H.). Expression and production of
monoclonal antibodies using a GS expression system in murine
myeloma cells is described in Bebbington et al., Bio/technology
10:169 (1992) and in Biblia and Robinson Biotechnol. Prog. 11:1
(1995), which are incorporated in their entireties by reference
herein.
[0175] The host cell may be co-transfected with two expression
vectors of the invention, the first vector encoding a heavy chain
derived polypeptide and the second vector encoding a light chain
derived polypeptide. The two vectors may contain identical
selectable markers that enable equal expression of heavy and light
chain polypeptides. Alternatively, a single vector may be used
which encodes, and is capable of expressing, both heavy and light
chain polypeptides. In such situations, the light chain is
preferably placed before the heavy chain to avoid an excess of
toxic free heavy chain (Proudfoot, Nature 322:52 (1986); Kohler,
Proc. Natl. Acad. Sci. USA 77:2 197 (1980)). The coding sequences
for the heavy and light chains may comprise cDNA or genomic
DNA.
[0176] Once an antibody molecule of the invention (including
molecules comprising, or alternatively consisting of, antibody
fragments or variants thereof) has been chemically synthesized or
recombinantly expressed, it may be purified by any method known in
the art for purification of an immunoglobulin molecule, or more
generally, a protein molecule, such as, for example, by
chromatography (e.g., ion exchange, affinity, particularly by
affinity for the specific antigen after Protein A, and sizing
column chromatography), centrifugation, differential solubility, or
by any other standard technique for the purification of proteins.
Further, the antibodies of the present invention may be fused to
heterologous polypeptide sequences described herein or otherwise
known in the art, to facilitate purification.
[0177] Antibodies of the present invention include naturally
purified products, products of chemical synthetic procedures, and
products produced by recombinant techniques from a prokaryotic or
eukaryotic host, including, for example, bacterial, yeast, higher
plant, insect and mammalian cells. Depending upon the host employed
in a recombinant production procedure, the antibodies of the
present invention may be glycosylated or may be non-glycosylated.
In addition, antibodies of the invention may also include an
initial modified methionine residue, in some cases as a result of
host-mediated processes.
[0178] Antibodies of the invention can be chemically synthesized
using techniques known in the art (e.g., see Creighton, 1983,
Proteins: Structures and Molecular Principles, W.H. Freeman &
Co., N.Y., and Hunkapiller, M., et al., 1984, Nature 310:105-111).
For example, a peptide corresponding to a fragment of an antibody
of the invention can be synthesized by use of a peptide
synthesizer. Furthermore, if desired, nonclassical amino acids or
chemical amino acid analogs can be introduced as a substitution or
addition into the antibody polypeptide sequence. Non-classical
amino acids include, but are not limited to, to the D-isomers of
the common amino acids, 2,4-diaminobutyric acid, a-amino isobutyric
acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, g-Abu, e-Ahx,
6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino
propionic acid, ornithine, norleucine, norvaline, hydroxyproline,
sarcosine, citrulline, homocitrulline, cysteic acid,
t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,
b-alanine, fluoro-amino acids, designer amino acids such as
b-methyl amino acids, Ca-methyl amino acids, Na-methyl amino acids,
and amino acid analogs in general. Furthermore, the amino acid can
be D (dextrorotary) or L (levorotary).
[0179] The invention encompasses antibodies which are
differentially modified during or after translation, e.g., by
glycosylation, acetylation, phosphorylation, amidation,
derivatization by known protecting/blocking groups, proteolytic
cleavage, linkage to an antibody molecule or other cellular ligand,
etc. Any of numerous chemical modifications may be carried out by
known techniques, including but not limited, to specific chemical
cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8
protease, NaBH4, acetylation, formylation, oxidation, reduction,
metabolic synthesis in the presence of tunicamycin, etc.
[0180] Additional post-translational modifications encompassed by
the invention include, for example, e.g., N-linked or O-linked
carbohydrate chains, processing of N-terminal or C-terminal ends),
attachment of chemical moieties to the amino acid backbone,
chemical modifications of N-linked or O-linked carbohydrate chains,
and addition or deletion of an N-terminal methionine residue as a
result of procaryotic host cell expression. The antibodies may also
be modified with a detectable label, such as an enzymatic,
fluorescent, radioisotopic or affinity label to allow for detection
and isolation of the antibody.
[0181] Examples of suitable enzymes include horseradish peroxidase,
alkaline phosphatase, beta-galactosidase, glucose oxidase or
acetylcholinesterase; examples of suitable prosthetic group
complexes include streptavidin/biotin and avidin/biotin; examples
of suitable fluorescent materials include biotin, umbelliferone,
fluorescein, fluorescein isothiocyanate, rhodamine,
dichlorotriazinylamine fluorescein, dansyl chloride or
phycoerythrin; an example of a luminescent material includes
luminol; examples of bioluminescent materials include luciferase,
luciferin, and aequorin; and examples of suitable radioactive
material include a radioactive metal ion, e.g., alpha-emitters such
as, for example, 213Bi, or other radioisotopes such as, for
example, iodine (131I, 125I, 123I, 121I), carbon (14C), sulfur
(35S), tritium (3H), indium (115mIn, 113mIn, 112In, 111In), and
technetium (99Tc, 99mTc), thallium (201Ti), gallium (68Ga, 67Ga),
palladium (103Pd), molybdenum (99Mo), xenon (133Xe), fluorine
(18F), 153Sm, 177Lu, 159Gd, 149Pm, 140La, 175Yb, .sup.166Ho, 90Y,
47Sc, 186Re, 188Re, 142Pr, 105Rh, 97Ru, 68Ge, 57Co, 65Zn, 85Sr,
32P, 153Gd, 169Yb, 51Cr, 54Mn, 75Se, 113Sn, and 117Tin.
[0182] In specific embodiments, antibodies of the invention may be
labeled with Europium. For example, antibodies of the invention may
be labelled with Europium using the DELFIA Eu-labeling kit
(catalog# 1244-302, Perkin Elmer Life Sciences, Boston, Mass.)
following manufacturer's instructions.
[0183] In specific embodiments, antibodies of the invention are
attached to macrocyclic chelators useful for conjugating radiometal
ions, including but not limited to, 111In, 177Lu, 90Y, 166Ho,
153Sm, 215Bi and 225Ac to polypeptides. In a preferred embodiment,
the radiometal ion associated with the macrocyclic chelators
attached to antibodies of the invention is 111In. In another
preferred embodiment, the radiometal ion associated with the
macrocyclic chelator attached to antibodies polypeptides of the
invention is 90Y. In specific embodiments, the macrocyclic chelator
is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid
(DOTA). In specific embodiments, the macrocyclic chelator is
.alpha.-(5-isothiocyanato-2-methoxyphenyl)-1,4,7,10-tetraaza-cyclododecan-
e-1,4,7,10-tetraacetic acid. In other specific embodiments, the
DOTA is attached to the antibody of the invention via a linker
molecule. Examples of linker molecules useful for conjugating a
macrocyclic chelator such as DOTA to a polypeptide are commonly
known in the art--see, for example, DeNardo et al., Clin Cancer
Res. 4(10):2483-90, 1998; Peterson et al., Bioconjug. Chem.
10(4):553-7, 1999; and Zimmerman et al, Nucl. Med. Biol.
26(8):943-50, 1999 which are hereby incorporated by reference in
their entirety. In addition, U.S. Pat. Nos. 5,652,361 and
5,756,065, which disclose chelating agents that may be conjugated
to antibodies, and methods for making and using them, are hereby
incorporated by reference in their entireties.
[0184] In one embodiment, antibodies of the invention are labeled
with biotin. In other related embodiments, biotinylated antibodies
of the invention may be used, for example, as an imaging agent or
as a means of identifying one or more TRAIL receptor coreceptor or
ligand molecules.
[0185] Also provided by the invention are chemically modified
derivatives of antibodies of the invention which may provide
additional advantages such as increased solubility, stability and
in vivo or in vitro circulating time of the polypeptide, or
decreased immunogenicity (see U.S. Pat. No. 4,179,337). The
chemical moieties for derivitization may be selected from water
soluble polymers such as polyethylene glycol, ethylene
glycol/propylene glycol copolymers, carboxymethylcellulose,
dextran, polyvinyl alcohol and the like. The antibodies may be
modified at random positions within the molecule, or at
predetermined positions within the molecule and may include one,
two, three or more attached chemical moieties.
[0186] The polymer may be of any molecular weight, and may be
branched or unbranched. For polyethylene glycol, the preferred
molecular weight is between about 1 kDa and about 100 kDa (the term
"about" indicating that in preparations of polyethylene glycol,
some molecules will weigh more, some less, than the stated
molecular weight) for ease in handling and manufacturing. Other
sizes may be used, depending on the desired therapeutic profile
(e.g., the duration of sustained release desired, the effects, if
any on biological activity, the ease in handling, the degree or
lack of antigenicity and other known effects of the polyethylene
glycol to a therapeutic protein or analog). For example, the
polyethylene glycol may have an average molecular weight of about
200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000,
5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000,
10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000,
14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000,
18,500, 19,000, 19,500, 20,000, 25,000, 30,000, 35,000, 40,000,
50,000, 55,000, 60,000, 65,000, 70,000, 75,000, 80,000, 85,000,
90,000, 95,000, or 100,000 kDa.
[0187] As noted above, the polyethylene glycol may have a branched
structure. Branched polyethylene glycols are described, for
example, in U.S. Pat. No. 5,643,575; Morpurgo et al., Appl.
Biochem. Biotechnol. 56:59-72 (1996); Vorobjev et al., Nucleosides
Nucleotides 18:2745-2750 (1999); and Caliceti et al., Bioconjug.
Chem. 10:638-646 (1999), the disclosures of each of which are
incorporated herein by reference.
[0188] The polyethylene glycol molecules (or other chemical
moieties) should be attached to the antibody with consideration of
effects on functional or antigenic domains of the antibody. There
are a number of attachment methods available to those skilled in
the art, e.g., EP 0 401 384, herein incorporated by reference
(coupling PEG to G-CSF), see also Malik et al., Exp. Hematol.
20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl
chloride). For example, polyethylene glycol may be covalently bound
through amino acid residues via a reactive group, such as, a free
amino or carboxyl group. Reactive groups are those to which an
activated polyethylene glycol molecule may be bound. The amino acid
residues having a free amino group may include, for example, lysine
residues and the N-terminal amino acid residues; those having a
free carboxyl group may include aspartic acid residues, glutamic
acid residues, and the C-terminal amino acid residue. Sulfhydryl
groups may also be used as a reactive group for attaching the
polyethylene glycol molecules. Preferred for therapeutic purposes
is attachment at an amino group, such as attachment at the
N-terminus or lysine group.
[0189] As suggested above, polyethylene glycol may be attached to
proteins, e.g., antibodies, via linkage to any of a number of amino
acid residues. For example, polyethylene glycol can be linked to a
proteins via covalent bonds to lysine, histidine, aspartic acid,
glutamic acid, or cysteine residues. One or more reaction
chemistries may be employed to attach polyethylene glycol to
specific amino acid residues (e.g., lysine, histidine, aspartic
acid, glutamic acid, or cysteine) of the protein or to more than
one type of amino acid residue (e.g., lysine, histidine, aspartic
acid, glutamic acid, cysteine and combinations thereof) of the
protein.
[0190] One may specifically desire antibodies chemically modified
at the N-terminus of either the heavy chain or the light chain or
both. Using polyethylene glycol as an illustration, one may select
from a variety of polyethylene glycol molecules (by molecular
weight, branching, etc.), the proportion of polyethylene glycol
molecules to protein (or peptide) molecules in the reaction mix,
the type of pegylation reaction to be performed, and the method of
obtaining the selected N-terminally pegylated protein. The method
of obtaining the N-terminally pegylated preparation (i.e.,
separating this moiety from other monopegylated moieties if
necessary) may be by purification of the N-terminally pegylated
material from a population of pegylated protein molecules.
Selective chemical modification at the N-terminus may be
accomplished by reductive alkylation which exploits differential
reactivity of different types of primary amino groups (lysine
versus the N-terminal) available for derivatization in a particular
protein. Under the appropriate reaction conditions, substantially
selective derivatization of the protein at the N-terminus with a
carbonyl group containing polymer is achieved.
[0191] As indicated above, pegylation of the antibodies of the
invention may be accomplished by any number of means. For example,
polyethylene glycol may be attached to the antibody either directly
or by an intervening linker. Linkerless systems for attaching
polyethylene glycol to proteins are described in Delgado et al.,
Crit. Rev. Thera. Drug Carrier Sys. 9:249-304 (1992); Francis et
al., Intern. J. of Hematol. 68:1-18 (1998); U.S. Pat. No.
4,002,531; U.S. Pat. No. 5,349,052; WO 95/06058; and WO 98/32466,
the disclosures of each of which are incorporated herein by
reference.
[0192] One system for attaching polyethylene glycol directly to
amino acid residues of antibodies without an intervening linker
employs tresylated MPEG, which is produced by the modification of
monmethoxy polyethylene glycol (MPEG) using tresylchloride
(ClSO2CH2CF3). Upon reaction of protein with tresylated MPEG,
polyethylene glycol is directly attached to amine groups of the
protein. Thus, the invention includes antibody-polyethylene glycol
conjugates produced by reacting antibodies of the invention with a
polyethylene glycol molecule having a 2,2,2-trifluoreothane
sulphonyl group.
[0193] Polyethylene glycol can also be attached to antibodies using
a number of different intervening linkers. For example, U.S. Pat.
No. 5,612,460, the entire disclosure of which is incorporated
herein by reference, discloses urethane linkers for connecting
polyethylene glycol to proteins. Antibody-polyethylene glycol
conjugates wherein the polyethylene glycol is attached to the
antibody by a linker can also be produced by reaction of antibodies
with compounds such as MPEG-succinimidylsuccinate, MPEG activated
with 1,1'-carbonyldiimidazole, MPEG-2,4,5-trichloropenylcarbonate,
MPEG-p-nitrophenolcarbonate, and various MPEG-succinate
derivatives. A number additional polyethylene glycol derivatives
and reaction chemistries for attaching polyethylene glycol to
proteins are described in WO 98/32466, the entire disclosure of
which is incorporated herein by reference. Pegylated antibody
products produced using the reaction chemistries set out herein are
included within the scope of the invention.
[0194] The number of polyethylene glycol moieties attached to each
antibody of the invention (i.e., the degree of substitution) may
also vary. For example, the pegylated antibodies of the invention
may be linked, on average, to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12,
15, 17, 20, or more polyethylene glycol molecules. Similarly, the
average degree of substitution within ranges such as 1-3, 2-4, 3-5,
4-6, 5-7, 6-8, 7-9, 8-10, 9-11, 10-12, 11-13, 12-14, 13-15, 14-16,
15-17, 16-18, 17-19, or 18-20 polyethylene glycol moieties per
antibody molecule. Methods for determining the degree of
substitution are discussed, for example, in Delgado et al., Crit.
Rev. Thera. Drug Carrier Sys. 9:249-304 (1992).
Characterization of Anti-Neurokinin B Antibodies
[0195] Antibodies of the present invention (including molecules
comprising, or alternatively consisting of, antibody fragments or
variants thereof) may also be described or specified in terms of
their binding to neurokinin B polypeptides or fragments or variants
of neurokinin B polypeptides. In specific embodiments, antibodies
of the invention bind neurokinin B polypeptides, or fragments or
variants thereof, with a dissociation constant or K.sub.D of less
than or equal to 5.times.10.sup.-2 M, 10.sup.-2 M,
5.times.10.sup.-3 M, 10.sup.-3 M, 5.times.10.sup.-4 M, 10.sup.-4 M,
5.times.10.sup.-5 M, or 10.sup.-5 M. More preferably, antibodies of
the invention bind neurokinin B polypeptides or fragments or
variants thereof with a dissociation constant or K.sub.D less than
or equal to 5.times.10.sup.-6 M, 10.sup.-6 M, 5.times.10.sup.-7 M,
10.sup.-7 M, 5.times.10.sup.-8 M, or 10.sup.-8 M. Even more
preferably, antibodies of the invention bind neurokinin B
polypeptides or fragments or variants thereof with a dissociation
constant or K.sub.D less than or equal to 5.times.10.sup.-9 M,
10.sup.-9 M, 5.times.10.sup.-10 M, 10 M, 5.times.10.sup.-11 M,
10.sup.-11 M, 5.times.10.sup.-12 M, 10.sup.-12 M,
5.times.10.sup.-13 M, 10.sup.-13 M, 5.times.10.sup.-14 M,
10.sup.-14 M, 5.times.10.sup.-15 M, or 10.sup.-15 M. The invention
encompasses antibodies that bind neurokinin B polypeptides with a
dissociation constant or K.sub.D that is within any one of the
ranges that are between each of the individual recited values.
[0196] In specific embodiments, antibodies of the invention bind
neurokinin B polypeptides or fragments or variants thereof with an
off rate (k.sub.off) of less than or equal to 5.times.10.sup.-2
sec.sup.-1, 10.sup.-2 sec.sup.-1, 5.times.10.sup.-3 sec.sup.-1 or
10.sup.-3 sec.sup.-1. More preferably, antibodies of the invention
bind neurokinin B polypeptides or fragments or variants thereof
with an off rate (k.sub.off) less than or equal to
5.times.10.sup.-4 sec.sup.-1, 10.sup.-4 sec.sup.-1,
5.times.10.sup.-5 sec.sup.-1, or 10.sup.-5 sec.sup.-1
5.times.10.sup.-6 sec.sup.-1, 10.sup.-6 sec.sup.-1,
5.times.10.sup.-7 sec.sup.-1 or 10.sup.-7 sec.sup.-1. The invention
encompasses antibodies that bind neurokinin B polypeptides with an
off rate (k.sub.off) that is within any one of the ranges that are
between each of the individual recited values.
[0197] In other embodiments, antibodies of the invention bind
neurokinin B polypeptides or fragments or variants thereof with an
on rate (k.sub.on) of greater than or equal to 10.sup.3 M.sup.-1
sec.sup.-1, 5.times.10.sup.3 M.sup.-1 sec.sup.-1, 10.sup.4 M.sup.-1
sec.sup.-1 or 5.times.10.sup.4 M.sup.-1 sec.sup.-1. More
preferably, antibodies of the invention bind neurokinin B
polypeptides or fragments or variants thereof with an on rate
(k.sub.on) greater than or equal to 10.sup.5 M.sup.-1 sec.sup.-1,
5.times.10.sup.5 M.sup.-1 sec.sup.-1, 10.sup.6 M.sup.-1 sec.sup.-1,
or 5.times.10.sup.6 M.sup.-1 sec.sup.-1 or 10.sup.7 M.sup.-1
sec.sup.-1. The invention encompasses antibodies that bind
neurokinin B polypeptides with on rate (k.sub.on) that is within
any one of the ranges that are between each of the individual
recited values.
[0198] The antibodies of the invention (including molecules
comprising, or alternatively consisting of, antibody fragments or
variants thereof) specifically bind to a polypeptide or polypeptide
fragment or variant of human neurokinin B (e.g., SEQ ID NO:2). In
another embodiment, the antibodies of the invention specifically
bind to a polypeptide or polypeptide fragment or variant of simian
neurokinin B polypeptides. In yet another embodiment, the
antibodies of the invention specifically bind to a polypeptide or
polypeptide fragment or variant of murine neurokinin B
polypeptides. In one embodiment, the antibodies of the invention
bind specifically to human and simian neurokinin B polypeptides. In
another embodiment, the antibodies of the invention bind
specifically to human neurokinin B polypeptides and murine
neurokinin B polypeptides. More preferably, antibodies of the
invention, preferentially bind to human neurokinin B polypeptides
compared to murine neurokinin B polypeptides.
[0199] In preferred embodiments, the antibodies of the present
invention (including molecules comprising, or alternatively
consisting of, antibody fragments or variants thereof),
specifically bind to neurokinin B polypeptides and do not
cross-react with any other antigens. In preferred embodiments, the
antibodies of the invention specifically bind to neurokinin B
polypeptides (e.g., SEQ ID NO:2 or fragments or variants thereof)
and do not cross-react with one or more additional members of the
tachykinin family (e.g., substance P, neurokinin A).
[0200] In another embodiment, the antibodies of the present
invention (including molecules comprising, or alternatively
consisting of, antibody fragments or variants thereof),
specifically bind to neurokinin B polypeptides and cross-react with
other antigens. In other embodiments, the antibodies of the
invention specifically bind to neurokinin B polypeptides (e.g., SEQ
ID NO:2, or fragments or variants thereof) and cross-react with one
or more additional members of the tachykinin family (e.g.,
substance P, neurokinin A).
[0201] By way of non-limiting example, an antibody may be
considered to bind a first antigen preferentially if it binds said
first antigen with a dissociation constant (K.sub.D) that is less
than the antibody's K.sub.D for the second antigen. In another
non-limiting embodiment, an antibody may be considered to bind a
first antigen preferentially if it binds said first antigen with an
affinity (i.e., K.sub.D) that is at least one order of magnitude
less than the antibody's K.sub.D for the second antigen. In another
non-limiting embodiment, an antibody may be considered to bind a
first antigen preferentially if it binds said first antigen with an
affinity (i.e., K.sub.D) that is at least two orders of magnitude
less than the antibody's K.sub.D for the second antigen.
[0202] In another non-limiting embodiment, an antibody may be
considered to bind a first antigen preferentially if it binds said
first antigen with an off rate (k.sub.off) that is less than the
antibody's k.sub.off for the second antigen. In another
non-limiting embodiment, an antibody may be considered to bind a
first antigen preferentially if it binds said first antigen with a
k.sub.off that is at least one order of magnitude less than the
antibody's k.sub.off for the second antigen. In another
non-limiting embodiment, an antibody may be considered to bind a
first antigen preferentially if it binds said first antigen with a
k.sub.off that is at least two orders of magnitude less than the
antibody's k.sub.off for the second antigen.
[0203] The invention also encompasses antibodies (including
molecules comprising, or alternatively consisting of, antibody
fragments or variants thereof) that have one or more of the same
biological characteristics as one or more of the antibodies
described herein. By "biological characteristics" is meant, the in
vitro or in vivo activities or properties of the antibodies, such
as, for example, the ability to bind to neurokinin B polypeptides,
the ability to inhibit neurokinin B mediated biological activity
(e.g., the ability to inhibit neurokinin B-mediated
vasoconstriction of blood vessels or the ability to inhibit
neurokinin B-mediated intracellular calcium flux (see Example 3));
or the ability to substantially block binding of neurokinin B, or a
fragment, variant or fusion protein thereof, to a neurokinin
receptor (e.g., NK3R; GenBank ID: JQ1517, NK2R; GenBank ID:M57414,
or NK1R; GenBank ID:M81797). Other biological activities that
antibodies against neurokinin B polypeptides may have, include, but
are not limited to, the ability to stimulate neurokinin B mediated
biological activity (e.g., to stimulate neurokinin B-mediated
vasoconstriction of blood vessels). Optionally, the antibodies of
the invention will bind to the same epitope as at least one of the
antibodies specifically referred to herein e.g., any one of the
antibodies expressed by the cell lines referred to in Table 1. Such
epitope binding can be routinely determined using assays known in
the art.
[0204] The present invention also provides for antibodies
(including molecules comprising, or alternatively consisting of,
antibody fragments or variants thereof), that inhibit binding of a
neurokinin B polypeptide to a neurokinin receptor (e.g., NK3R,
NK1R, NK2R). In one embodiment, an antibody that inhibits binding
of neurokinin B polypeptides to a neurokinin receptor comprises, or
alternatively consists of a VH and/or a VL domain of at least one
of the scFvs referred to in Table 1, or fragment or variant
thereof. In a specific embodiment, an antibody that inhibits
binding of neurokinin B polypeptides to a neurokinin receptor
comprises, or alternatively consists of, a VH and a VL domain of
any one of the scFvs referred to in Table 1, or fragment or variant
thereof. Nucleic acid molecules encoding these antibodies are also
encompassed by the invention.
[0205] The present invention also provides for antibodies
(including molecules comprising, or alternatively consisting of,
antibody fragments or variants thereof), that inhibit one or more
neurokinin B polypeptide mediated biological activities. In one
embodiment, an antibody that inhibits one or more neurokinin B
polypeptide mediated biological activities comprises, or
alternatively consists of a VH and/or a VL domain of at least one
of the scFvs referred to in Table 1, or fragment or variant
thereof. In a specific embodiment, an antibody that inhibits one or
more neurokinin B polypeptide mediated biological activities
comprises, or alternatively consists of a VH and a VL domain of any
one of the scFvs referred to in Table 1, or fragment or variant
thereof. Nucleic acid molecules encoding these antibodies are also
encompassed by the invention.
[0206] The present invention also provides for antibodies
(including molecules comprising, or alternatively consisting of,
antibody fragments or variants thereof) that inhibit neurokinin
B-mediated vasoconstriction of blood vessels (e.g., hepatic portal
vein, mesenteric vascular bed, and placental blood vessels). In one
embodiment, an antibody that inhibits neurokinin B-mediated
vasoconstriction of blood vessels comprises, or alternatively
consists of a VH and/or a VL domain of at least one of the scFvs
referred to in Table 1, or fragment or variant thereof. In a
specific embodiment, an antibody that inhibits neurokinin
B-mediated vasoconstriction of blood vessels comprises, or
alternatively consists of a VH and a VL domain of any one of the
scFvs referred to in Table 1, or fragment or variant thereof.
Nucleic acid molecules encoding these antibodies are also
encompassed by the invention.
[0207] The present invention also provides for antibodies
(including molecules comprising, or alternatively consisting of,
antibody fragments or variants thereof), that stimulate neurokinin
B-mediated vasoconstriction of blood vessels (e.g., hepatic portal
vein, mesenteric vascular bed, and placental blood vessels). In one
embodiment, an antibody that stimulates neurokinin B-mediated
vasoconstriction of blood vessels comprises, or alternatively
consists of a VH and/or a VL domain of at least one of the scFvs
referred to in Table 1, or fragment or variant thereof. In a
specific embodiment, an antibody that stimulates neurokinin
B-mediated vasoconstriction of blood vessels comprises, or
alternatively consists of a VH and a VL domain of any one of the
scFvs referred to in Table 1, or fragment or variant thereof.
Nucleic acid molecules encoding these antibodies are also
encompassed by the invention.
[0208] Antibodies of the present invention (including antibody
fragments or variants thereof) may be characterized in a variety of
ways. In particular, antibodies and related molecules of the
invention may be assayed for the ability to specifically bind to
neurokinin B polypeptides or a fragment or variant of neurokinin B
polypeptides using techniques described herein or routinely
modifying techniques known in the art. Assays for the ability of
the antibodies of the invention to specifically bind neurokinin B
polypeptides or a fragment of neurokinin B polypeptides may be
performed in solution (e.g., Houghten, Bio/Techniques 13:412-421
(1992)), on beads (e.g., Lam, Nature 354:82-84 (1991)), on chips
(e.g., Fodor, Nature 364:555-556 (1993)), on bacteria (e.g., U.S.
Pat. No. 5,223,409), on spores (e.g., U.S. Pat. Nos. 5,571,698;
5,403,484; and 5,223,409), on plasmids (e.g., Cull et al., Proc.
Natl. Acad. Sci. USA 89:1865-1869 (1992)) or on phage (e.g., Scott
and Smith, Science 249:386-390 (1990); Devlin, Science 249:404-406
(1990); Cwirla et al., Proc. Natl. Acad. Sci. USA 87:7178-7182
(1990); and Felici, J. Mol. Biol. 222:301-310 (1991)) (each of
these references is incorporated herein in its entirety by
reference). Antibodies that have been identified to specifically
bind to neurokinin B polypeptides or a fragment or variant of
neurokinin B polypeptides can then be assayed for their specificity
and affinity for neurokinin B polypeptides or a fragment or variant
of a neurokinin B polypeptide using or routinely modifying
techniques described herein or otherwise known in the art.
[0209] The antibodies of the invention may be assayed for specific
binding to neurokinin B polypeptides and cross-reactivity with
other antigens by any method known in the art. Immunoassays which
can be used to analyze specific binding and cross-reactivity
include, but are not limited to, competitive and non-competitive
assay systems using techniques such as BIAcore.TM. analysis, FACS
(fluorescence activated cell sorter) analysis, immunofluorescence,
immunocytochemistry, radioimmunoassays, ELISA (enzyme linked
immunosorbent assay), "sandwich" immunoassays, immunoprecipitation
assays, western blots, precipitin reactions, gel diffusion
precipitin reactions, immunodiffusion assays, agglutination assays,
complement-fixation assays, immunoradiometric assays, fluorescent
immunoassays, and protein A immunoassays, to name but a few. Such
assays are routine and well known in the art (see, e.g., Ausubel et
al., eds, 1994, Current Protocols in Molecular Biology, Vol. 1,
John Wiley & Sons, Inc., New York, which is incorporated by
reference herein in its entirety). Exemplary immunoassays are
described briefly below (but are not intended by way of
limitation).
[0210] ELISAs comprise preparing antigen, coating the well of a
96-well microtiter plate with the antigen, washing away antigen
that did not bind the wells, adding the antibody of interest
conjugated to a detectable compound such as an enzymatic substrate
(e.g., horseradish peroxidase or alkaline phosphatase) to the wells
and incubating for a period of time, washing away unbound
antibodies or non-specifically bound antibodies, and detecting the
presence of the antibodies specifically bound to the antigen
coating the well. In ELISAs, the antibody of interest does not have
to be conjugated to a detectable compound; instead, a second
antibody (which recognizes the antibody of interest) conjugated to
a detectable compound may be added to the well. Alternatively, the
antigen need not be directly coated to the well; instead the ELISA
plates may be coated with an anti-Ig Fc antibody, and the antigen
in the form of a neurokinin B-Fc fusion protein, may be bound to
the anti-Ig Fc coated to the plate. This may be desirable so as to
maintain the antigen protein (e.g., the neurokinin B polypeptides)
in a more native conformation than it may have when it is directly
coated to a plate. In another alternative, instead of coating the
well with the antigen, the antibody may be coated to the well. In
this case, the detectable molecule could be the antigen conjugated
to a detectable compound such as an enzymatic substrate (e.g.,
horseradish peroxidase or alkaline phosphatase). One of skill in
the art would be knowledgeable as to the parameters that can be
modified to increase the signal detected as well as other
variations of ELISAs known in the art. For further discussion
regarding ELISAs see, e.g., Ausubel et al., eds, 1994, Current
Protocols in Molecular Biology, Vol. 1, John Wiley & Sons,
Inc., New York at 11.2.1.
[0211] The binding affinity of an antibody (including an scFv or
other molecule comprising, or alternatively consisting of, antibody
fragments or variants thereof) to an antigen and the off-rate of an
antibody-antigen interaction can be determined by competitive
binding assays. One example of a competitive binding assay is a
radioimmunoassay comprising the incubation of labeled antigen
(e.g., antigen labeled with .sup.3H or .sup.125I), or fragment or
variant thereof with the antibody of interest in the presence of
increasing amounts of unlabeled antigen, and the detection of the
antibody bound to the labeled antigen. The affinity of the antibody
of the present invention for neurokinin B and the binding off-rates
can be determined from the data by Scatchard plot analysis.
Competition with a second antibody can also be determined using
radioimmunoassays. In this case, neurokinin B polypeptide is
incubated with an antibody of the present invention conjugated to a
labeled compound (e.g., compound labeled with .sup.3H or .sup.125I)
in the presence of increasing amounts of an unlabeled second
anti-neurokinin B antibody. This kind of competitive assay between
two antibodies, may also be used to determine if two antibodies
bind the same, closely associated (e.g., overlapping) or different
epitopes.
[0212] In a preferred embodiment, BIAcore.TM. kinetic analysis is
used to determine the binding on and off rates of antibodies
(including antibody fragments or variants thereof) to neurokinin B,
or fragments of neurokinin B. BIAcore.TM. kinetic analysis
comprises analyzing the binding and dissociation of antibodies from
chips with immobilized neurokinin B on their surface.
[0213] Immunoprecipitation protocols generally comprise lysing a
population of cells in a lysis buffer such as RIPA buffer (1% NP-40
or Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl,
0.01 M sodium phosphate at pH 7.2, 1% Trasylol) supplemented with
protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF,
aprotinin, sodium vanadate), adding the antibody of interest to the
cell lysate, incubating for a period of time (e.g., 1 to 4 hours)
at 40 degrees C., adding protein A and/or protein G sepharose beads
to the cell lysate, incubating for about an hour or more at 40
degrees C., washing the beads in lysis buffer and resuspending the
beads in SDS/sample buffer. The ability of the antibody of interest
to immunoprecipitate a particular antigen can be assessed by, e.g.,
western blot analysis. One of skill in the art would be
knowledgeable as to the parameters that can be modified to increase
the binding of the antibody to an antigen and decrease the
background (e.g., pre-clearing the cell lysate with sepharose
beads). For further discussion regarding immunoprecipitation
protocols see, e.g., Ausubel et al., eds, 1994, Current Protocols
in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York
at 10.16.1.
[0214] Western blot analysis generally comprises preparing protein
samples, electrophoresis of the protein samples in a polyacrylamide
gel (e.g., 8%-20% SDS-PAGE depending on the molecular weight of the
antigen), transferring the protein sample from the polyacrylamide
gel to a membrane such as nitrocellulose, PVDF or nylon, blocking
the membrane in blocking solution (e.g., PBS with 3% BSA or non-fat
milk), washing the membrane in washing buffer (e.g., PBS-Tween 20),
blocking the membrane with primary antibody (the antibody of
interest) diluted in blocking buffer, washing the membrane in
washing buffer, blocking the membrane with a secondary antibody
(which recognizes the primary antibody, e.g., an anti-human
antibody) conjugated to an enzymatic substrate (e.g., horseradish
peroxidase or alkaline phosphatase) or radioactive molecule (e.g.,
.sup.32P or .sup.125I) diluted in blocking buffer, washing the
membrane in wash buffer, and detecting the presence of the antigen.
One of skill in the art would be knowledgeable as to the parameters
that can be modified to increase the signal detected and to reduce
the background noise. For further discussion regarding western blot
protocols see, e.g., Ausubel et al., eds, 1994, Current Protocols
in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York
at 10.8.1.
Antibody Conjugates
[0215] The present invention encompasses antibodies (including
antibody fragments or variants thereof), recombinantly fused or
chemically conjugated (including both covalent and non-covalent
conjugations) to a heterologous polypeptide (or portion thereof,
preferably at least 10, at least 20, at least 30, at least 40, at
least 50, at least 60, at least 70, at least 80, at least 90 or at
least 100 amino acids of the polypeptide) to generate fusion
proteins. The fusion does not necessarily need to be direct, but
may occur through linker sequences. For example, antibodies of the
invention may be used to target heterologous polypeptides to
particular cell types (e.g., cancer cells), either in vitro or in
vivo, by fusing or conjugating the heterologous polypeptides to
antibodies of the invention that are specific for particular cell
surface antigens or which bind antigens that bind particular cell
surface receptors. Antibodies of the invention may also be fused to
albumin (including but not limited to recombinant human serum
albumin (see, e.g., U.S. Pat. No. 5,876,969, issued Mar. 2, 1999,
EP Patent 0 413 622, and U.S. Pat. No. 5,766,883, issued Jun. 16,
1998, herein incorporated by reference in their entirety)),
resulting in chimeric polypeptides. In a preferred embodiment,
polypeptides and/or antibodies of the present invention (including
fragments or variants thereof) are fused with the mature form of
human serum albumin (i.e., amino acids 1-585 of human serum albumin
as shown in FIGS. 1 and 2 of EP Patent 0 322 094) which is herein
incorporated by reference in its entirety. In another preferred
embodiment, polypeptides and/or antibodies of the present invention
(including fragments or variants thereof) are fused with
polypeptide fragments comprising, or alternatively consisting of,
amino acid residues 1-z of human serum albumin, where z is an
integer from 369 to 419, as described in U.S. Pat. No. 5,766,883
herein incorporated by reference in its entirety. Polypeptides
and/or antibodies of the present invention (including fragments or
variants thereof) may be fused to either the N- or C-terminal end
of the heterologous protein (e.g., immunoglobulin Fc polypeptide or
human serum albumin polypeptide). Polynucleotides encoding fusion
proteins of the invention are also encompassed by the invention.
Such fusion proteins may, for example, facilitate purification and
may increase half-life in vivo. Antibodies fused or conjugated to
heterologous polypeptides may also be used in in vitro immunoassays
and purification methods using methods known in the art. See e.g.,
Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095;
Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Pat. No.
5,474,981; Gillies et al., PNAS 89:1428-1432 (1992); Fell et al.,
J. Immunol. 146:2446-2452 (1991), which are incorporated by
reference in their entireties.
[0216] The present invention further includes compositions
comprising, or alternatively consisting of, heterologous
polypeptides fused or conjugated to antibody fragments. For
example, the heterologous polypeptides may be fused or conjugated
to a Fab fragment, Fd fragment, Fv fragment, F(ab).sub.2 fragment,
or a portion thereof. Methods for fusing or conjugating
polypeptides to antibody portions are known in the art. See, e.g.,
U.S. Pat. Nos. 5,356,603; 5,622,929; 5,359,046; 5,349,053;
5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO
96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA
88: 10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600
(1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11357-11341
(1992) (said references incorporated by reference in their
entireties).
[0217] Additional fusion proteins of the invention may be generated
through the techniques of gene-shuffling, motif-shuffling,
exon-shuffling, and/or codon-shuffling (collectively referred to as
"DNA shuffling"). DNA shuffling may be employed to modulate the
activities of antibodies (including molecules comprising, or
alternatively consisting of, antibody fragments or variants
thereof), such methods can be used to generate antibodies with
altered activity (e.g., antibodies with higher affinities and lower
dissociation rates). See, generally, U.S. Pat. Nos. 5,605,793;
5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al.,
Curr. Opinion Biotechnol. 8:724-35 (1997); Harayama, Trends
Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. Biol.
287:265-76 (1999); and Lorenzo and Blasco, Biotechniques
24(2):308-13 (1998) (each of these patents and publications are
hereby incorporated by reference in its entirety). In one
embodiment, polynucleotides encoding antibodies of the invention
may be altered by being subjected to random mutagenesis by
error-prone PCR, random nucleotide insertion or other methods prior
to recombination. In another embodiment, one or more portions of a
polynucleotide encoding an antibody which portions specifically
bind to neurokinin B may be recombined with one or more components,
motifs, sections, parts, domains, fragments, etc. of one or more
heterologous molecules.
[0218] Moreover, the antibodies of the present invention (including
antibody fragments or variants thereof), can be fused to marker
sequences, such as a polypeptides to facilitate purification. In
preferred embodiments, the marker amino acid sequence is a
hexa-histidine polypeptide, such as the tag provided in a pQE
vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, Calif., 91311),
among others, many of which are commercially available. As
described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824
(1989), for instance, hexa-histidine provides for convenient
purification of the fusion protein. Other peptide tags useful for
purification include, but are not limited to, the hemagglutinin
"HA" tag, which corresponds to an epitope derived from the
influenza hemagglutinin protein (Wilson et al., Cell 37:767 (1984))
and the FLAG.RTM. tag (STRATAGENE.TM., La Jolla, Calif.).
[0219] The present invention further encompasses antibodies
(including antibody fragments or variants thereof), conjugated to a
diagnostic or therapeutic agent. The antibodies can be used
diagnostically to, for example, monitor or prognose the development
or progression of a tumor as part of a clinical testing procedure
to, e.g., determine the efficacy of a given treatment regimen.
Detection can be facilitated by coupling the antibody to a
detectable substance. Examples of detectable substances include,
but are not limited to, various enzymes, prosthetic groups,
fluorescent materials, luminescent materials, bioluminescent
materials, radioactive materials, positron emitting metals using
various positron emission tomographies, and nonradioactive
paramagnetic metal ions. The detectable substance may be coupled or
conjugated either directly to the antibody or indirectly, through
an intermediate (such as, for example, a linker known in the art)
using techniques known in the art. See, for example, U.S. Pat. No.
4,741,900 for metal ions that can be conjugated to antibodies for
use as diagnostics according to the present invention. Examples of
suitable enzymes include, but are not limited to, horseradish
peroxidase, alkaline phosphatase, beta-galactosidase, or
acetylcholinesterase; examples of suitable prosthetic group
complexes include, but are not limited to, streptavidin/biotin and
avidin/biotin; examples of suitable fluorescent materials include,
but are not limited to, umbelliferone, fluorescein, fluorescein
isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein,
dansyl chloride or phycoerythrin; an example of a luminescent
material includes, but is not limited to, luminol; examples of
bioluminescent materials include, but are not limited to,
luciferase, luciferin, and aequorin; and examples of suitable
radioactive material include, but are not limited to, iodine
(.sup.121I, .sup.123I, .sup.125I, .sup.131I), carbon (.sup.14C),
sulfur (.sup.35S), tritium (.sup.3H), indium (.sup.111In
.sup.112In, .sup.113In, .sup.115In), technetium
(.sup.99Tc,.sup.99mTc), thallium (.sup.201Ti), gallium (.sup.68Ga,
.sup.67Ga), palladium (.sup.103Pd), molybdenum (.sup.99Mo), xenon
(.sup.135Xe), fluorine (.sup.18F), .sup.153Sm, .sup.177Lu,
.sup.159Gd, .sup.149Pm, .sup.140La, .sup.175Yb, .sup.166Ho,
.sup.90Y, .sup.47Sc, .sup.186Re, .sup.88Re, .sup.142Pr, .sup.105Rh,
and .sup.97Ru.
[0220] Further, an antibody of the invention (including an scFv or
other molecule comprising, or alternatively consisting of, antibody
fragments or variants thereof), may be coupled or conjugated to a
therapeutic moiety such as a cytotoxin, e.g., a cytostatic or
cytocidal agent, a therapeutic agent or a radioactive metal ion,
e.g., alpha-emitters such as, for example, .sup.213Bi, or other
radioisotopes such as, for example, .sup.103Pd, .sup.135Xe,
.sup.131I, .sup.68Ge, .sup.57Co, .sup.65Zn, .sup.85Sr, .sup.32P,
.sup.35S, .sup.90Y, .sup.153Sm, .sup.153Gd, .sup.169Yb, .sup.51Cr,
.sup.54Mn, .sup.75Se, .sup.113Sn, .sup.90Y, .sup.117Tin,
.sup.186Re, .sup.188Re and .sup.166Ho. In specific embodiments, an
antibody or fragment thereof is attached to macrocyclic chelators
that chelate radiometal ions, including but not limited to,
.sup.177Lu, .sup.90Y, .sup.166Ho, and .sup.153Sm, to polypeptides.
In specific embodiments, the macrocyclic chelator is
1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid
(DOTA). In other specific embodiments, the DOTA is attached to the
an antibody of the invention or fragment thereof via a linker
molecule. Examples of linker molecules useful for conjugating DOTA
to a polypeptide are commonly known in the art--see, for example,
DeNardo et al., Clin Cancer Res. 4(10):2483-90, 1998; Peterson et
al., Bioconjug. Chem. 10(4):553-7, 1999; and Zimmerman et al.,
Nucl. Med. Biol. 26(8):943-50, 1999, which are hereby incorporated
by reference in their entirety.
[0221] A cytotoxin or cytotoxic agent includes any agent that is
detrimental to cells. Examples include, but are not limited to,
paclitaxol, cytochalasin B, gramicidin D, ethidium bromide,
emetine, mitomycin, etoposide, tenoposide, vincristine,
vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy
anthracin dione, mitoxantrone, mithramycin, actinomycin D,
1-dehydrotestosterone, glucocorticoids, procaine, tetracaine,
lidocaine, propranolol, thymidine kinase, endonuclease, RNAse, and
puromycin and fragments, variants or homologs thereof. Therapeutic
agents include, but are not limited to, antimetabolites (e.g.,
methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine,
5-fluorouracil decarbazine), alkylating agents (e.g.,
mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU)
and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol,
streptozotocin, mitomycin C, and cisdichlorodiamine platinum (II)
(DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly
daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin
(formerly actinomycin), bleomycin, mithramycin, and anthramycin
(AMC)), and anti-mitotic agents (e.g., vincristine and
vinblastine).
[0222] Techniques known in the art may be applied to label
antibodies of the invention. Such techniques include, but are not
limited to, the use of bifunctional conjugating agents (see e.g.,
U.S. Pat. Nos. 5,756,065; 5,714,711; 5,696,239; 5,652,371;
5,505,931; 5,489,425; 5,435,990; 5,428,139; 5,342,604; 5,274,119;
4,994,560; and 5,808,003; the contents of each of which are hereby
incorporated by reference in its entirety) and direct coupling
reactions (e.g., Bolton-Hunter and Chloramine-T reaction).
[0223] The antibodies of the invention that are conjugates can be
used for modifying a given biological response, the therapeutic
agent or drug moiety is not to be construed as limited to classical
chemical therapeutic agents. For example, the drug moiety may be a
protein or polypeptide possessing a desired biological activity.
Such proteins may include, but are not limited to, for example, a
toxin such as abrin, ricin A, alpha toxin, pseudomonas exotoxin, or
diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral
protein, alpha-sarcin and cholera toxin; a protein such as tumor
necrosis factor, alpha-interferon, beta-interferon, nerve growth
factor, platelet derived growth factor, tissue plasminogen
activator, an apoptotic agent, e.g., TNF-alpha, TNF-beta, AIM I
(see, International Publication No. WO 97/35899), Fas Ligand
(Takahashi et al., Int. Immunol., 6:1567-1574 (1994)), VEGI (see,
International Publication No. WO 99/23105), a thrombotic agent or
an anti-angiogenic agent, e.g., angiostatin or endostatin; or,
biological response modifiers such as, for example, lymphokines,
interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-6 (IL-6),
granulocyte macrophage colony stimulating factor (GM-CSF),
granulocyte colony stimulating factor (G-CSF), or other growth
factors.
[0224] Antibodies of the invention (including antibody fragments or
variants thereof), may also be attached to solid supports, which
are particularly useful for immunoassays or purification of the
target antigen. Such solid supports include, but are not limited
to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl
chloride or polypropylene.
[0225] Techniques for conjugating a therapeutic moiety to
antibodies are well known, see, e.g., Amon et al., "Monoclonal
Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in
Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.),
pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies
For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson
et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe,
"Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A
Review", in Monoclonal Antibodies '84: Biological And Clinical
Applications, Pinchera et al. (eds.), pp. 475-506 (1985);
"Analysis, Results, And Future Prospective Of The Therapeutic Use
Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal
Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.),
pp. 303-16 (Academic Press 1985), and Thorpe et al., "The
Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates",
Immunol. Rev. 62:119-58 (1982).
[0226] Alternatively, an antibody of the invention can be
conjugated to a second antibody to form an antibody heteroconjugate
as described by Segal in U.S. Pat. No. 4,676,980, which is
incorporated herein by reference in its entirety.
[0227] An antibody of the invention (including an other molecules
comprising, or alternatively consisting of, an antibody fragment or
variant thereof), with or without a therapeutic moiety conjugated
to it, administered alone or in combination with cytotoxic
factor(s) and/or cytokine(s) can be used as a therapeutic.
Uses of Antibodies of the Invention
[0228] Antibodies of the present invention may be used, for
example, but not limited to, to purify, detect, and target the
polypeptides of the present invention, including both in vitro and
in vivo diagnostic and therapeutic methods. For example, the
antibodies have use in immunoassays for qualitatively and
quantitatively measuring levels of neurokinin B polypeptides (e.g.,
the mature form of neurokinin B) in biological samples. See, e.g.,
Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor
Laboratory Press, 2nd ed. 1988) (incorporated by reference herein
in its entirety).
Immunophenotyping
[0229] The antibodies of the invention may be utilized for
immunophenotyping of cell lines and biological samples. The
translation product of the gene of the present invention may be
useful as a cell specific marker, or more specifically as a
cellular marker that is differentially expressed at various stages
of differentiation and/or maturation of particular cell types, such
as neurons. Monoclonal antibodies directed against a specific
epitope, or combination of epitopes, will allow for the screening
of cellular populations expressing the marker. Various techniques
can be utilized using monoclonal antibodies to screen for cellular
populations expressing the marker(s), and include magnetic
separation using antibody-coated magnetic beads, "panning" with
antibody attached to a solid matrix (i.e., plate), and flow
cytometry (See, e.g., U.S. Pat. No. 5,985,660; and Morrison et al.,
Cell, 96:737-49 (1999)).
[0230] Epitope Mapping
[0231] The present invention provides antibodies (including
antibody fragments or variants thereof) that can be used to
identify epitopes of a neurokinin B polypeptide. In particular, the
antibodies of the present invention can be used to identify
epitopes of a human neurokinin B polypeptide (e.g., SEQ ID NO:2); a
murine neurokinin B; a rat neurokinin B polypeptide; or a monkey
neurokinin B polypeptide, using techniques described herein or
otherwise known in the art. Fragments which function as epitopes
may be produced by any conventional means. (See, e.g., Houghten,
Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985), further described
in U.S. Pat. No. 4,711,211.) Identified epitopes of antibodies of
the present invention may, for example, be used as vaccine
candidates, i.e., to immunize an individual to elicit antibodies
against the naturally occurring forms of neurokinin B
polypeptides.
[0232] Diagnostic Uses of Antibodies
[0233] Labeled antibodies of the invention (including molecules
comprising, or alternatively consisting of, antibody fragments or
variants thereof) that specifically bind to a neurokinin B
polypeptide can be used for diagnostic purposes to detect,
diagnose, prognose, or monitor diseases and/or disorders. In
specific embodiments, labeled antibodies of the invention
(including molecules comprising, or alternatively consisting of,
antibody fragments or variants thereof) that specifically bind to a
neurokinin B polypeptide can be used for diagnostic purposes to
detect, diagnose, prognose, or monitor diseases and/or disorders
associated with the aberrant expression and/or activity of a
neurokinin B polypeptide. In a specific embodiment, labeled
antibodies of the invention that specifically bind to a neurokinin
B polypeptide can be used for diagnostic purposes to detect,
diagnose, prognose, or monitor pre-eclampsia.
[0234] The invention provides for the detection of expression of a
neurokinin B polypeptide comprising: (a) assaying the expression of
a neurokinin B polypeptide in a biological sample from an
individual using one or more antibodies of the invention that
specifically binds to a neurokinin B polypeptide; and (b) comparing
the level of a neurokinin B polypeptide with a standard level of a
neurokinin B polypeptide, (e.g., the level in normal biological
samples).
[0235] The invention provides for the detection of aberrant
expression of a neurokinin B polypeptide comprising: (a) assaying
the expression of a neurokinin B polypeptide in a biological sample
from an individual using one or more antibodies of the invention
that specifically binds to a neurokinin B polypeptide; and (b)
comparing the level of a neurokinin B polypeptide with a standard
level of a neurokinin B polypeptide, e.g., in normal biological
samples, whereby an increase or decrease in the assayed level of a
neurokinin B polypeptide compared to the standard level of a
neurokinin B polypeptide is indicative of aberrant expression.
[0236] By "biological sample" is intended any fluids and/or cells
obtained from an individual, body fluid, body tissue, body cell,
cell line, tissue culture, or other source which may contain a
neurokinin B polypeptide protein or mRNA. Body fluids include, but
are not limited to, sera, plasma, urine, synovial fluid, spinal
fluid, saliva, and mucous. Tissues samples may be taken from
virtually any tissue in the body. Tissue samples may also be
obtained from autopsy material. Methods for obtaining tissue
biopsies and body fluids from mammals are well known in the art.
Where the biological sample is to include mRNA, a tissue biopsy is
the preferred source.
[0237] One aspect of the invention is the detection and diagnosis
of a disease or disorder associated with aberrant expression of a
neurokinin B polypeptide or a neurokinin B polypeptide receptor
(e.g., NK3R) in an animal, preferably a mammal and most preferably
a human. In one embodiment, diagnosis comprises: a) administering
(for example, parenterally, subcutaneously, or intraperitoneally)
to a subject an effective amount of a labeled antibody of the
invention (including molecules comprising, or alternatively
consisting of, antibody fragments or variants thereof) that
specifically binds to a neurokinin B polypeptide; b) waiting for a
time interval following the administering for permitting the
labeled antibody to preferentially concentrate at sites in the
subject where neurokinin B polypeptide is expressed (and for
unbound labeled molecule to be cleared to background level); c)
determining background level; and d) detecting the labeled antibody
in the subject, such that detection of labeled antibody or fragment
thereof above the background level and above or below the level
observed in a person without the disease or disorder indicates that
the subject has a particular disease or disorder associated with
aberrant expression of a neurokinin B polypeptide or a neurokinin B
polypeptide receptor. Background level can be determined by various
methods including, comparing the amount of labeled molecule
detected to a standard value previously determined for a particular
system.
[0238] It will be understood in the art that the size of the
subject and the imaging system used will determine the quantity of
imaging moiety needed to produce diagnostic images. In the case of
a radioisotope moiety, for a human subject, the quantity of
radioactivity injected will normally range from about 5 to 20
millicuries of .sup.99Tc. The labeled antibody will then
preferentially accumulate at the location of cells that contain the
specific protein. In vivo tumor imaging is described in S. W.
Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies
and Their Fragments." (Chapter 13 in Tumor Imaging: The
Radiochemical Detection of Cancer, S. W. Burchiel and B. A. Rhodes,
eds., Masson Publishing Inc. (1982).
[0239] Depending on several variables, including the type of label
used and the mode of administration, the time interval following
the administration for permitting the labeled molecule to
preferentially concentrate at sites in the subject and for unbound
labeled molecule to be cleared to background level is 6 to 48 hours
or 6 to 24 hours or 6 to 12 hours. In another embodiment the time
interval following administration is 5 to 20 days or 5 to 10
days.
[0240] In one embodiment, monitoring of the disease or disorder is
carried out by repeating the method for diagnosing the disease or
disorder, for example, one month after initial diagnosis, six
months after initial diagnosis, one year after initial diagnosis,
etc.
[0241] Presence of the labeled molecule can be detected in the
patient using methods known in the art for in vivo scanning. These
methods depend upon the type of label used. Skilled artisans will
be able to determine the appropriate method for detecting a
particular label. Methods and devices that may be used in the
diagnostic methods of the invention include, but are not limited
to, computed tomography (CT), whole body scan such as position
emission tomography (PET), magnetic resonance imaging (MRI), and
sonography.
[0242] In a specific embodiment, the molecule is labeled with a
radioisotope and is detected in the patient using a radiation
responsive surgical instrument (Thurston et al., U.S. Pat. No.
5,441,050). In another embodiment, the molecule is labeled with a
fluorescent compound and is detected in the patient using a
fluorescence responsive scanning instrument. In another embodiment,
the molecule is labeled with a positron emitting metal and is
detected in the patient using positron emission-tomography. In yet
another embodiment, the molecule is labeled with a paramagnetic
label and is detected in a patient using magnetic resonance imaging
(MRI).
[0243] In specific embodiments, antibodies of the present invention
may be used to detect elevated levels of neurokinin B during
pregnancy. Excessive concentrations of neurokinin B were detected
in plasma during pregnancy-induced hypertension and pre-eclampsia
(Page et al. Nature 405:797-800 (2000)). Thus, elevated levels of
neurokinin B in early pregnancy may be an indicator of
pregnancy-induced hypertension and pre-eclampsia.
[0244] In specific embodiments, antibodies of the present invention
may be used in the diagnosis, prevention, and treatment of
hypertension, inflammation, asthma, gastrointestinal disorders,
anxiety, depression, addiction, or pain particularly those diseases
and/or disorders described in the "Therapeutic Uses of Antibodies"
sections below.
[0245] Therapeutic Uses of Antibodies
[0246] One or more antibodies of the present invention (including
molecules comprising, or alternatively consisting of, antibody
fragments or variants thereof) that specifically bind to neurokinin
B may be used locally or systemically in the body as a therapeutic.
The present invention is further directed to antibody-based
therapies which involve administering antibodies of the invention
(including molecules comprising, or alternatively consisting of,
antibody fragments or variants thereof) to an animal, preferably a
mammal, and most preferably a human, for preventing or treating one
or more of the disclosed diseases, disorders, or conditions.
Therapeutic compounds of the invention include, but are not limited
to, antibodies of the invention and nucleic acids encoding
antibodies (and anti-idiotypic antibodies) of the invention as
described herein. In one embodiment, the antibodies of the
invention can be used to treat, ameliorate or prevent diseases,
disorders or conditions, including, but not limited to, any one or
more of the diseases, disorders, or conditions described herein.
The treatment and/or prevention of diseases, disorders, or
conditions includes, but is not limited to, alleviating symptoms
associated with those diseases, disorders or conditions. Antibodies
of the invention may be provided in pharmaceutically acceptable
compositions as known in the art or as described herein.
[0247] Therapeutic Uses of Antibodies for Treating Vascular
Disorders
[0248] In highly preferred embodiments, antibodies of the present
invention are used to treat, prevent, and/or diagnose
pre-eclampsia.
[0249] In highly preferred embodiments, antibodies of the present
invention are used to treat, prevent, diagnose, and/or prognose
hypertension.
[0250] In additional embodiments, antibodies of the present
invention may be used to treat, prevent, diagnose, and/or prognose
hypotension.
[0251] Other cardiovascular disorders that are treated, prevented,
or diagnosed with antibodies of the present invention include, but
are not limited to, heart disease, such as arrhythmias, carcinoid
heart disease, high cardiac output, low cardiac output, cardiac
tamponade, endocarditis (including bacterial), heart aneurysm,
cardiac arrest, congestive heart failure, congestive
cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart
hypertrophy, congestive cardiomyopathy, left ventricular
hypertrophy, right ventricular hypertrophy, post-infarction heart
rupture, ventricular septal rupture, heart valve diseases,
myocardial diseases, myocardial ischemia, pericardial effusion,
pericarditis (including constrictive and tuberculous),
pneumopericardium, postpericardiotomy syndrome, pulmonary heart
disease, rheumatic heart disease, ventricular dysfunction,
hyperemia, cardiovascular pregnancy complications, Scimitar
Syndrome, cardiovascular syphilis, and cardiovascular
tuberculosis.
[0252] Other cardiovascular disorders that are treated, prevented,
or diagnosed with antibodies of the present invention include, but
are not limited to, vascular diseases such as aneurysms,
angiodysplasia, angiomatosis, bacillary angiomatosis, Hippel-Lindau
Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome,
angioneurotic edema, aortic diseases, Takayasu's Arteritis,
aortitis, Leriche's Syndrome, arterial occlusive diseases,
arteritis, enarteritis, polyarteritis nodosa, cerebrovascular
disorders, diabetic angiopathies, diabetic retinopathy, embolisms,
thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive
disease, hypertension, hypotension, ischemia, peripheral vascular
diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's
disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome,
superior vena cava syndrome, telangiectasia, atacia telangiectasia,
hereditary hemorrhagic telangiectasia, varicocele, varicose veins,
varicose ulcer, vasculitis, and venous insufficiency.
[0253] Other cardiovascular disorders that are treated, prevented,
or diagnosed with antibodies of the present invention include, but
are not limited to, carotid artery diseases, cerebral amyloid
angiopathy, cerebral aneurysm, cerebral anoxia, cerebral
arteriosclerosis, cerebral arteriovenous malformation, cerebral
artery diseases, cerebral embolism and thrombosis, carotid artery
thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral
hemorrhage, epidural hematoma, subdural hematoma, subaraxhnoid
hemorrhage, cerebral infarction, cerebral ischemia (including
transient), subclavian steal syndrome, periventricular
leukomalacia, vascular headache, cluster headache, migraine, and
vertebrobasilar insufficiency.
[0254] Therapeutic Uses of Antibodies for Treating Inflammatory
Disorders
[0255] In highly preferred embodiments, antibodies and antibody
compositions of the invention are useful for treating, diagnosing,
preventing, and/or detecting inflammatory diseases, such as
irritable bowel syndrome and/or inflammatory bowel disease.
[0256] In highly preferred embodiments, antibodies and antibody
compositions of the invention are useful for treating, diagnosing,
preventing, and/or detecting allergy and/or asthma.
[0257] In other preferred embodiments, antibodies and antibody
compositions of the invention are useful in the diagnosis and
treatment or prevention of immune diseases and disorders including,
but not limited to, inflammation associated with infection (e.g.,
septic shock, sepsis, or systemic inflammatory response syndrome),
ischemia-reperfusion injury, endotoxin lethality,
complement-mediated hyperacute rejection, nephritis, cytokine or
chemokine induced lung injury, inflammatory bowel disease, Crohn's
disease, over production of cytokines (e.g., TNF or IL-1.),
respiratory disorders (e.g., asthma and allergy); gastrointestinal
disorders (e.g., inflammatory bowel disease); cancers (e.g.,
gastric, ovarian, lung, bladder, liver, and breast); CNS disorders
(e.g., multiple sclerosis; ischemic brain injury and/or stroke,
traumatic brain injury, neurodegenerative disorders (e.g.,
Parkinson's disease and Alzheimer's disease); AIDS-related
dementia; and prion disease); cardiovascular disorders (e.g.,
atherosclerosis, myocarditis, cardiovascular disease, and
cardiopulmonary bypass complications); as well as many additional
diseases, conditions, and disorders that are characterized by
inflammation (e.g., hepatitis, rheumatoid arthritis, gout, trauma,
pancreatitis, sarcoidosis, dermatitis, renal ischemia-reperfusion
injury, Grave's disease, systemic lupus erythematosus, diabetes
mellitus, and allogenic transplant rejection).
[0258] Because inflammation is a fundamental defense mechanism,
inflammatory disorders can affect virtually any tissue of the body.
Accordingly, antibodies of the invention have uses in the treatment
of tissue-specific inflammatory disorders, including, but not
limited to, adrenalitis, alveolitis, angiocholecystitis,
appendicitis, balanitis, blepharitis, bronchitis, bursitis,
carditis, cellulitis, cervicitis, cholecystitis, chorditis,
cochlitis, colitis, conjunctivitis, cystitis, dermatitis,
diverticulitis, encephalitis, endocarditis, esophagitis,
eustachitis, fibrositis, folliculitis, gastritis, gastroenteritis,
gingivitis, glossitis, hepatosplenitis, keratitis, labyrinthitis,
laryngitis, lymphangitis, mastitis, media otitis, meningitis,
metritis, mucitis, myocarditis, myosititis, myringitis, nephritis,
neuritis, orchitis, osteochondritis, otitis, pericarditis,
peritendonitis, peritonitis, pharyngitis, phlebitis, poliomyelitis,
prostatitis, pulpitis, retinitis, rhinitis, salpingitis, scleritis,
sclerochoroiditis, scrotitis, sinusitis, spondylitis, steatitis,
stomatitis, synovitis, syringitis, tendonitis, tonsillitis,
urethritis, and vaginitis.
[0259] In another highly preferred embodiment, antibodies and
antibody compositions of the invention are used as an adjuvant to
enhance immune responsiveness to specific antigens, such as in
anti-viral immune responses.
[0260] More generally, antibodies and antibody compositions of the
invention are useful in regulating (i.e., elevating or reducing)
immune response. For example, antibodies and antibody compositions
of the invention may be useful in preparation or recovery from
surgery, trauma, radiation therapy, chemotherapy, and
transplantation, or may be used to boost immune response and/or
recovery in the elderly and immunocompromised individuals.
Alternatively, antibodies and antibody compositions of the
invention are useful as immunosuppressive agents, for example in
the treatment or prevention of autoimmune disorders. In specific
embodiments, antibodies and antibody compositions of the invention
are used to treat or prevent chronic inflammatory, allergic or
autoimmune conditions, such as those described herein or are
otherwise known in the art.
[0261] Therapeutic and Diagnostic Uses of Antibodies for Treating
Gastrointestinal Disorders
[0262] Antibodies of the present invention are used to treat,
prevent, diagnose, and/or prognose gastrointestinal disorders,
including inflammatory diseases (irritable bowel syndrome,
inflammatory bowel disorder) and/or conditions, infections,
cancers, and ulcers, such as peptic ulcers.
[0263] Other gastrointestinal disorders that are treated,
prevented, or diagnosed with antibodies of the present invention
include, but are not limited to, dysphagia, odynophagia,
inflammation of the esophagus, peptic esophagitis, gastric reflux,
submucosal fibrosis and stricturing, Mallory-Weiss lesions,
leiomyomas, lipomas, epidermal cancers, adeoncarcinomas, gastric
retention disorders, gastroenteritis, gastric atrophy,
gastric/stomach cancers, polyps of the stomach, autoimmune
disorders such as pernicious anemia, pyloric stenosis, gastritis
(bacterial, viral, eosinophilic, stress-induced, chronic erosive,
atrophic, plasma cell, and Menetrier's), and peritoneal diseases
(e.g., chyloperioneum, hemoperitoneum, mesenteric cyst, mesenteric
lymphadenitis, mesenteric vascular occlusion, panniculitis,
neoplasms, peritonitis, pneumoperitoneum, and bubphrenic
abscess).
[0264] Other gastrointestinal disorders that are treated,
prevented, or diagnosed with antibodies of the present invention
include, but are not limited to, disorders associated with the
small intestine, such as malabsorption syndromes, distension,
irritable bowel syndrome, sugar intolerance, celiac disease,
duodenal ulcers, duodenitis, tropical sprue, Whipple's disease,
intestinal lymphangiectasia, Crohn's disease, appendicitis,
obstructions of the ileum, Meckel's diverticulum, multiple
diverticula, failure of complete rotation of the small and large
intestine, lymphoma, and bacterial and parasitic diseases (such as
Traveler's diarrhea, typhoid and paratyphoid, cholera, infection by
Roundworms (Ascariasis lumbricoides), Hookworms (Ancylostoma
duodenale), Threadworms (Enterobius vermicularis), Tapeworms
(Taenia saginata, Echinococcus granulosus, Diphyllobothrium spp.,
and T. solium).
[0265] Other gastrointestinal disorders that are treated,
prevented, or diagnosed with antibodies of the present invention
include, but are not limited to, liver diseases and/or disorders
include intrahepatic cholestasis (alagille syndrome, biliary liver
cirrhosis), fatty liver (alcoholic fatty liver, reye syndrome),
hepatic vein thrombosis, hepatolentricular degeneration,
hepatomegaly, hepatopulmonary syndrome, hepatorenal syndrome,
portal hypertension (esophageal and gastric varices), liver abscess
(amebic liver abscess), liver cirrhosis (alcoholic, biliary and
experimental), alcoholic liver diseases (fatty liver, hepatitis,
cirrhosis), parasitic (hepatic echinococcosis, fascioliasis, amebic
liver abscess), jaundice (hemolytic, hepatocellular, and
cholestatic), cholestasis, portal hypertension, liver enlargement,
ascites, hepatitis (alcoholic hepatitis, animal hepatitis, chronic
hepatitis (autoimmune, hepatitis B, hepatitis C, hepatitis D, drug
induced), toxic hepatitis, viral human hepatitis (hepatitis A,
hepatitis B, hepatitis C, hepatitis D, hepatitis E), Wilson's
disease, granulomatous hepatitis, secondary biliary cirrhosis,
hepatic encephalopathy, portal hypertension, varices, hepatic
encephalopathy, primary biliary cirrhosis, primary sclerosing
cholangitis, hepatocellular adenoma, hemangiomas, bile stones,
liver failure (hepatic encephalopathy, acute liver failure), and
liver neoplasms (angiomyolipoma, calcified liver metastases, cystic
liver metastases, epithelial tumors, fibrolamellar hepatocarcinoma,
focal nodular hyperplasia, hepatic adenoma, hepatobiliary
cystadenoma, hepatoblastoma, hepatocellular carcinoma, hepatoma,
liver cancer, liver hemangioendothelioma, mesenchymal hamartoma,
mesenchymal tumors of liver, nodular regenerative hyperplasia,
benign liver tumors (Hepatic cysts [Simple cysts, Polycystic liver
disease, Hepatobiliary cystadenoma, Choledochal cyst], Mesenchymal
tumors [Mesenchymal hamartoma, Infantile hemangioendothelioma,
Hemangioma, Peliosis hepatis, Lipomas, Inflammatory pseudotumor,
Miscellaneous], Epithelial tumors [Bile duct epithelium (Bile duct
hamartoma, Bile duct adenoma), Hepatocyte (Adenoma, Focal nodular
hyperplasia, Nodular regenerative hyperplasia)], malignant liver
tumors [hepatocellular, hepatoblastoma, hepatocellular carcinoma,
cholangiocellular, cholangiocarcinoma, cystadenocarcinoma, tumors
of blood vessels, angiosarcoma, Karposi's sarcoma,
hemangioendothelioma, other tumors, embryonal sarcoma,
fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, carcinosarcoma,
teratoma, carcinoid, squamous carcinoma, primary lymphoma]),
peliosis hepatis, erythrohepatic porphyria, hepatic porphyria
(acute intermittent porphyria, porphyria cutanea tarda), Zellweger
syndrome).
[0266] Other gastrointestinal disorders that are treated,
prevented, or diagnosed with antibodies of the present invention
include, but are not limited to, pancreatic diseases and/or
disorders include acute pancreatitis, chronic pancreatitis (acute
necrotizing pancreatitis, alcoholic pancreatitis), neoplasms
(adenocarcinoma of the pancreas, cystadenocarcinoma, insulinoma,
gastrinoma, and glucagonoma, cystic neoplasms, islet-cell tumors,
pancreoblastoma), and other pancreatic diseases (e.g., cystic
fibrosis, cyst (pancreatic pseudocyst, pancreatic fistula,
insufficiency)).
[0267] Other gastrointestinal disorders that are treated,
prevented, or diagnosed with antibodies of the present invention
include, but are not limited to, gallbladder diseases include
gallstones (cholelithiasis and choledocholithiasis),
postcholecystectomy syndrome, diverticulosis of the gallbladder,
acute cholecystitis, chronic cholecystitis, bile duct tumors, and
mucocele.
[0268] Other gastrointestinal disorders that are treated,
prevented, or diagnosed with antibodies of the present invention
include, but are not limited to, diseases and/or disorders of the
large intestine include antibiotic-associated colitis,
diverticulitis, ulcerative colitis, acquired megacolon, abscesses,
fungal and bacterial infections, anorectal disorders (e.g.,
fissures, hemorrhoids), colonic diseases (colitis, colonic
neoplasms [colon cancer, adenomatous colon polyps (e.g., villous
adenoma), colon carcinoma, colorectal cancer], colonic
diverticulitis, colonic diverticulosis, megacolon [Hirschsprung
disease, toxic megacolon]; sigmoid diseases [proctocolitis, sigmoin
neoplasms]), constipation, Crohn's disease, diarrhea (infantile
diarrhea, dysentery), duodenal diseases (duodenal neoplasms,
duodenal obstruction, duodenal ulcer, duodenitis), enteritis
(enterocolitis), HIV enteropathy, ileal diseases (ileal neoplasms,
ileitis), immunoproliferative small intestinal disease,
inflammatory bowel disease (ulcerative colitis, Crohn's disease),
intestinal atresia, parasitic diseases (anisakiasis, balantidiasis,
blastocystis infections, cryptosporidiosis, dientamoebiasis, amebic
dysentery, giardiasis), intestinal fistula (rectal fistula),
intestinal neoplasms (cecal neoplasms, colonic neoplasms, duodenal
neoplasms, ileal neoplasms, intestinal polyps, jejunal neoplasms,
rectal neoplasms), intestinal obstruction (afferent loop syndrome,
duodenal obstruction, impacted feces, intestinal pseudo-obstruction
[cecal volvulus], intussusception), intestinal perforation,
intestinal polyps (colonic polyps, gardner syndrome, peutz-jeghers
syndrome), jejunal diseases (ejunal neoplasms), malabsorption
syndromes (blind loop syndrome, celiac disease, lactose
intolerance, short bowl syndrome, tropical sprue, whipple's
disease), mesenteric vascular occlusion, pneumatosis cystoides
intestinalis, protein-losing enteropathies (intestinal
lymphagiectasis), rectal diseases (anus diseases, fecal
incontinence, hemorrhoids, proctitis, rectal fistula, rectal
prolapse, rectocele), peptic ulcer (duodenal ulcer, peptic
esophagitis, hemorrhage, perforation, stomach ulcer,
Zollinger-Ellison syndrome), postgastrectomy syndromes (dumping
syndrome), stomach diseases (e.g., achlorhydria, duodenogastric
reflux (bile reflux), gastric antral vascular ectasia, gastric
fistula, gastric outlet obstruction, gastritis (atrophic or
hypertrophic), gastroparesis, stomach dilatation, stomach
diverticulum, stomach neoplasms (gastric cancer, gastric polyps,
gastric adenocarcinoma, hyperplastic gastric polyp), stomach
rupture, stomach ulcer, stomach volvulus), tuberculosis,
visceroptosis, vomiting (e.g., hematemesis, hyperemesis gravidarum,
postoperative nausea and vomiting) and hemorrhagic colitis.
[0269] Other gastrointestinal disorders that are treated,
prevented, or diagnosed with antibodies of the present invention
include, but are not limited to, biliary tract diseases, such as,
gastroschisis, fistula (e.g., biliary fistula, esophageal fistula,
gastric fistula, intestinal fistula, pancreatic fistula), neoplasms
(e.g., biliary tract neoplasms, esophageal neoplasms, such as
adenocarcinoma of the esophagus, esophageal squamous cell
carcinoma, gastrointestinal neoplasms, pancreatic neoplasms, such
as adenocarcinoma of the pancreas, mucinous cystic neoplasm of the
pancreas, pancreatic cystic neoplasms, pancreatoblastoma, and
peritoneal neoplasms), esophageal disease (e.g., bullous diseases,
candidiasis, glycogenic acanthosis, ulceration, barrett esophagus
varices, atresia, cyst, diverticulum (e.g., Zenker's diverticulum),
fistula (e.g., tracheoesophageal fistula), motility disorders
(e.g., CREST syndrome, deglutition disorders, achalasia, spasm,
gastroesophageal reflux), neoplasms, perforation (e.g., Boerhaave
syndrome, Mallory-Weiss syndrome), stenosis, esophagitis,
diaphragmatic hernia (e.g., hiatal hernia); gastrointestinal
diseases, such as, gastroenteritis (e.g., cholera morbus, norwalk
virus infection), hemorrhage (e.g., hematemesis, melena, peptic
ulcer hemorrhage), stomach neoplasms (gastric cancer, gastric
polyps, gastric adenocarcinoma, stomach cancer)), hernia (e.g.,
congenital diaphragmatic hernia, femoral hernia, inguinal hernia,
obturator hernia, umbilical hernia, ventral hernia), and intestinal
diseases (e.g., cecal diseases (appendicitis, cecal
neoplasms)).
[0270] Therapeutic Uses of Antibodies for Treating Neurological
Disorders
[0271] In preferred embodiments antibodies and/or antibody
compositions are used to treat, detect, diagnose, and/or ameliorate
neurologic diseases such as pain, depression, anxiety, and
addiction.
[0272] Additional neurologic disorders that are treated, detected,
diagnosed, and/or ameliorated with antibodies of the invention
include hereditary motor and sensory neuropathies which include
Charcot-Marie Disease, Hereditary optic atrophy, Refsum's Disease,
hereditary spastic paraplegia, Werdnig-Hoffmann Disease, Hereditary
Sensory and Autonomic Neuropathies such as Congenital Analgesia and
Familial Dysautonomia, Neurologic manifestations (such as agnosia
that include Gerstmann's Syndrome, Amnesia such as retrograde
amnesia, apraxia, neurogenic bladder, cataplexy, communicative
disorders such as hearing disorders that includes deafness, partial
hearing loss, loudness recruitment and tinnitus, language disorders
such as aphasia which include agraphia, anomia, broca aphasia, and
Wernicke Aphasia, Dyslexia such as Acquired Dyslexia, language
development disorders, speech disorders such as aphasia which
includes anomia, broca aphasia and Wernicke Aphasia, articulation
disorders, communicative disorders such as speech disorders which
include dysarthria, echolalia, mutism and stuttering, voice
disorders such as aphonia and hoarseness, decerebrate state,
delirium, fasciculation, hallucinations, meningism, movement
disorders such as angelman syndrome, ataxia, athetosis, chorea,
dystonia, hypokinesia, muscle hypotonia, myoclonus, tic,
torticollis and tremor, muscle hypertonia such as muscle rigidity
such as stiff-man syndrome, muscle spasticity, paralysis such as
facial paralysis which includes Herpes Zoster Oticus,
Gastroparesis, Hemiplegia, opthalmoplegia such as diplopia, Duane's
Syndrome, Horner's Syndrome, Chronic progressive external
opthalmoplegia such as Kearns Syndrome, Bulbar Paralysis, Tropical
Spastic Paraparesis, Paraplegia such as Brown-Sequard Syndrome,
quadriplegia, respiratory paralysis and vocal cord paralysis,
paresis, phantom limb, taste disorders such as ageusia and
dysgeusia, vision disorders such as amblyopia, blindness, color
vision defects, diplopia, hemianopsia, scotoma and subnormal
vision, sleep disorders such as hypersomnia which includes
Kleine-Levin Syndrome, insomnia, and somnambulism, spasm such as
trismus, unconsciousness such as coma, persistent vegetative state
and syncope and vertigo, neuromuscular diseases such as amyotonia
congenita, amyotrophic lateral sclerosis, Lambert-Eaton Myasthenic
Syndrome, motor neuron disease, muscular atrophy such as spinal
muscular atrophy, Charcot-Marie Disease and Werdnig-Hoffmann
Disease, Postpoliomyelitis Syndrome, Muscular Dystrophy, Myasthenia
Gravis, Myotonia Atrophica, Myotonia Confenita, Nemaline Myopathy,
Familial Periodic Paralysis, Multiplex Paramyloclonus, Tropical
Spastic Paraparesis and Stiff-Man Syndrome, peripheral nervous
system diseases such as acrodynia, amyloid neuropathies, autonomic
nervous system diseases such as Adie's Syndrome, Barre-Lieou
Syndrome, Familial Dysautonomia, Horner's Syndrome, Reflex
Sympathetic Dystrophy and Shy-Drager Syndrome, Cranial Nerve
Diseases such as Acoustic Nerve Diseases such as Acoustic Neuroma
which includes Neurofibromatosis 2, Facial Nerve Diseases such as
Facial Neuralgia, Melkersson-Rosenthal Syndrome, ocular motility
disorders which includes amblyopia, nystagmus, oculomotor nerve
paralysis, opthalmoplegia such as Duane's Syndrome, Horner's
Syndrome, Chronic Progressive External Opthalmoplegia which
includes Kearns Syndrome, Strabismus such as Esotropia and
Exotropia, Oculomotor Nerve Paralysis, Optic Nerve Diseases such as
Optic Atrophy which includes Hereditary Optic Atrophy, Optic Disk
Drusen, Optic Neuritis such as Neuromyelitis Optica, Papilledema,
Trigeminal Neuralgia, Vocal Cord Paralysis, Demyelinating Diseases
such as Neuromyelitis Optica and Swayback, and Diabetic
neuropathies such as diabetic foot.
[0273] Additional neurologic diseases that are treated or detected
with antibodies of the present invention include cerebrovascular
disorders (such as carotid artery diseases which include carotid
artery thrombosis, carotid stenosis and Moyamoya Disease), cerebral
amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral
arteriosclerosis, cerebral arteriovenous malformations, cerebral
artery diseases, cerebral embolism and thrombosis such as carotid
artery thrombosis, sinus thrombosis and Wallenberg's Syndrome,
cerebral hemorrhage such as epidural hematoma, subdural hematoma
and subarachnoid hemorrhage, cerebral infarction, cerebral ischemia
such as transient cerebral ischemia, Subclavian Steal Syndrome and
vertebrobasilar insufficiency, vascular dementia such as
multi-infarct dementia, periventricular leukomalacia, vascular
headache such as cluster headache and migraine.
[0274] The antibodies and/or antibody compositions of the invention
are also useful in the treatment or prevention of neurodegenerative
disease states and/or behavioural disorders. Such neurodegenerative
disease states and/or behavioral disorders include, but are not
limited to, Alzheimer's Disease, Parkinson's Disease, Huntington's
Disease, Tourette Syndrome, schizophrenia, mania, dementia,
paranoia, obsessive compulsive disorder, panic disorder, learning
disabilities, ALS, psychoses, autism, and altered behaviors,
including disorders in feeding, sleep patterns, balance, and
perception.
[0275] Additional Therapeutic Uses of Antibodies
[0276] The antibodies of the invention are used to diagnose, treat,
ameliorate or prevent diseases, disorders or conditions associated
with aberrant expression and/or activity of neurokinin B,
including, but not limited to, any one or more of the diseases,
disorders, or conditions described herein. The treatment and/or
prevention of diseases, disorders, or conditions associated with
aberrant neurokinin B expression and/or activity includes, but is
not limited to, alleviating symptoms associated with those
diseases, disorders or conditions. Antibodies of the invention may
be provided in pharmaceutically acceptable compositions as known in
the art or as described herein.
[0277] Antibodies of the present invention (including molecules
comprising, or alternatively consisting of, antibody fragments or
variants thereof) that function as agonists or antagonists of a
neurokinin B, preferably of neurokinin B signal transduction, can
be administered to an animal to diagnose, treat, prevent or
ameliorate a disease or disorder associated aberrant neurokinin B
expression, function, or aberrant neurokinin B receptor expression
or function. For example, antibodies of the invention which mimic
the action of neurokinin B binding to the neurokinin B receptor, in
full or in part, (e.g., antibodies that act as neurokinin B
agonists), may be administered to an animal to diagnose, treat,
prevent or ameliorate a disease or disorder with associated
aberrant neurokinin B expression and/or function or aberrant
neurokinin B receptor expression and/or function. As an alternative
example, antibodies of the invention which disrupt or prevent the
interaction between neurokinin B and its receptor or inhibit,
reduce, or prevent signal transduction through one or more
neurokinin B receptors, may be administered to an animal to
diagnose, treat, prevent or ameliorate a disease or disorder
associated with associated aberrant neurokinin B expression and/or
function or aberrant neurokinin B receptor expression and/or
function. Antibodies of the invention which do not prevent
neurokinin B from binding its ligand but inhibit or downregulate
neurokinin B signal transduction can be administered to an animal
to diagnose, treat, prevent or ameliorate a disease or disorder
associated with aberrant neurokinin B expression, lack of
neurokinin B function, aberrant neurokinin B receptor expression,
or lack of neurokinin B receptor function. The ability of an
antibody of the invention to enhance, inhibit, upregulate or
downregulate neurokinin B signal transduction may be determined by
techniques described herein or otherwise known in the art. For
example, neurokinin B-induced receptor activation and the
activation of signaling molecules can be determined by detecting
the association of adaptor proteins with the neurokinin B
receptors, by immunoprecipitation followed by western blot analysis
(for example, as described herein).
[0278] Further, antibodies of the present invention (including
molecules comprising, or alternatively consisting of, antibody
fragments or variants thereof) which inhibit neurokinin B-mediated
biological activities (e.g., neurokinin B-mediated vasoconstriction
of blood vessels) can be administered to an animal to diagnose,
treat, prevent or ameliorate a disease or disorder described
herein, particularly pre-eclampsia, hypertension, and other
vascular disorders. These antibodies may inhibit or abolish either
all or a subset of the biological activities of neurokinin B, for
example, by inducing a conformational change in neurokinin B. In a
specific embodiment, an antibody of the present invention that
decreases neurokinin B activity by at least 95%, at least 90%, at
least 85%, at least 80%, at least 75%, at least 70%, at least 65%,
at least 60%, at least 55%, at least 50%, at least 45%, at least
40%, at least 45%, at least 35%, at least 30%, at least 25%, at
least 20%, or at least 10% relative to neurokinin B activity in
absence of the antibody is administered to an animal to diagnose,
treat, prevent or ameliorate a disease or disorder. In another
embodiment, a combination of antibodies, a combination of antibody
fragments, a combination of antibody variants, or a combination of
antibodies, antibody fragments and/or antibody variants that
decrease neurokinin B activity by at least 95%, at least 90%, at
least 85%, at least 80%, at least 75%, at least 70%, at least 65%,
at least 60%, at least 55%, at least 50%, at least 45%, at least
40%, at least 45%, at least 35%, at least 30%, at least 25%, at
least 20%, or at least 10% relative to neurokinin B activity in
absence of the said antibodies or antibody fragments and/or
antibody variants is administered to an animal to diagnose, treat,
prevent or ameliorate a disease or disorder.
[0279] In a specific embodiment, an antibody of the present
invention (including molecules comprising, or alternatively
consisting of, antibody fragments or variants thereof) that
stimulates or upregulates, in full or in part, neurokinin B
activity (e.g., neurokinin B-mediated vasoconstriction of blood
vessels) by at least 5%, at least 10%, at least 15%, at least 20%,
at least 25%, at least 30%, at least 35%, at least 40%, at least
45%, at least 50%, at least 55%, at least 60%, at least 65%, at
least 70%, at least 75%, at least 80%, at least 85%, at least 90%,
at least 95%, at least 99%, at least two-fold, at least three-fold,
at least four fold, at least five fold, at least ten-fold, at least
twenty-fold, at least fifty-fold, or at least one hundred-fold
relative to neurokinin B activity in absence of the antibody is
administered to an animal to diagnose, treat, prevent or ameliorate
a disease or disorder associated with associated aberrant
neurokinin B expression and/or function or aberrant neurokinin B
receptor expression and/or function. In another embodiment, a
combination of antibodies, a combination of antibody fragments, a
combination of antibody variants, or a combination of antibodies,
antibody fragments, and/or variants that stimulate or upregulate
neurokinin B activity by at least 5%, at least 10%, at least 15%,
at least 20%, at least 25%, at least 30%, at least 35%, at least
40%, at least 45%, at least 50%, at least 55%, at least 60%, at
least 65%, at least 70%, at least 75%, at least 80%, at least 85%,
at least 90%, at least 95%, at least 99%, at least two-fold, at
least three-fold, at least four fold, at least five fold, at least
ten-fold, at least twenty-fold, at least fifty-fold, or at least
one hundred-fold relative to neurokinin B activity in absence of
said antibodies, antibody fragments, and/or antibody variants are
administered to an animal to diagnose, treat, prevent or ameliorate
a disease or disorder associated with associated aberrant
neurokinin B expression and/or function or aberrant neurokinin B
receptor expression and/or function.
[0280] Suitable agents, which also block binding of neurokinin B to
a neurokinin B receptor (e.g., NK3R) that may be administered with
the antibodies of the present invention include, but are not
limited to, soluble neurokinin B receptor polypeptides; multimeric
forms of soluble neurokinin B receptor polypeptides;
anti-neurokinin B antibodies that bind the neurokinin B without
transducing the biological signal that results in vasoconstriction;
anti-neurokinin B antibodies that block binding of neurokinin B to
one or more neurokinin B receptors; and muteins of neurokinin B
that bind neurokinin B receptors but do not transduce the
biological signal that results in vasoconstriction.
Therapeutic/Prophylactic Compositions and Administration
[0281] The invention provides methods of treatment, inhibition and
prophylaxis by administration to a subject of an effective amount
of antibody (or fragment or variant thereof) or pharmaceutical
composition of the invention, preferably an antibody of the
invention. In a preferred aspect, an antibody or fragment or
variant thereof is substantially purified (i.e., substantially free
from substances that limit its effect or produce undesired
side-effects). The subject is preferably an animal, including but
not limited to, animals such as cows, pigs, horses, chickens, cats,
dogs, etc., and is preferably a mammal, and most preferably a
human.
[0282] Formulations and methods of administration that can be
employed when the compound comprises a nucleic acid or an
immunoglobulin are described above; additional appropriate
formulations and routes of administration can be selected from
among those described herein below.
[0283] Various delivery systems are known and can be used to
administer an antibody of the invention or a fragment or variant
thereof, e.g., encapsulation in liposomes, microparticles,
microcapsules, recombinant cells capable of expressing the antibody
or antibody fragment, receptor-mediated endocytosis (see, e.g., Wu
and Wu, J. Biol. Chem. 262:4429-4432 (1987)), construction of a
nucleic acid as part of a retroviral or other vector, etc. Methods
of introduction include, but are not limited to, intradermal,
intramuscular, intraperitoneal, intravenous, subcutaneous,
intranasal, epidural, and oral routes. The compositions may be
administered by any convenient route, for example by infusion or
bolus injection, by absorption through epithelial or mucocutaneous
linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and
may be administered together with other biologically active agents.
Administration can be systemic or local. In addition, it may be
desirable to introduce the pharmaceutical compositions of the
invention into the central nervous system by any suitable route,
including intraventricular and intrathecal injection;
intraventricular injection may be facilitated by an
intraventricular catheter, for example, attached to a reservoir,
such as an Ommaya reservoir. Pulmonary administration can also be
employed, e.g., by use of an inhaler or nebulizer, and formulation
with an aerosolizing agent.
[0284] In a specific embodiment, it may be desirable to administer
the pharmaceutical compositions of the invention locally to the
area in need of treatment; this may be achieved by, for example,
and not by way of limitation, local infusion during surgery,
topical application, e.g., in conjunction with a wound dressing
after surgery, by injection, by means of a catheter, by means of a
suppository, or by means of an implant, said implant being of a
porous, non-porous, or gelatinous material, including membranes,
such as sialastic membranes, or fibers. Preferably, when
administering a protein, including an antibody, of the invention,
care must be taken to use materials to which the protein does not
absorb.
[0285] In another embodiment, the composition can be delivered in a
vesicle, in particular a liposome (see Langer, Science
249:1527-1535 (1990); Treat et al., in Liposomes in the Therapy of
Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.),
Liss, New York, pp. 353-365 (1989); Lopez-Berestein, ibid., pp.
317-327; see generally ibid.).
[0286] In yet another embodiment, the composition can be delivered
in a controlled release system. In one embodiment, a pump may be
used (see Langer, supra; Sefton, CRC Crit. Ref. Biomed. Eng. 14:20
1 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N.
Engl. J. Med. 321:574 (1989)). In another embodiment, polymeric
materials can be used (see Medical Applications of Controlled
Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla.
(1974); Controlled Drug Bioavailability, Drug Product Design and
Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger
and Peppas, J., Macromol. Sci. Rev. Macromol. Chem. 23:71 (1983);
see also Levy et al., Science 228:190 (1985); During et al., Ann.
Neurol. 25:35 1 (1989); Howard et al., J. Neurosurg. 7 1:105
(1989)). In yet another embodiment, a controlled release system can
be placed in proximity of the therapeutic target, i.e., the brain,
thus requiring only a fraction of the systemic dose (see, e.g.,
Goodson, in Medical Applications of Controlled Release, supra, vol.
2, pp. 115-138 (1984)).
[0287] Other controlled release systems are discussed in the review
by Langer (Science 249:1527-1535 (1990)).
[0288] In a specific embodiment where the composition of the
invention is a nucleic acid encoding a protein, the nucleic acid
can be administered in vivo to promote expression of its encoded
protein, by constructing it as part of an appropriate nucleic acid
expression vector and administering it so that it becomes
intracellular, e.g., by use of a retroviral vector (see U.S. Pat.
No. 4,980,286), or by direct injection, or by use of microparticle
bombardment (e.g., a gene gun; BIOLISTIC.TM., DUPONT.TM.), or
coating with lipids or cell-surface receptors or transfecting
agents, or by administering it in linkage to a homeobox-like
peptide which is known to enter the nucleus (see e.g., Joliot et
al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc.
Alternatively, a nucleic acid can be introduced intracellularly and
incorporated within host cell DNA for expression, by homologous
recombination.
[0289] The present invention also provides pharmaceutical
compositions. Such compositions comprise a therapeutically
effective amount of an antibody or a fragment thereof, and a
pharmaceutically acceptable carrier. In a specific embodiment, the
term "pharmaceutically acceptable" means approved by a regulatory
agency of the Federal or a state government or listed in the U.S.
Pharmacopeia or other generally recognized pharmacopeia for use in
animals, and more particularly in humans. The term "carrier" refers
to a diluent, adjuvant, excipient, or vehicle with which the
therapeutic is administered. Such pharmaceutical carriers can be
sterile liquids, such as water and oils, including those of
petroleum, animal, vegetable or synthetic origin, such as peanut
oil, soybean oil, mineral oil, sesame oil and the like. Water is a
preferred carrier when the pharmaceutical composition is
administered intravenously. Saline solutions and aqueous dextrose
and glycerol solutions can also be employed as liquid carriers,
particularly for injectable solutions. Suitable pharmaceutical
excipients include starch, glucose, lactose, sucrose, gelatin,
malt, rice, flour, chalk, silica gel, sodium stearate, glycerol
monostearate, talc, sodium chloride, dried skim milk, glycerol,
propylene, glycol, water, ethanol and the like. The composition, if
desired, can also contain minor amounts of wetting or emulsifying
agents, or pH buffering agents. These compositions can take the
form of solutions, suspensions, emulsion, tablets, pills, capsules,
powders, sustained-release formulations and the like. The
composition can be formulated as a suppository, with traditional
binders and carriers such as triglycerides. Oral formulation can
include standard carriers such as pharmaceutical grades of
mannitol, lactose, starch, magnesium stearate, sodium saccharine,
cellulose, magnesium carbonate, etc. Examples of suitable
pharmaceutical carriers are described in "Remington's
Pharmaceutical Sciences" by E. W. Martin. Such compositions will
contain a therapeutically effective amount of the antibody or
fragment thereof, preferably in purified form, together with a
suitable amount of carrier so as to provide the form for proper
administration to the patient. The formulation should suit the mode
of administration.
[0290] In a preferred embodiment, the composition is formulated in
accordance with routine procedures as a pharmaceutical composition
adapted for intravenous administration to human beings. Typically,
compositions for intravenous administration are solutions in
sterile isotonic aqueous buffer. Where necessary, the composition
may also include a solubilizing agent and a local anesthetic such
as lignocamne to ease pain at the site of the injection. Generally,
the ingredients are supplied either separately or mixed together in
unit dosage form, for example, as a dry lyophilized powder or water
free concentrate in a hermetically sealed container such as an
ampoule or sachette indicating the quantity of active agent. Where
the composition is to be administered by infusion, it can be
dispensed with an infusion bottle containing sterile pharmaceutical
grade water or saline. Where the composition is administered by
injection, an ampoule of sterile water for injection or saline can
be provided so that the ingredients may be mixed prior to
administration.
[0291] The compositions of the invention can be formulated as
neutral or salt forms. Pharmaceutically acceptable salts include
those formed with anions such as those derived from hydrochloric,
phosphoric, acetic, oxalic, tartaric acids, etc., and those formed
with cations such as those derived from sodium, potassium,
ammonium, calcium, ferric hydroxides, isopropylamine,
triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.
[0292] The amount of the composition of the invention which will be
effective in the treatment, inhibition and prevention of a disease
or disorder associated with aberrant expression and/or activity of
a polypeptide of the invention can be determined by standard
clinical techniques. In addition, in vitro assays may optionally be
employed to help identify optimal dosage ranges. The precise dose
to be employed in the formulation will also depend on the route of
administration, and the seriousness of the disease or disorder, and
should be decided according to the judgment of the practitioner and
each patient's circumstances. Effective doses may be extrapolated
from dose-response curves derived from in vitro or animal model
test systems.
[0293] For antibodies, the dosage administered to a patient is
typically 0.1 mg/kg to 100 mg/kg of the patient's body weight.
Preferably, the dosage administered to a patient is between 0.1
mg/kg and 20 mg/kg of the patient's body weight, more preferably 1
mg/kg to 10 mg/kg of the patient's body weight. Generally, human
antibodies have a longer half-life within the human body than
antibodies from other species due to the immune response to the
foreign polypeptides. Thus, lower dosages of human antibodies and
less frequent administration is often possible. Further, the dosage
and frequency of administration of therapeutic or pharmaceutical
compositions of the invention may be reduced by enhancing uptake
and tissue penetration (e.g., into the brain) of the antibodies by
modifications such as, for example, lipidation.
[0294] Generally, administration of products of a species origin or
species reactivity (in the case of antibodies) that is the same
species as that of the patient is preferred. Thus, in a preferred
embodiment, human antibodies, fragments, or variants, (e.g.,
derivatives), or nucleic acids, are administered to a human patient
for therapy or prophylaxis.
[0295] It is preferred to use high affinity and/or potent in vivo
inhibiting and/or neutralizing antibodies of the invention
(including molecules comprising, or alternatively consisting of,
antibody fragments or variants thereof) that specifically bind to
neurokinin B polypeptides, or polynucleotides encoding antibodies
that specifically bind to neurokinin B polypeptides, for both
immunoassays and therapy of disorders related to neurokinin B
polynucleotides or polypeptides, including fragments thereof. Such
antibodies will preferably have an affinity for neurokinin B
polypeptides and/or neurokinin B polypeptide fragments. Preferred
binding affinities include those with a dissociation constant or
K.sub.D of less than or equal to 5.times.10.sup.-2 M, 10.sup.-2 M,
5.times.10.sup.-3 M, 10.sup.-3 M, 5.times.10.sup.-4 M, 10.sup.-4 M,
5.times.10.sup.-5 M, or 10.sup.-5 M. More preferably, antibodies of
the invention bind neurokinin B polypeptides or fragments or
variants thereof with a dissociation constant or K.sub.D less than
or equal to 5.times.10.sup.-6 M, 10.sup.-6 M, 5.times.10.sup.-7 M,
10.sup.-7 M, 5.times.10.sup.-8 M, or 10.sup.-8 M. Even more
preferably, antibodies of the invention bind neurokinin B
polypeptides or fragments or variants thereof with a dissociation
constant or K.sub.D less than or equal to 5.times.10.sup.-9 M,
10.sup.-9 M, 5.times.10.sup.-10 M, 10.sup.-10 M, 5.times.10.sup.-11
M, 10.sup.-11 M, 5.times.10.sup.-12 M, 10.sup.-12 M,
5.times.10.sup.-13 M, 10.sup.-13 M, 5.times.10.sup.-14 M,
10.sup.-14 M, 5.times.10.sup.-15 M, or 10.sup.-15 M. In a preferred
embodiment, antibodies of the invention inhibit vasoconstriction of
blood vessels (e.g., hepatic portal vein, mesenteric vascular bed).
In an additional preferred embodiment, antibodies of the invention
induce vasoconstriction of blood vessels (e.g., hepatic portal
vein, mesenteric vascular bed).
[0296] As discussed in more detail below, the antibodies of the
present invention may be used either alone or in combination with
other compositions. The antibodies may further be recombinantly
fused to a heterologous polypeptide at the N- or C-terminus or
chemically conjugated (including covalent and non-covalent
conjugations) to polypeptides or other compositions. For example,
antibodies of the present invention may be recombinantly fused or
conjugated to molecules useful as labels in detection assays and
effector molecules such as heterologous polypeptides, drugs,
radionuclides, or toxins. See, e.g., PCT publications WO 92/08495;
WO 91/14438; WO 89/12624; U.S. Pat. No. 5,314,995; and EP
396,387.
[0297] The antibody and antibody compositions of the invention may
be administered alone or in combination with other therapeutic
agents, including but not limited to chemotherapeutic agents,
antibiotics, antivirals, anti-retroviral agents, steroidal and
non-steroidal anti-inflammatories, conventional immunotherapeutic
agents and cytokines. Combinations may be administered either
concomitantly, e.g., as an admixture, separately but simultaneously
or concurrently; or sequentially. This includes presentations in
which the combined agents are administered together as a
therapeutic mixture, and also procedures in which the combined
agents are administered separately but simultaneously, e.g., as
through separate intravenous lines into the same individual.
Administration "in combination" further includes the separate
administration of one of the compounds or agents given first,
followed by the second.
Combination Therapies with Anti-Neurokinin B Antibodies,
Immunomodulatory Agents, Neurokinin B, and/or
Anti-Hypertensives
[0298] Anti-neurokinin B antibodies may be administered in
combination with other anti-neurokinin B antibodies,
immunomodulatory agents, neurokinin B, and/or
anti-hypertensives.
[0299] In specific embodiments, an antibody of the invention that
specifically binds neurokinin B is used or administered in
combination with a second antibody that specifically binds
neurokinin B. In another embodiment, the antibodies specific for
neurokinin B are antagonistic antibodies that inhibit neurokinin
B-mediated vasoconstriction of blood vessels. In a specific
embodiment, the combination of anti-neurokinin B treatment inhibits
more vasoconstriction of blood vessels than either anti-neurokinin
B antibody treatment alone. In additional embodiments,
anti-neurokinin B antibodies are administered with agents that
block the function of other tachykinins such as neutralizing
anti-SP, anti-NKA, antagonistic NK1R, and/or antagonistic NK2R
antibodies or soluble forms of NK1R, NK2R, and/or NK3R. The
anti-neurokinin B antibodies and/or agents that block the function
of other tachykinins may be administered either simultaneously,
sequentially, or a combination of simultaneous or sequential
administration throughout the dosage regimen.
[0300] In another specific embodiment anti-neurokinin B antibodies
are used or administered in combination with an anti-hypertensive,
antipsychotic, immunomodulatory, and/or treatment for
gastrointestinal disorders. In a particular embodiment, the
inhibition and/or stimulation of vasoconstriction of blood vessels
resulting from anti-neurokinin B antibody treatment, is more
evident or more pronounced when the anti-neurokinin B antibodies
are used or administered in combination with an anti-hypertensive,
antipsychotic, immunomodulatory agent, treatment for
gastrointestinal disorder, and/or a cross-linking reagent.
[0301] In a highly preferred embodiment, compositions of the
invention are administered in combination with an anti-hypertensive
agent. Anti-hypertensive agents that may be administered with the
compositions of the invention include, but are not limited to
diuretic agents, such as carbonic anhydrase-inhibiting agents
(e.g., acetazolamide, dichlorphenamide, and methazolamide), osmotic
diuretics (e.g., glycerin, isosorbide, mannitol, and urea),
diuretics that inhibit Na.sup.+--K.sup.+-2Cl.sup.- symport (e.g.,
furosemide, bumetanide, azosemide, piretanide, tripamide,
ethacrynic acid, muzolimine, and torsemide), thiazide and
thiazide-like diuretics (e.g., bendroflumethiazide, benzthiazide,
chlorothiazide, hydrochlorothiazide, hydroflumethiazide,
methyclothiazide, polythiazide, trichormethiazide, chlorthalidone,
indapamide, metolazone, and quinethazone), potassium sparing
diuretics (e.g., amiloride and triamterene), mineralcorticoid
receptor antagonists (e.g., spironolactone, canrenone, and
potassium canrenoate), adrenergic blockers (e.g., acebutolol,
atenolol, betaxolol, bisoprolol, carteolol, labetalol, metoprolol,
nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol,
and timolol), angiotensin Converting Enzyme (ACE) inhibitors (e.g.,
papaverine, isoxsuprine, benazepril, captopril, cilazapril,
enalapril, enalaprilat, fosinopril, lisinopril, moexipril,
perindopril, quinapril, ramipril, spirapril, trandolapril, and
nylidrin), nitrates (e.g., isosorbide dinitrate, isosorbide
mononitrate, and nitroglycerin), and calcium channel blocking
agents (e.g., amlodipine, bepridil, diltiazem, felodipine,
flunarizine, isradipine, nicardipine, nifedipine, nimodipine, and
verapamil).
[0302] In an additional embodiment, the antibody and antibody
compositions of the invention are administered alone or in
combination with an anti-inflammatory agent. Anti-inflammatory
agents that may be administered with the antibody and antibody
compositions of the invention include, but are not limited to,
glucocorticoids and the nonsteroidal anti-inflammatories,
aminoarylcarboxylic acid derivatives, arylacetic acid derivatives,
arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic
acid derivatives, pyrazoles, pyrazolones, salicylic acid
derivatives, thiazinecarboxamides, e-acetamidocaproic acid,
S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine,
bendazac, benzydamine, bucolome, difenpiramide, ditazol,
emorfazone, guaiazulene, nabumetone, nimesulide, orgotein,
oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole,
and tenidap.
[0303] In certain embodiments, the antibodies of the present
invention are administered in combination with agents used to treat
psychiatric disorders. Psychiatric drugs that may be administered
include, but are not limited to, antipsychotic agents (e.g.,
chlorpromazine, chlorprothixene, clozapine, fluphenazine,
haloperidol, loxapine, mesoridazine, molindone, olanzapine,
perphenazine, pimozide, quetiapine, risperidone, thioridazine,
thiothixene, trifluoperazine, and triflupromazine), antimanic
agents (e.g., carbamazepine, divalproex sodium, lithium carbonate,
and lithium citrate), antidepressants (e.g., amitriptyline,
amoxapine, bupropion, citalopram, clomipramine, desipramine,
doxepin, fluvoxamine, fluoxetine, imipramine, isocarboxazid,
maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine,
phenelzine, protriptyline, sertraline, tranylcypromine, trazodone,
trimipramine, and venlafaxine), antianxiety agents (e.g.,
alprazolam, buspirone, chlordiazepoxide, clorazepate, diazepam,
halazepam, lorazepam, oxazepam, and prazepam), stimulants (e.g.,
d-amphetamine, methylphenidate, and pemoline), antiepileptic agents
(e.g., carbamazepine, clonazepam, ethosuximide, phenobarbital,
phenyloin, primidone, valproic acid, divalproex sodium, felbamate,
gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine,
topiramate, zonisamide, diazepam, lorazepam, and clonazepam),
antiparkinsonian agents (e.g., levodopa/carbidopa, selegiline,
amantidine, bromocriptine, pergolide, ropinirole, pramipexole,
benztropine; biperiden; ethopropazine; procyclidine;
trihexyphenidyl, tolcapone), and ALS therapeutics (e.g.,
riluzole).
[0304] In certain embodiments, the antibodies of the invention are
administered in combination with treatments for gastrointestinal
disorders. Treatments for gastrointestinal disorders that may be
administered include, but are not limited to, H.sub.2 histamine
receptor antagonists (e.g., TAGAMET.TM. (cimetidine), ZANTAC.TM.
(ranitidine), PEPCID.TM. (famotidine), and AXID.TM. (nizatidine));
inhibitors of H.sup.+, K.sup.+ ATPase (e.g., PREVACID.TM.
(lansoprazole) and PRILOSEC.TM. (omeprazole)); Bismuth compounds
(e.g., PEPTO-BISMOL.TM. (bismuth subsalicylate) and DE-NOL.TM.
(bismuth subcitrate)); various antacids; sucralfate; prostaglandin
analogs (e.g., CYTOTEC.TM. (misoprostol)); muscarinic cholinergic
antagonists; laxatives (e.g., surfactant laxatives, stimulant
laxatives, saline and osmotic laxatives); antidiarrheal agents
(e.g., LOMOTIL.TM. (diphenoxylate), MOTOFEN.TM. (diphenoxin), and
IMODIUM.TM. (loperamide hydrochloride)), synthetic analogs of
somatostatin such as SANDOSTATIN.TM. (octreotide), antiemetic
agents (e.g., ZOFRAN.TM. (ondansetron), KYTRIL.TM. (granisetron
hydrochloride), tropisetron, dolasetron, metoclopramide,
chlorpromazine, perphenazine, prochlorperazine, promethazine,
thiethylperazine, triflupromazine, domperidone, haloperidol,
droperidol, trimethobenzamide, dexamethasone, methylprednisolone,
dronabinol, and nabilone); D2 antagonists (e.g., metoclopramide,
trimethobenzamide and chlorpromazine); bile salts; chenodeoxycholic
acid; ursodeoxycholic acid; and pancreatic enzyme preparations such
as pancreatin and pancrelipase.
[0305] In specific embodiments, an antibody of the invention that
specifically binds neurokinin B is used or administered in
combination with a second antibody that specifically binds
neurokinin B. In another embodiment, the antibodies specific for
neurokinin B are agonistic antibodies that stimulate neurokinin
B-mediated vasoconstriction of blood vessels. In a specific
embodiment, the combination of anti-neurokinin B treatment
stimulates more vasoconstriction of blood vessels than either
anti-neurokinin B antibody treatment alone.
[0306] In additional embodiments, anti-neurokinin B antibodies of
the present invention may be administered in combination with a
soluble form of other tachykinins which include, but are not
limited to, neurokinin A and/or substance P.
Demonstration of Therapeutic or Prophylactic Utility of a
Composition
[0307] The compounds of the invention are preferably tested in
vitro, and then in vivo for the desired therapeutic or prophylactic
activity, prior to use in humans. For example, in vitro assays
which can be used to determine whether administration of a specific
antibody or composition of the present invention is indicated,
include in vitro cell culture assays in which a patient tissue
sample is grown in culture, and exposed to or otherwise
administered an antibody or composition of the present invention,
and the effect of such an antibody or composition of the present
invention upon the tissue sample is observed. In various specific
embodiments, in vitro assays can be carried out with representative
cells of cell types involved in a patient's disorder, to determine
if an antibody or composition of the present invention has a
desired effect upon such cell types. Preferably, the antibodies or
compositions of the invention are also tested in in vitro assays
and animal model systems prior to administration to humans.
[0308] Antibodies or compositions of the present invention for use
in therapy can be tested for their toxicity in suitable animal
model systems, including but not limited to rats, mice, chicken,
cows, monkeys, and rabbits. For in vivo testing of an antibody or
composition's toxicity any animal model system known in the art may
be used.
[0309] Antibodies or compositions of the invention can be tested
for their ability to reduce vasoconstriction of blood vessels in in
vitro, ex vivo and in vivo assays. Antibodies or compositions of
the invention can also be tested for their ability to inhibit
inflammation in in vitro and in vivo assays. Antibodies or
compositions of the invention can also be tested for their ability
to alleviate of one or more symptoms associated with pre-eclampsia,
an inflamatory disorder, a neurological disorder or a
gastrointestinal disease. Antibodies or compositions of the
invention can also be tested for their ability to decrease the time
course of an inflammatory disease. Further, antibodies or
compositions of the invention can be tested for their ability to
increase the survival period of animals suffering from disease or
disorder, including pre-eclampsia, an inflammatory disorder, a
neurological disorder or a gastrointestinal disease. Techniques
known to those of skill in the art can be used to analyze the
function of the antibodies or compositions of the invention in
vivo.
[0310] Efficacy in treating or preventing hypertension may be
demonstrated by detecting the ability of an antibody or composition
of the invention to inhibit the vasoconstriction of blood vessels,
to inhibit an increase in blood pressure, or to prevent, ameliorate
or alleviate the symptoms of disease progression. The treatment is
considered therapeutic if there is, for example, a reduction in
blood pressure, amelioration of one or more symptoms, or a decrease
in mortality and/or morbidity following administration of an
antibody or composition of the invention.
[0311] Antibodies or compositions of the invention can be tested
for their ability to modulate the biological activity of immune
cells by contacting immune cells, preferably human immune cells
(e.g., T cells, B-cells, and Natural Killer cells), with an
antibody or composition of the invention or a control compound and
determining the ability of the antibody or composition of the
invention to modulate (i.e., increase or decrease) the biological
activity of immune cells. The ability of an antibody or composition
of the invention to modulate the biological activity of immune
cells can be assessed by detecting the expression of antigens,
detecting the proliferation of immune cells (i.e., T-cell
proliferation), detecting the activation of signaling molecules,
detecting the effector function of immune cells, or detecting the
differentiation of immune cells. Techniques known to those of skill
in the art can be used for measuring these activities. In specific
embodiments, the ability of an antibody or composition of the
invention to modulate the biological activity of immune cells can
be assessed by detecting the localization or migration of immune
cells. For example, cellular proliferation can be assayed by
3H-thymidine incorporation assays and trypan blue cell counts.
Antigen expression can be assayed, for example, by immunoassays
including, but not limited to, competitive and non-competitive
assay systems using techniques such as western blots,
immunohistochemistry radioimmunoassays, ELISA (enzyme linked
immunosorbent assay), "sandwich" immunoassays, immunoprecipitation
assays, precipitin reactions, gel diffusion precipitin reactions,
immunodiffusion assays, agglutination assays, complement-fixation
assays, immunoradiometric assays, fluorescent immunoassays, protein
A immunoassays and FACS analysis. The activation of signaling
molecules can be assayed, for example, by kinase assays and
electrophoretic shift assays (EMSAs).
Panels/Mixtures
[0312] The present invention also provides for mixtures of
antibodies (including scFvs and other molecules comprising, or
alternatively consisting of, antibody fragments or variants
thereof) that specifically bind to neurokinin B or a fragment or
variant thereof, wherein the mixture has at least one, two, three,
four, five or more different antibodies of the invention. In
specific embodiments, the invention provides mixtures of at least
2, preferably at least 4, at least 6, at least 8, at least 10, at
least 12, at least 15, at least 20, or at least 25 different
antibodies that specifically bind to neurokinin B or fragments or
variants thereof, wherein at least 1, at least 2, at least 4, at
least 6, or at least 10, antibodies of the mixture is an antibody
of the invention. In a specific embodiment, each antibody of the
mixture is an antibody of the invention.
[0313] The present invention also provides for panels of antibodies
(including scFvs and other molecules comprising, or alternatively
consisting of, antibody fragments or variants thereof) that
specifically bind to neurokinin B or a fragment or variant thereof,
wherein the panel has at least one, two, three, four, five or more
different antibodies of the invention. In specific embodiments, the
invention provides for panels of antibodies that have different
affinities for neurokinin B, different specificities for neurokinin
B, or different dissociation rates. The invention provides panels
of at least 10, preferably at least 25, at least 50, at least 75,
at least 100, at least 125, at least 150, at least 175, at least
200, at least 250, at least 300, at least 350, at least 400, at
least 450, at least 500, at least 550, at least 600, at least 650,
at least 700, at least 750, at least 800, at least 850, at least
900, at least 950, or at least 1000 antibodies. Panels of
antibodies can be used, for example, in 96 well plates for assays
such as ELISAs.
[0314] The present invention further provides for compositions
comprising, one or more antibodies (including molecules comprising,
or alternatively consisting of antibody fragments or variants of
the invention). In one embodiment, a composition of the present
invention comprises, one, two, three, four, five, or more
antibodies that comprise or alternatively consist of, a polypeptide
having an amino acid sequence of any one or more of the VH domains
of a one or more of the scFvs referred to in Table 1, or a variant
thereof. In another embodiment, a composition of the present
invention comprises, one, two, three, four, five, or more
antibodies that comprise, or alternatively consist of, a
polypeptide having an amino acid sequence of any one or more of the
VH CDR1s of a VH domain of one or more of the scFvs referred to in
Table 1, or a variant thereof. In another embodiment, a composition
of the present invention comprises, one, two, three, four, five or
more antibodies that comprise, or alternatively consist of, a
polypeptide having an amino acid sequence of any one or more of the
VH CDR2s of a VH domain of one or more of the scFvs referred to in
Table 1, or a variant thereof. In a preferred embodiment, a
composition of the present invention comprises, one, two, three,
four, five, or more antibodies that comprise, or alternatively
consist of, a polypeptide having an amino acid sequence of any one
or more of the VH CDR3s as of a VH domain of one or more of the
scFvs referred to in Table 1, or a variant thereof.
[0315] Other embodiments of the present invention providing for
compositions comprising, one or more antibodies (including
molecules comprising, or alternatively consisting of antibody
fragments or variants of the invention) are listed below. In
another embodiment, a composition of the present invention
comprises, one, two, three, four, five, or more antibodies that
comprise, or alternative consist of, a polypeptide having an amino
acid sequence of any one or more of the VL domains of one or more
of the scFvs referred to in Table 1, or a variant thereof. In
another embodiment, a composition of the present invention
comprises, one, two, three, four, five, or more antibodies that
comprise, or alternatively consist of, a polypeptide having an
amino acid sequence of any one or more of the VL CDR1s domains of
one or more of the scFvs referred to in Table 1, or a variant
thereof. In another embodiment, a composition of the present
invention comprises, one, two, three, four, five, or more
antibodies that comprise, or alternatively consist of, a
polypeptide having an amino acid sequence of any one or more of the
VL CDR2s of one or more of the scFvs referred to in Table 1, or a
variant thereof. In a preferred embodiment, a composition of the
present invention comprises, one, two, three, four, five, or more
antibodies that comprise, or alternatively consist of, a
polypeptide having an amino acid sequence of any one or more of the
VL CDR3s domains of one or more of the scFvs referred to in Table
1, or a variant thereof.
Kits
[0316] The invention also provides a pharmaceutical pack or kit
comprising one or more containers filled with one or more of the
ingredients of the pharmaceutical compositions of the invention.
Optionally associated with such container(s) can be a notice in the
form prescribed by a governmental agency regulating the
manufacture, use or sale of pharmaceuticals or biological products,
which notice reflects approval by the agency of manufacture, use or
sale for human administration.
[0317] The present invention provides kits that can be used in the
above methods. In one embodiment, a kit comprises an antibody of
the invention, preferably a purified antibody, in one or more
containers. In an alternative embodiment, a kit comprises an
antibody fragment that specifically binds to neurokinin B
polypeptides or fragments or variants thereof. In a specific
embodiment, the kits of the present invention contain a
substantially isolated neurokinin B polypeptide or fragment or
variant thereof as a control. Preferably, the kits of the present
invention further comprise a control antibody that does not react
with any, some or all neurokinin B. In another specific embodiment,
the kits of the present invention contain a means for detecting the
binding of an antibody to neurokinin B polypeptides (e.g., the
antibody may be conjugated to a detectable substrate such as a
fluorescent compound, an enzymatic substrate, a radioactive
compound or a luminescent compound, or a second antibody which
recognizes the first antibody may be conjugated to a detectable
substrate). In specific embodiments, the kit may include a
recombinantly produced or chemically synthesized neurokinin B. The
neurokinin B provided in the kit may also be attached to a solid
support. In a more specific embodiment the detecting means of the
above-described kit includes a solid support to which neurokinin B
is attached. Such a kit may also include a non-attached
reporter-labeled anti-human antibody. In this embodiment, binding
of the antibody to neurokinin B can be detected by binding of the
said reporter-labeled antibody.
[0318] In an additional embodiment, the invention includes a
diagnostic kit for use in screening serum containing antigens of
the polypeptide of the invention. The diagnostic kit includes a
substantially isolated antibody specifically immunoreactive with
neurokinin B, and means for detecting the binding of neurokinin B
polypeptides to the antibody. In one embodiment, the antibody is
attached to a solid support. In a specific embodiment, the antibody
may be a monoclonal antibody. The detecting means of the kit may
include a second, labeled monoclonal antibody. Alternatively, or in
addition, the detecting means may include a labeled, competing
antigen.
[0319] In one diagnostic configuration, test serum is reacted with
a solid phase reagent having surface-bound neurokinin B obtained by
the methods of the present invention. After neurokinin B
polypeptides bind to a specific antibody, the unbound serum
components are removed by washing, reporter-labeled anti-human
antibody is added, unbound anti-human antibody is removed by
washing, and a reagent is reacted with reporter-labeled anti-human
antibody to bind reporter to the reagent in proportion to the
amount of bound anti-neurokinin B antibody on the solid support.
Typically, the reporter is an enzyme that is detected by incubating
the solid phase in the presence of a suitable fluorometric,
luminescent or calorimetric substrate.
[0320] The solid surface reagent in the above assay is prepared by
known techniques for attaching protein material to solid support
material, such as polymeric beads, dip sticks, 96-well plate or
filter material. These attachment methods generally include
non-specific adsorption of the protein to the support or covalent
attachment of the protein, typically through a free amine group, to
a chemically reactive group on the solid support, such as an
activated carboxyl, hydroxyl, or aldehyde group. Alternatively,
streptavidin coated plates can be used in conjunction with
biotinylated antigen(s).
[0321] Thus, the invention provides an assay system or kit for
carrying out this diagnostic method. The kit generally includes a
support with surface-bound recombinant neurokinin B, and a
reporter-labeled anti-human antibody for detecting surface-bound
anti-neurokinin B antibody.
Gene Therapy
[0322] In a specific embodiment, nucleic acids comprising sequences
encoding antibodies or functional derivatives thereof, are
administered to diagnose, treat, inhibit or prevent a disease or
disorder associated with aberrant expression and/or activity of
neurokinin B and/or its receptors (e.g., NK3R), by way of gene
therapy. Gene therapy refers to therapy performed by the
administration to a subject of an expressed or expressible nucleic
acid. In this embodiment of the invention, the nucleic acids
produce their encoded protein that mediates a therapeutic
effect.
[0323] Any of the methods for gene therapy available in the art can
be used according to the present invention. Exemplary methods are
described below.
[0324] For general reviews of the methods of gene therapy, see
Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu,
Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol.
Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993);
and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217 (1993); May,
TIBTECH 1 1(5):155-215 (1993). Methods commonly known in the art of
recombinant DNA technology which can be used are described in
Ausubel et al. (eds.), Current Protocols in Molecular Biology, John
Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and
Expression, A Laboratory Manual, Stockton Press, NY (1990).
[0325] In a preferred aspect, a composition of the invention
comprises, or alternatively consists of, nucleic acids encoding an
antibody, said nucleic acids being part of an expression vector
that expresses the antibody or fragments or chimeric proteins or
heavy or light chains thereof in a suitable host. In particular,
such nucleic acids have promoters, preferably heterologous
promoters, operably linked to the antibody coding region, said
promoter being inducible or constitutive, and, optionally,
tissue-specific. In another particular embodiment, nucleic acid
molecules are used in which the antibody coding sequences and any
other desired sequences are flanked by regions that promote
homologous recombination at a desired site in the genome, thus
providing for intrachromosomal expression of the antibody encoding
nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA
86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In
specific embodiments, the expressed antibody molecule is an scFv;
alternatively, the nucleic acid sequences include sequences
encoding both the heavy and light chains, or fragments or variants
thereof, of an antibody.
[0326] Delivery of the nucleic acids into a patient may be either
direct, in which case the patient is directly exposed to the
nucleic acid or nucleic acid-carrying vectors, or indirect, in
which case, cells are first transformed with the nucleic acids in
vitro, then transplanted into the patient. These two approaches are
known, respectively, as in vivo or ex vivo gene therapy.
[0327] In a specific embodiment, the nucleic acid sequences are
directly administered in vivo, where it is expressed to produce the
encoded product. This can be accomplished by any of numerous
methods known in the art, e.g., by constructing them as part of an
appropriate nucleic acid expression vector and administering it so
that they become intracellular, e.g., by infection using defective
or attenuated retrovirals or other viral vectors (see U.S. Pat. No.
4,980,286), or by direct injection of naked DNA, or by use of
microparticle bombardment (e.g., a gene gun; BIOLISTIC.TM.,
DUPONT.TM.), or coating with lipids or cell-surface receptors or
transfecting agents, encapsulation in liposomes, microparticles, or
microcapsules, or by administering them in linkage to a peptide
which is known to enter the nucleus, by administering it in linkage
to a ligand subject to receptor-mediated endocytosis (see, e.g., Wu
and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to
target cell types specifically expressing the receptors), etc. In
another embodiment, nucleic acid-ligand complexes can be formed in
which the ligand comprises a fusogenic viral peptide to disrupt
endosomes, allowing the nucleic acid to avoid lysosomal
degradation. In yet another embodiment, the nucleic acid can be
targeted in vivo for cell specific uptake and expression, by
targeting a specific receptor (see, e.g., PCT Publications WO
92/06180; WO 92/22715; WO92/20316; WO93/14188, WO 93/20221).
Alternatively, the nucleic acid can be introduced intracellularly
and incorporated within host cell DNA for expression, by homologous
recombination (Koller and Smithies, Proc. Natl. Acad. Sci. USA
86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438
(1989)).
[0328] In a specific embodiment, viral vectors that contains
nucleic acid sequences encoding an antibody of the invention or
fragments or variants thereof are used. For example, a retroviral
vector can be used (see Miller et al., Meth. Enzymol. 217:581-599
(1993)). These retroviral vectors contain the components necessary
for the correct packaging of the viral genome and integration into
the host cell DNA. The nucleic acid sequences encoding the antibody
to be used in gene therapy are cloned into one or more vectors,
which facilitates delivery of the gene into a patient. More detail
about retroviral vectors can be found in Boesen et al., Biotherapy
6:29 1-302 (1994), which describes the use of a retroviral vector
to deliver the mdr 1 gene to hematopoietic stem cells in order to
make the stem cells more resistant to chemotherapy. Other
references illustrating the use of retroviral vectors in gene
therapy are: Clowes et al., J. Clin. Invest. 93:644-651 (1994);
Klein et al., Blood 83:1467-1473 (1994); Salmons and Gunzberg,
Human Gene Therapy 4:129-141 (1993); and Grossman and Wilson, Curr.
Opin. in Genetics and Devel. 3:110-114 (1993).
[0329] Adenoviruses are other viral vectors that can be used in
gene therapy. Adenoviruses are especially attractive vehicles for
delivering genes to respiratory epithelia. Adenoviruses naturally
infect respiratory epithelia where they cause a mild disease. Other
targets for adenovirus-based delivery systems are liver, the
central nervous system, endothelial cells, and muscle. Adenoviruses
have the advantage of being capable of infecting non-dividing
cells. Kozarsky and Wilson, Current Opinion in Genetics and
Development 3:499-503 (1993) present a review of adenovirus-based
gene therapy. Bout et al., Human Gene Therapy 5:3-10 (1994)
demonstrated the use of adenovirus vectors to transfer genes to the
respiratory epithelia of rhesus monkeys. Other instances of the use
of adenoviruses in gene therapy can be found in Rosenfeld et al.,
Science 252:431-434 (1991); Rosenfeld et al., Cell 68:143-155
(1992); Mastrangeli et al., J. Clin. Invest. 91:225-234 (1993); PCT
Publication WO94/12649; and Wang, et al., Gene Therapy 2:775-783
(1995). In a preferred embodiment, adenovirus vectors are used.
[0330] Adeno-associated virus (AAV) has also been proposed for use
in gene therapy (Walsh et al, Proc. Soc. Exp. Biol. Med.
204:289-300 (1993); U.S. Pat. No. 5,436,146).
[0331] Another approach to gene therapy involves transferring a
gene to cells in tissue culture by such methods as electroporation,
lipofection, calcium phosphate mediated transfection, or viral
infection. Usually, the method of transfer includes the transfer of
a selectable marker to the cells. The cells are then placed under
selection to isolate those cells that have taken up and are
expressing the transferred gene. Those cells are then delivered to
a patient.
[0332] In this embodiment, the nucleic acid is introduced into a
cell prior to administration in vivo of the resulting recombinant
cell. Such introduction can be carried out by any method known in
the art, including but not limited to transfection,
electroporation, microinjection, infection with a viral or
bacteriophage vector containing the nucleic acid sequences, cell
fusion, chromosome-mediated gene transfer, microcell-mediated gene
transfer, spheroplast fusion, etc. Numerous techniques are known in
the art for the introduction of foreign genes into cells (see,
e.g., Loeffler and Behr, Meth. Enzymol. 217:599-718 (1993); Cohen
et al., Meth. Enzymol. 217:718-644 (1993); Clin. Pharma. Ther.
29:69-92m (1985)) and may be used in accordance with the present
invention, provided that the necessary developmental and
physiological functions of the recipient cells are not disrupted.
The technique should provide for the stable transfer of the nucleic
acid to the cell, so that the nucleic acid is expressible by the
cell and preferably heritable and expressible by its cell
progeny.
[0333] The resulting recombinant cells can be delivered to a
patient by various methods known in the art. Recombinant blood
cells (e.g., hematopoietic stem or progenitor cells) are preferably
administered intravenously. The amount of cells envisioned for use
depends on the desired effect, patient state, etc., and can be
determined by one skilled in the art.
[0334] Cells into which a nucleic acid can be introduced for
purposes of gene therapy encompass any desired, available cell
type, and include but are not limited to epithelial cells,
endothelial cells, keratinocytes, fibroblasts, muscle cells,
hepatocytes; blood cells such as T lymphocytes, B lymphocytes,
monocytes, macrophages, neutrophils, eosinophils, megakaryocytes,
granulocytes; various stem or progenitor cells, in particular
hematopoietic stem or progenitor cells, e.g., as obtained from bone
marrow, umbilical cord blood, peripheral blood, fetal liver,
etc.
[0335] In a preferred embodiment, the cell used for gene therapy is
autologous to the patient.
[0336] In an embodiment in which recombinant cells are used in gene
therapy, nucleic acid sequences encoding an antibody or fragment
thereof are introduced into the cells such that they are
expressible by the cells or their progeny, and the recombinant
cells are then administered in vivo for therapeutic effect. In a
specific embodiment, stem or progenitor cells are used. Any stem
and/or progenitor cells which can be isolated and maintained in
vitro can potentially be used in accordance with this embodiment of
the present invention (see e.g., PCT Publication WO 94/08598;
Stemple and Anderson, Cell 7 1:973-985 (1992); Rheinwald, Meth.
Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic
Proc. 71:771 (1986)).
[0337] In a specific embodiment, the nucleic acid to be introduced
for purposes of gene therapy comprises an inducible promoter
operably linked to the coding region, such that expression of the
nucleic acid is controllable by controlling the presence or absence
of the appropriate inducer of transcription.
[0338] Having generally described the invention, the same will be
more readily understood by reference to the following examples,
which are provided by way of illustration and are not intended as
limiting.
EXAMPLES
Example 1
Generation of Anti-Neurokinin B Antibodies
General Methods
[0339] Rescue of the Library.
[0340] A library of scFvs is constructed from the RNA of human PBLs
as described in WO92/01047 (which is hereby incorporated by
reference in its entirety). To rescue phage displaying antibody
fragments, approximately 109 E. coli harboring the phagemid are
used to inoculate 50 ml of 2.times.TY containing 1% glucose and 100
micrograms/ml of ampicillin (2.times.TY-AMP-GLU) and grown to an
O.D. of 0.8 with shaking. Five ml of this culture is used to
inoculate 50 ml of 2.times.TY-AMP-GLU, 2.times.108 TU of delta gene
3 helper (M13 delta gene III, see WO92/01047) are added and the
culture incubated at 37.degree. C. for 45 minutes without shaking
and then at 37.degree. C. for 45 minutes with shaking. The culture
is centrifuged at 4000 r.p.m. for 10 min. and the pellet
resuspended in 2 liters of 2.times.TY containing 100 micrograms/ml
ampicillin and 50 micrograms/ml kanamycin and grown overnight.
Phage are prepared as described in WO92/01047.
[0341] M13 delta gene III is prepared as follows: M13 delta gene
III helper phage does not encode gene III protein, hence the
phage(mid) displaying antibody fragments have a greater avidity of
binding to antigen. Infectious M13 delta gene III particles are
made by growing the helper phage in cells harboring a pUC19
derivative supplying the wild type gene III protein during phage
morphogenesis. The culture is incubated for 1 hour at 37.degree. C.
without shaking and then for a further hour at 37.degree. C. with
shaking. Cells were spun down (IEC-Centra 8, 4000 revs/min for 10
min), resuspended in 300 ml 2.times.TY broth containing 100
micrograms ampicillin/ml and 25 micrograms kanamycin/ml
(2.times.TY-AMP-KAN) and grown overnight, shaking at 37.degree. C.
Phage particles are purified and concentrated from the culture
medium by two PEG-precipitations (Sambrook et al., 1990),
resuspended in 2 ml PBS and passed through a 0.45 micrometer filter
(Minisart NML; Sartorius) to give a final concentration of
approximately 1013 transducing units/ml (ampicillin-resistant
clones).
[0342] Panning the Library.
[0343] Immunotubes (Nunc) are coated overnight in PBS with 4 ml of
either 100 micrograms/ml or 10 micrograms/ml of a TR2 receptor
polypeptide. Tubes are blocked with 2% Marvel-PBS for 2 hours at
37.degree. C. and then washed 3 times in PBS. Approximately 1013 TU
of phage is applied to the tube and incubated for 30 minutes at
room temperature tumbling on an over and under turntable and then
left to stand for another 1.5 hours. Tubes are washed 10 times with
PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding
1 ml of 100 mM triethylamine and rotating 15 minutes on an under
and over turntable after which the solution is immediately
neutralized with 0.5 ml of 10M Tris-HCl, pH 7.4. Phage are then
used to infect 10 ml of mid-log E. coli TG1 by incubating eluted
phage with bacteria for 30 minutes at 37.degree. C. The E. coli are
then plated on TYE plates containing 1% glucose and 100
micrograms/ml ampicillin. The resulting bacterial library is then
rescued with delta gene 3 helper phage as described above to
prepare phage for a subsequent round of selection. This process is
usually repeated for a total of 2-4 rounds of affinity
purification.
[0344] Characterization of Binders.
[0345] Eluted phage from the final rounds of selection are used to
infect E. coli HB 2151 and soluble scFv is produced (Marks, et al.,
1991) from single colonies for assay. ELISAs are performed with
microtiter plates coated with either 10 picograms/ml of the
polypeptide of the present invention in 50 mM bicarbonate pH 9.6.
Clones positive in ELISA are further characterized by PCR
fingerprinting (see e.g., WO92/01047) and then by sequencing.
Example 2
Identification and Cloning of VH and VL Domains
[0346] One method to identify and clone VH and VL domains from cell
lines expressing a particular antibody is to perform PCR with VH
and VL specific primers on cDNA made from the antibody expressing
cell lines. Briefly, RNA is isolated from the cell lines and used
as a template for RT-PCR designed to amplify the VH and VL domains
of the antibodies expressed by the cell lines. Cells may lysed in
the TRIzol.RTM. reagent (LIFE TECHNOLOGIES.TM., Rockville. Md) and
extracted with one fifth volume of chloroform. After addition of
chloroform, the solution is allowed to incubate at room temperature
for 10 minutes, and the centrifuged at 14,000 rpm for 15 minutes at
4.degree. C. in a tabletop centrifuge. The supernatant is collected
and RNA is precipitated using an equal volume of isopropanol.
Precipitated RNA is pelleted by centrifuging at 14,000 rpm for 15
minutes at 4.degree. C. in a tabletop centrifuge. Following
centrifugation, the supernatant is discarded and washed with 75%
ethanol. Following washing, the RNA is centrifuged again at 800 rpm
for 5 minutes at 4.degree. C. The supernatant is discarded and the
pellet allowed to air dry. RNA is the dissolved in DEPC water and
heated to 60.degree. C. for 10 minutes. Quantities of RNA can be
determined using optical density measurements.
[0347] cDNA may be synthesized, according to methods well-known in
the art, from micrograms of RNA using reverse transcriptase and
random hexamer primers. cDNA is then used as a template for PCR
amplification of VH and VL domains. Alternatively, DNA encoding an
scFv, e.g., a vector containing the scFv expression construct, may
be used as template material for the following PCR reaction.
Primers used to amplify VH and VL genes are shown in Table 3.
Typically a PCR reaction makes use of a single 5' primer and a
single 3' primer. Sometimes, when the amount of available RNA
template is limiting, or for greater efficiency, groups of 5'
and/or 3' primers may be used. For example, sometimes all five
VH-5' primers and all JH3' primers are used in a single PCR
reaction. The PCR reaction is carried out in a 50 microliter volume
containing 1.times.PCR buffer, 2 mM of each dNTP, 0.7 units of High
Fidelity Taq polymerase, 5' primer mix, 3' primer mix and 7.5
microliters of cDNA. The 5' and 3' primer mix of both VH and VL can
be made by pooling together 22 pmole and 28 pmole, respectively, of
each of the individual primers. PCR conditions are: 96.degree. C.
for 5 minutes; followed by 25 cycles of 94.degree. C. for 1 minute,
50.degree. C. for 1 minute, and 72.degree. C. for 1 minute;
followed by an extension cycle of 72.degree. C. for 10 minutes.
After the reaction is completed, sample tubes were stored 4.degree.
C.
TABLE-US-00003 TABLE 3 Primer Sequences Used to Amplify VH and VL
domains. Primer name SEQ ID NO Primer Sequence (5'-3') VH Primers
Hu VH1-5' 41 CAGGTGCAGCTGGTGCAGTCTGG Hu VH2-5' 42
CAGGTCAACTTAAGGGAGTCTGG Hu VH3-5' 43 GAGGTGCAGCTGGTGGAGTCTGG Hu
VH4-5' 44 CAGGTGCAGCTGCAGGAGTCGGG Hu VH5-5' 45
GAGGTGCAGCTGTTGCAGTCTGC Hu VH6-5' 46 CAGGTACAGCTGCAGCAGTCAGG Hu
JH1,2-5' 47 TGAGGAGACGGTGACCAGGGTGCC Hu JH3-5' 48
TGAAGAGACGGTGACCATTGTCCC Hu JH4,5-5' 49 TGAGGAGACGGTGACCAGGGTTCC Hu
JH6-5' 50 TGAGGAGACGGTGACCGTGGTCCC VL Primers Hu Vkappa1-5' 51
GACATCCAGATGACCCAGTCTCC Hu Vkappa2a-5' 52 GATGTTGTGATGACTCAGTCTCC
Hu Vkappa2b-5' 53 GATATTGTGATGACTCAGTCTCC Hu Vkappa3-5' 54
GAAATTGTGTTGACGCAGTCTCC Hu Vkappa4-5' 55 GACATCGTGATGACCCAGTCTCC Hu
Vkappa5-5' 56 GAAACGACACTCACGCAGTCTCC Hu Vkappa6-5' 57
GAAATTGTGCTGACTCAGTCTCC Hu Vlambda1-5' 58 CAGTCTGTGTTGACGCAGCCGCC
Hu Vlambda2-5' 59 CAGTCTGCCCTGACTCAGCCTGC Hu Vlambda3-5' 60
TCCTATGTGCTGACTCAGCCACC Hu Vlambda3b-5' 61 TCTTCTGAGCTGACTCAGGACCC
Hu Vlambda4-5' 62 CACGTTATACTGACTCAACCGCC Hu Vlambda5-5' 63
CAGGCTGTGCTCACTCAGCCGTC Hu Vlambda6-5' 64 AATTTTATGCTGACTCAGCCCCA
Hu Jkappa1-3' 65 ACGTTTGATTTCCACCTTGGTCCC Hu Jkappa2-3' 66
ACGTTTGATCTCCAGCTTGGTCCC Hu Jkappa3-3' 67 ACGTTTGATATCCACTTTGGTCCC
Hu Jkappa4-3' 68 ACGTTTGATCTCCACCTTGGTCCC Hu Jkappa5-3' 69
ACGTTTAATCTCCAGTCGTGTCCC Hu Jlambda1-3' 70 CAGTCTGTGTTGACGCAGCCGCC
Hu Jlambda2-3' 71 CAGTCTGCCCTGACTCAGCCTGC Hu Jlambda3--3' 72
TCCTATGTGCTGACTCAGCCACC Hu Jlambda3b-3' 73 TCTTCTGAGCTGACTCAGGACCC
Hu Jlambda4-3' 74 CACGTTATACTGACTCAACCGCC Hu Jlambda5-3' 75
CAGGCTGTGCTCACTCAGCCGTC Hu Jlambda6-3' 76
AATTTTATGCTGACTCAGCCCCA
[0348] PCR samples are then electrophoresed on a 1.3% agarose gel.
DNA bands of the expected sizes (.about.506 base pairs for VH
domains, and 344 base pairs for VL domains) can be cut out of the
gel and purified using methods well known in the art. Purified PCR
products can be ligated into a PCR cloning vector (TA vector from
Invitrogen Inc., Carlsbad, Calif.). Individual cloned PCR products
can be isolated after transfection of E. coli and blue/white color
selection. Cloned PCR products may then be sequenced using methods
commonly known in the art.
Example 3
Detecting Inhibition of Intracellular Calcium Flux Using
Anti-Neurokinin B Antibodies
[0349] General Methods
[0350] Binding of Neurokinin B to its receptor (e.g., NK3R), may
alter intracellular levels of calcium. These alterations can be
measured in an assay using Fluorometric Imaging Plate Reader
("FLIPR"; Molecular Probes) to measure changes in fluorescent
molecules that bind small molecules. Clearly, any fluorescent
molecule detecting a small molecule can be used instead of the
calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.;
catalog no. F-14202), used here.
[0351] For adherent cells transfected with a Neurokinin B receptor,
seed the cells at 1-2.times.10.sup.5 cells/well in a Co-star black
96-well plate with clear bottom. The plate is incubated in a
CO.sub.2 incubator for 20 hours. The adherent cells are washed two
times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt
Solution) leaving 100 ul of buffer after the final wash.
[0352] A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic
acid in DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml
fluo-4 is added to each well. The plate is incubated at 37 degrees
C. in a CO.sub.2 incubator for 60 min. The plate is washed four
times in the Biotek washer with HBSS leaving 100 ul of buffer.
[0353] For non-adherent cells transfected with a Neurokinin B
receptor, the cells are spun down from culture media. Cells are
re-suspended to 2-5.times.10.sup.6 cells/ml with HBSS in a 50-ml
conical tube. Four microliters of 1 mg/ml fluo-4 solution in 10%
pluronic acid DMSO is added to each ml of cell suspension. The tube
is then placed in a 37 degrees C. water bath for 30-60 min. The
cells are washed twice with HBSS, resuspended to 1.times.10.sup.6
cells/ml, and dispensed into a microplate, 100 ul/well. The plate
is centrifuged at 1000 rpm for 5 min. The plate is then washed once
in Denley Cell Wash with 200 ul of HBSS, followed by an aspiration
step to 100 ul final volume.
[0354] To measure the fluorescence of intracellular calcium, the
FLIPR is set for the following parameters: (1) System gain is
300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is
F/2; (4) Excitation is 488 nm; and (5) Emission is 530 nm. The
first sample addition consists of 4 ul of Buffer only or a solution
of Buffer and anti-Neurokinin B. The second addition consists of 6
ul of Neurokinin B. Appropriate concentrations of Neurokinin B and
Neurokinin B antisera can be determined by one of ordinary skill in
the art. Increased emission at 530 nm indicates an extracellular
signaling event caused by Neurokinin B or a molecule induced by
Neurokinin B, which has resulted in an increase in the
intracellular Ca.sup.++ concentration.
[0355] It will be clear that the invention may be practiced
otherwise than as particularly described in the foregoing
description and examples.
[0356] Numerous modifications and variations of the present
invention are possible in light of the above teachings and,
therefore, are within the scope of the appended claims.
[0357] The entire disclosure of all publications (including
patents, patent applications, journal articles, laboratory manuals,
books, or other documents) cited herein are hereby incorporated by
reference.
[0358] Further, the Sequence Listing submitted herewith, in both
computer and paper forms, is hereby incorporated by reference in
its entirety.
[0359] The entire disclosures (including the specification,
sequence listing, and drawings) of International Application No.
PCT/US03/16802 filed May 29, 2003 and of U.S. Provisional
Application No. 60/383,802 filed May 30, 2002 are herein
incorporated by reference in their entirety.
Sequence CWU 1
1
761832DNAHomo sapiensCDS(141)..(503)misc_feature(821)..(821)n equal
any a, t g or c 1ggcacgagct ccactcggtt tctctctttg caggagcacc
ggcagcacca gtgtgtgagg 60ggagcaggca gcggtcctag ccagttcctt gatcctgcca
gaccacccag cccctggcac 120agagctgctc cacaggcacc atg agg atc atg ctg
cta ttc aca gcc atc ctg 173 Met Arg Ile Met Leu Leu Phe Thr Ala Ile
Leu 1 5 10gcc ttc agc cta gct cag agc ttt ggg gct gtc tgt aag gag
cca cag 221Ala Phe Ser Leu Ala Gln Ser Phe Gly Ala Val Cys Lys Glu
Pro Gln 15 20 25gag gag gtg gtt cct ggc ggg ggc cgc agc aag agg gat
cca gat ctc 269Glu Glu Val Val Pro Gly Gly Gly Arg Ser Lys Arg Asp
Pro Asp Leu 30 35 40tac cag ctg ctc cag aga ctc ttc aaa agc cac tca
tct ctg gag gga 317Tyr Gln Leu Leu Gln Arg Leu Phe Lys Ser His Ser
Ser Leu Glu Gly 45 50 55ttg ctc aaa gcc ctg agc cag gct agc aca gat
cct aag gaa tca aca 365Leu Leu Lys Ala Leu Ser Gln Ala Ser Thr Asp
Pro Lys Glu Ser Thr60 65 70 75tct ccc gag aaa cgt gac atg cat gac
ttc ttt gtg gga ctt atg ggc 413Ser Pro Glu Lys Arg Asp Met His Asp
Phe Phe Val Gly Leu Met Gly 80 85 90aag agg agc gtc cag cca gac tct
cct acg gat gtg aat caa gag aac 461Lys Arg Ser Val Gln Pro Asp Ser
Pro Thr Asp Val Asn Gln Glu Asn 95 100 105gtc ccc agc ttt ggc atc
ctc aag tat ccc ccg aga gca gaa taggtac 510Val Pro Ser Phe Gly Ile
Leu Lys Tyr Pro Pro Arg Ala Glu 110 115 120tccacttccg gactcctgga
ctgcattagg aagacctctt tccctgtccc aatccccagg 570tgcgcacgct
cctgttaccc tttctcttcc ctgttcttgt aacattcttg tgctttgact
630ccttctccat cttttctacc tgaccctggt gtggaaactg catagtgaat
atccccaacc 690ccaatgggca ttgactgtag aataccctag agttcctgta
gtgtcctaca ttaaaaatat 750aatgtctctc tctattcctc aacaataaag
gatttttgca tatgaaaaaa aaaaaaaaaa 810aaaaaaaaaa naaanaaaaa aa
8322121PRTHomo sapiens 2Met Arg Ile Met Leu Leu Phe Thr Ala Ile Leu
Ala Phe Ser Leu Ala1 5 10 15Gln Ser Phe Gly Ala Val Cys Lys Glu Pro
Gln Glu Glu Val Val Pro 20 25 30Gly Gly Gly Arg Ser Lys Arg Asp Pro
Asp Leu Tyr Gln Leu Leu Gln 35 40 45Arg Leu Phe Lys Ser His Ser Ser
Leu Glu Gly Leu Leu Lys Ala Leu 50 55 60Ser Gln Ala Ser Thr Asp Pro
Lys Glu Ser Thr Ser Pro Glu Lys Arg65 70 75 80Asp Met His Asp Phe
Phe Val Gly Leu Met Gly Lys Arg Ser Val Gln 85 90 95Pro Asp Ser Pro
Thr Asp Val Asn Gln Glu Asn Val Pro Ser Phe Gly 100 105 110Ile Leu
Lys Tyr Pro Pro Arg Ala Glu 115 1203750DNAArtificial sequenceDNA
encoding N024C01 scFv 3caggtacagc tgcagcagtc aggagctgag gtgaagaacc
ctgggtcctc ggtgaaggtc 60tcctgcaagc cttctagaga caccctcagt ggagacaact
tcagcagctc tgtcttcagt 120tgggtccgac aggcccctgg acaagggctt
gagtggatgg gagggatcat tcctatcttt 180ggtgtagcaa actacgcaca
gaaattccag cccagagtca ccattagcgc ggacatgtcc 240acgaacacag
cctacatgga gctgagcagc ctgagatctg aggacacggc cgtgtattac
300tgtgctagca cttgggagct gcgcaatgct tttgatatct ggggcaaggg
caccctggtc 360accgtctcga gtggtggagg cggttcaggc ggaggtggca
gcggcggtgg cggatcgcag 420tctgtgttga cgcagccgcc ctcagtgtct
gcggccccag gacagaaggt caccatttcc 480tgctctggaa gcacctccaa
cattgggaat aattatgtct cctggtacca acagcaccca 540ggcaaagccc
ccaaactcat gatttatgat gtcagtaagc ggccctcagg ggtccctgac
600cgattctctg gctccaagtc tggcaactca gcctccctgg acatcagtgg
gctccagtct 660gaggatgagg ctgattatta ctgtgcagca tgggatgaca
gcctgagtga atttctcttc 720ggaactggga ccaagctgac cgtcctaggt
7504762DNAArtificial SequenceDNA encoding N025B07 scFv 4gaggtgcagc
tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgagggtt 60tcctgcaagg
catctggata cagcttcacc aacttctata tgcattggct ccgacaggcc
120cctggtcgag ggcctgagtg gatgggaata attgacccca gtaataatta
tacatattac 180gcacagaagt tccagggcag agtcaccgtg accagggaca
cgtccacgag cacagtctac 240atggagctga gcagcctgag atctgaggac
acggccatat attactgtgc tagacccgtc 300tattactatg atagtagtgg
ttattactac ggtcttaatg cttttgatat ctggggccga 360gggacaatgg
tcaccgtctc gagtggtgga ggcggttcag gcggaggtgg cagcggcggt
420ggcggatcgc agtctgtgtt gacgcagccg ccctcagtgt ctgcggcccc
aggacagaag 480gtcaccattt cctgctctgg aagcacctcc aacattggga
ataattatgt ctcctggtac 540caacagcacc caggcaaagc ccccaaactc
atgatttatg atgtcagtaa gcggccctca 600ggggtccctg accgattctc
tggctccaag tctggcaact cagcctccct ggacatcagt 660gggctccagt
ctgaggatga ggctgattat tactgtgcag catgggatga cagcctgagt
720gaatttctct tcggaactgg gaccaagctg accgtcctag gt
7625726DNAArtificial SequenceDNA encoding N015E08 scFv 5cagatgcagc
tgcaggagtc gggggctgag gtgaaaaagc ctgggtcctc ggtgaaggtc 60tcctgcaagg
cttctggaga cacttttcgc agctatatta tcagctgggt gcgacaggcc
120cctggacaag gacttgagtg gatgggaggg atcatcccta tgtttggcac
aacaaactat 180gcacagcaat tccagggcaa agtcaccatt accgcggacg
actccacgag tacttcttat 240atggagctga ggagcctgag atctgacgac
acggccgtgt attactgtgc gagaggaact 300aactacatgg acgtctgggg
gcaggggacc acggtcaccg tctcctcagg tggaggcggt 360tcaggcggag
gtggcagcgg cggtggcgga tcgcagtctg tgttgacgca gccgccctca
420gtgtctgcgg ccccaggaca gaaggtcacc atttcctgct ctggaagcac
ctccaacatt 480gggaataatt atgtctcctg gtaccaacag cacccaggca
aagcccccaa actcatgatt 540tatgatgtca gtaagcggcc ctcaggggtc
cctgaccgat tctctggctc caagtctggc 600aactcagcct ccctggacat
cagtgggctc cagtctgagg atgaggctga ttattactgt 660gcagcatggg
atgacagcct gagtgaattt ctcttcggaa ctgggaccaa gctgaccgtc 720ctaggt
7266744DNAArtificial SequenceDNA encoding N015F10 scFv 6caggtacagc
tgcagcagtc aggggctgag gtgaagaagc ctgggtcgtc ggtgaaggtc 60tcctgcaagg
cttctggagg caccttcagc agctatgcta tcagctgggt gcgccaggcc
120cctggacaag ggcttgagtg gatgggaggg agcatcccta aatttcgtac
agcaaactac 180gcaaagaagt tccagggcag agtcacgatt accgctgacg
aatccacgag cacagcctac 240atggagctga gcagcctgag atctgatgac
acggccgtgt attactgtgc gagagggagt 300gcctacaatc tacggaacgc
ttttgatatc tgggggcagg ggaccacggt caccgtctcg 360agtggaggcg
gcggttcagg cggaggtggc tctggcggtg gcggaagtgc acagtctgtc
420gtgacgcagc cgccctcagt gtctgcggcc ccaggacaga gggtcaccat
ctcctgctct 480ggaagcagct ccaacattgc gaataattat gtgtcctggt
accagcagct cccaggaaca 540gcccccaaac tcctcattta tgacaataat
aagcgaccct cagggattcc tgaccgattc 600tctggctcca agtctggcac
gtcagccacc ctgggcatca ccggactcca gactggggac 660gaggccgatt
attactgcgg aacatgggat agcagcctga gtgcttatgt cttcggaact
720gggaccaagg tcaccgtcct aggt 7447732DNAArtificial SequenceDNA
encoding N024D01 scFv 7caggtacagc tgcagcagtc agggggaggc gtggtccagc
ctgggaggtc cctgagactc 60tcctgtgcag cgtctggatt cacctttgat gattatgcca
tgcactgggt ccggcaagct 120ccagggaagg gcctggagtg ggtctcaggt
attagttgga atagtggtag cataggctat 180gcggactctg tgaagggccg
attcaccatc tccagagaca acgccaagaa ctccctgtat 240ctgcaaatga
acagtctgag agctgaggac acggccttgt attactgtgc aaaaacgggc
300ggtggtaact ctcttgacta ctggggccga ggaaccctgg tcaccgtctc
ctcaggtgga 360ggcggttcag gcggaggtgg cagcggcggt ggcggatcgc
agtctgtgtt gacgcagccg 420ccctcagtgt ctgcggcccc aggacagaag
gtcaccattt cctgctctgg aagcacctcc 480aacattggga ataattatgt
ctcctggtac caacagcacc caggcaaagc ccccaaactc 540atgatttatg
atgtcagtaa gcggccctca ggggtccctg accgattctc tggctccaag
600tctggcaact cagcctccct ggacatcagt gggctccagt ctgaggatga
ggctgattat 660tactgtgcag catgggatga cagcctgagt gaatttctct
tcggaactgg gaccaagctg 720accgtcctag gt 7328741DNAArtificial
SequenceDNA encoding N015D08 scFv 8caggtgcagc tgttgcagtc tgcgcctgag
gtgaagaagc ctgggtcctc ggttagggtc 60tcctgcaaga cttctggagg caccttcagc
agccaactta tcaactgggt gcgacagccc 120cctggacaag ggcctgaatg
gatgggaggg atcatcccta tctttggtac agcaaactac 180gcacagaagt
tccagggcag agtcacgatt accgcggacg aatccacgag cacagcctac
240atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc
gagagatctg 300actgccggac gttttgatgc ttttcatatc tggggcagag
gcaccctggt caccgtctcc 360tcaggtggag gcggttcagg cggaggtggc
agcggcggtg gcggatcgca gtctgtgttg 420acgcagccgc cctcagtgtc
tgcggcccca ggacagaagg tcaccatttc ctgctctgga 480agcacctcca
acattgggaa taattatgtc tcctggtacc aacagcaccc aggcaaagcc
540cccaaactca tgatttatga tgtcagtaag cggccctcag gggtccctga
ccgattctct 600ggctccaagt ctggcaactc agcctccctg gacatcagtg
ggctccagtc tgaggatgag 660gctgattatt actgtgcagc atgggatgac
agcctgagtg aatttctctt cggaactggg 720accaagctga ccgtcctagg t
7419744DNAArtificial SequenceDNA encoding N024B07 scFv 9caggtacagc
tgcagcagtc aggggctgag gtgaagaagc ctgggtcgtc ggtgaaggtc 60tcctgcaagg
cttctggagg caccttcagc agctatgcta tcagctgggt gcgccaggcc
120cctggacaag ggcttgagtg gatgggaggg agcatcccta aatttcgtac
agcaaactac 180gcaaagaagt tccagggcag agtcacgatt accgctgacg
aatccacgag cacagcctac 240atggagctga gcagcctgag atctgatgac
acggccgtgt attactgtgc gagagggagt 300acctacaatc tacggaacgc
ttttgatatc tggggcaagg gcaccctggt caccgtctcg 360agtggaggcg
gcggttcagg cggaggtggc tctggcggtg gcggaagtgc acagtctgtc
420gtgacgcagc cgccctcagc gtctgggacc cccgggcaga gggtcaccat
ctcttgttct 480ggaggcagct ccaacatcgg aaggaatact gttaactggt
accagcaggt cccaggaacg 540gcccccaaac tcctcatcta tactaataat
cagcggccct caggggtccc tgaccgattc 600tctggctcca agtctggcac
ctcagcctcc ctggccatca gtggactcca gtctgaggat 660gaggctgatt
attactgtgc agcatgggat gacagcctga atgatgtgga attcggcgga
720gggaccaagc tgaccgtcct aggt 74410729DNAArtificial SequenceDNA
encoding N024E07 scFv 10caggtgcagc tgcaggagtc ggggggaggc ttggaacagc
ctggcaggtc cctgagactc 60tcctgtacag cctctggatt cacctttgat gattatccca
tgcactgggt ccggcaagct 120ccagggaagg gcctggagtg ggtctcaggt
attagtggga atagtgatag aatagcctat 180gcggactctg tgaagggccg
attcaccatc tccagagaca actccaagaa cacgctgtgg 240ctgcaaatga
acagcctgag agctgaagac acggccatat attactgtgc gagagcagcg
300cggaactggt tcgacccctg gggccaagga accctggtca ccgtctcgag
tggtggaggc 360ggctcaggcg gaggtggcag cggcggtggc ggatcgcagt
ctgtgttgac gcagccgccc 420tcagtgtctg cggccccagg acagaaggtc
accatttcct gctctggaag cacctccaac 480attgggaata attatgtctc
ctggtaccaa cagcacccag gcaaagcccc caaactcatg 540atttatgatg
tcagtaagcg gccctcaggg gtccctgacc gattctctgg ctccaagtct
600ggcaactcag cctccctgga catcagtggg ctccagtctg aggatgaggc
tgattattac 660tgtgcagcat gggatgacag cctgagtgaa tttctcttcg
gaactgggac caagctgacc 720gtcctaggt 72911765DNAArtificial
SequenceDNA encoding N023F05 scFv 11caggtccagc tggtgcagtc
tggggctgag gtgaagaagc ctgggttctc ggtgaaggtc 60tcctgtaagg cttctggagg
cagcttcagc aactatgtta ttagctggct gcgacaggcc 120cctggacagg
ggctggagtg gatgggaggc atcatgccta tctttggtaa tgcaaattac
180gcacagaagt tccaggacag agtcacgatc accgcggaca aatccacgag
cacagcctac 240atggaactga gcagcctgag atctgacgac acggccgtat
attactgtgc gagagaccaa 300attgtcgtag acccagtgac taagggtgcc
tattacagcg gtttggacgt ctggggcaga 360gggacaatgg tcaccgtctc
gagtggaggc ggcggttcag gcggaggtgg ctctggcggt 420ggcggaagtg
cacagtctgt gctgactcag ccaccctcag cgtctgggac ccccgggcag
480agggtcacca tctcttgttc tggaggcagc tccaacatcg gagctaatgc
tataacctgg 540ttccagcagc tcccaggaac ggcccccaaa ctcctcatct
atcataataa tcaacgaccc 600tcaggggtcc ctgaccgatt ctctggctcc
aagtctggca cctcaggctc cctggccatc 660agtgggctcc agtctgagga
tgaggctgat tattactgtg cagtatggga taacagcctg 720aatgctatgt
tattcggcgg agggaccaag ctgaccgtcc taggt 76512735DNAArtificial
SequenceDNA encoding N024D08 scFv 12gaggtccagc tggtgcagtc
tggggctgag gtgaagaggc cgggggcctc agtcaagatc 60tcctgcagga cgtctggata
caccttcacc agttactata tacactgggt gcgacaggcc 120cctggacaag
gccttgagtg gctggcgata atcaacccta ctgctggcaa cacatactac
180acacaggact tccaggacag agtcaccgtg accagagaca cgtccacgag
cacagtgtac 240atggagctga ggggactgaa ctcagaggac acggccgtgt
attactgtgc gagcccgtac 300ggtgtccgaa atgcttttga tgtctggggc
caagggacaa tggtcaccgt ctcctcaggt 360ggaggcggtt caggcggagg
tggcagcggc ggtggcggat cgcagtctgt gttgacgcag 420ccgccctcag
tgtctgcggc cccaggacag aaggtcacca tttcctgctc tggaagcacc
480tccaacattg ggaataatta tgtctcctgg taccaacagc acccaggcaa
agcccccaaa 540ctcatgattt atgatgtcag taagcggccc tcaggggtcc
ctgaccgatt ctctggctcc 600aagtctggca actcagcctc cctggacatc
agtgggctcc agtctgagga tgaggctgat 660tattactgtg cagcatggga
tgacagcctg agtgaatttc tcttcggaac tgggaccaag 720ctgaccgtcc taggt
73513744DNAArtificial SequenceDNA encoding N023B03 scFv
13gaggtgcagc tgttggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc
60tcctgtgcag cctctggatt cacctttagc agctatgcca tgagctgggt ccgccaggct
120ccagggaagg ggctggagtg ggtctcagct attagtggta gtggtggtag
cacatactac 180gcagactccg tgaagggccg gttcaccatc tccagagaca
attccaagaa cacgctgtat 240ctgcaaatga acagcctgag agccgaggac
acggccgtgt attactgtgc gagacaggga 300agtgggagct atcctccccc
cgcttttgac tcctggggcc gagggacaat ggtcaccgtc 360tcgagtggag
gcggcggttc aggcggaggt ggctctggcg gtggcggaag tgcacaggct
420gtggtgatcc aggagccctc actgactgtg tccccaggag ggacagtcac
tctcacctgt 480gctttcaact ctggacaagt caccagtggt ttctatccaa
actggttcca gcagaaacct 540ggacaaccac cccggtcact gatctataat
acagacaaca aacattcctg gacccctgcc 600cgcttctcag gctccctcct
tgggggcaaa gctgccttga cactgtccgg tgtgcagcct 660gacgacgagg
ctgactatta ctgccttctc tattatgatc gtagtctggt gttcggcgga
720gggaccaagc tgaccgtcct aggt 74414729DNAArtificial SequenceDNA
encoding N023E01 scFv 14caggtgcagc tggtgcagtc tgggggaggc ttggtacagc
ctggcaggtc cctgagactc 60tcttgtgcag cctctggatt cacctttgat gattatgcca
tgcactgggt ccggcaagct 120ccagggaagg gcctggagtg ggtctcaggt
attagttgga atagtgccag cataggttat 180gcggactctg tgaagggccg
attcaccatc tccagagaca acgccaagaa ctccctgtat 240ctgcaaatga
acagtctgag aggtgaggac acggccttat attactgtgc aaaaggagcc
300cgtgatgctt tggatatctg gggcaaggga accctgctca ccgtctcctc
aggtggaggc 360ggttcaggcg gaggtggcag cggcggtggc ggatcgcagt
ctgtgttgac gcagccgccc 420tcagtgtctg cggccccagg acagaaggtc
accatttcct gctctggaag cacctccaac 480attgggaata attatgtctc
ctggtaccaa cagcacccag gcaaagcccc caaactcatg 540atttatgatg
tcagtaagcg gccctcaggg gtccctgacc gattctctgg ctccaagtct
600ggcaactcag cctccctgga catcagtggg ctccagtctg aggatgaggc
tgattattac 660tgtgcagcat gggatgacag cctgagtgaa tttctcttcg
gaactgggac caagctgacc 720gtcctaggt 72915753DNAArtificial
SequenceDNA encoding N024C05 scFv 15caggtacagc tgcagcagtc
aggtccagga ctggtgaagc cctcgcagac cctctcactc 60acctgtgcca tctccgggga
cagtgtctct agcaacactg ctgcctggag ctggatcagg 120cagtccccat
cgagaggcct tgagtggctg ggaaggacat actacagcag gtccaagtgg
180tataaagatt atgcagtatc tgtgaaaagt cgaataacca tcaatccaga
cacatccaag 240aaccagttct ccctgcagct ggactctgtg actcccgagg
acacggctgt gtattattgt 300acaagagagg gctactatga ttatagtggt
gtcgttgact actgggggca ggggaccacg 360gtcatcgtct cgagtggtgg
aggcggttca ggcggaggtg gcagcggcgg tggcggatcg 420cagtctgtgc
tgactcagcc tccctccgcg tccgggtctc ctggacagtc agtcaccatc
480tcctgcactg gaaccagcag tgatgttggt ggttataact atgtctcctg
gtaccaacag 540cacccaggca aagcccccaa attcatgatt tatgatgtca
gtaagcggcc ctcaggggtt 600tctaatcgct tctctggctc caagtctggc
aacacggcgt ccctgaccat ctctggggtc 660caggctgagg acgaggctga
ttattactgc agctcatata caagcgccag cactgtgata 720ttcggcggag
ggaccaagct gaccgtccta ggt 75316735DNAArtificial SequenceDNA
encoding N025E05 scFv 16caggtacagc tgcagcagtc aggggctgag gtgaagaagc
ctgggtcctc ggtgaaggtc 60tcctgcaagg cttctggaga caccttcagt agcaatacta
tcagctgggt acgacaggcc 120cctggacaag ggcttgagtg gatgggaggg
atcatcccta tcattggaac accacactac 180gcacagaaat tccagggcag
agtcacaata accgctgaca gatccacgag cacagcctac 240atggagctga
ccaacctgag atctgaggac acggccgtat atttctgtgc gagaaaccga
300gtggggacta gcagctttga cttctggggc caggggacaa tggtcaccgt
ctcgagtgga 360ggcggcggtt caggcggagg tggctctggc ggtggcggaa
gtgcactgcc tgtgctgact 420cagccaccct cagcgtctgg gacccccggg
cagagggtca ccatctcttg ttctggaagc 480agctccaaca tcggaagtaa
tactgtaaac tggtaccagc agctcccagg aacggccccc 540aaactcttca
tctatagtaa taatcagcgg ccctcagggg tccctgaccg attctctggc
600tccaagtctg gcacctcagc ctccctggcc atcagtgggc tccagtctga
agatgaggct 660gattattact gttcatcatg ggatgacagc ctgaatttga
tattcggcgg ggggaccaag 720gtcaccgtcc taggt 73517735DNAArtificial
SequenceDNA encoding N025C01 scFv 17caggtgcagc tggtgcagtc
tggggctgag gtgaagaagc ctgggacctc ggtgaaggtc 60tcctgcaagg ctgctggaga
cactttccgc agctatatta tcagctgggt gcgacaggcc 120cctggacaag
gacttgagtg ggtgggaggg atcatcccta tgtttggcac atcaaactac
180gcacagaagt tccagggcag agtcacgatt accgcggacg attccacgag
cacagcctac 240atggagctga gcagcctgag atctgaggac acggccgtgt
attactgtgc gaggacggcc 300caggggggga gctactacaa ctactggggc
caaggaaccc cggtcaccgt ctcgagtggt 360ggaggcggtt caggcggagg
tggcagcggc ggtggcggat cgcagtctgt gttgacgcag 420ccgccctcag
tgtctgcggc cccaggacag aaggtcacca tttcctgctc tggaagcacc
480tccaacattg ggaataatta tgtctcctgg taccaacagc acccaggcaa
agcccccaaa 540ctcatgattt atgatgtcag taagcggccc tcaggggtcc
ctgaccgatt ctctggctcc 600aagtctggca actcagcctc cctggacatc
agtgggctcc agtctgagga tgaggctgat 660tattactgtg cagcatggga
tgacggcctg agtgaatttc tcttcggaac tgggaccaag 720ctgaccgtcc
taggt 73518741DNAArtificial SequenceDNA encoding N024F09 scFv
18caggtacagc tgcagcagtc aggggctgag gtgaagaagc ctggggcctc agtgaaggtc
60tcctgcaagg cttctggata caccttcacc ggctactata tgcactgggt gcgacaggcc
120cctggacaac gacttgagtg gatgggaggg atcctccctt tttttggtac
aacaagctac 180gcacaaaatt tccacggcag actcacaatt accgcggacg
aatccacgcg cacagcctac 240atggagctga gcagcctaaa atctgaagac
acggccgttt attactgtgc gagagatgag 300tccgcggatc ccaaaaatgc
ttttgatatc tggggccgag ggacaatggt caccgtctct 360tcaggtggag
gcggttcagg cggaggtggc agcggcggtg gcggatcgca gtctgtgttg
420acgcagccgc ccccagtgtc tgcggcccca ggacagaagg tcaccatttc
ctgctctgga 480agcacctcca acattgggaa taattatgtc tcctggtacc
aacagcgccc aggcaaagcc 540cccaaactca tgatttatga tgtcagtaag
cggccctcag gggtccccga ccgattctct 600ggctccaagt ctggcaactc
agcctccctg gacatcagtg ggctccagtc tgaggatgag 660gctgattatt
actgtgcagc atgggatgac agcctgagtg aatttctctt cggaactggg
720accaagctga ccgtcctagg t 74119738DNAArtificial SequenceDNA
encoding N024B01 scFv 19caggtacagc tgcagcagtc agggaatgag gtgaagaagc
ctgggtcctc ggtgaagatc 60tcctgcaagg cttccggagc ccccttcaat agttatgtta
tcagttgggt gcggcaggcc 120cctggacaag ggcttgagtg ggtgggaggg
gtcgtcccca tctttggcac agcacactac 180gcacaccagt tccagggcag
agtcaccatt atcgcggaca agtcgacgag cacagtctac 240atggagttgc
gcggcctgac atcggacgac acggccgaat atttttgtgc gagacaaggc
300ccctatggca aacttgacga ttggggccag gggacaatgg tcaccgtctc
gagtggaggc 360ggcggttcag gcggaggtgg ctctggcggt ggcggaagtg
cactttccta tgagctgact 420cagccaccct cagcgtctgg aacccccggg
cagagggtca ccatctcttg ttctggaagc 480agctccaata tcggaagtaa
ttatgtatac tggtaccagc agttcccagg aacggccccc 540aaactcctca
tgtataggaa taatcagcgg ccctcagggg tccctgaccg attctctggc
600tccaagtttg gcacctcagc ctccctggcc atcagtgggc tccggtccga
ggatgaggct 660gattattact gtgcagcatg ggatgacagc ctgactggtc
gggtattcgg cggagggacc 720aaggtcaccg tcctaggt 73820744DNAArtificial
SequenceDNA encoding N024F07 scFv 20caggtacagc tgcagcagtc
aggggctgag gtgaagaagc ctgggtcctc ggtgaacgtc 60tcctgcaagg cttctggagg
caccttcgac acttttggca tcagctgggt gcggcaggct 120ccaggcaagg
gtctggagtg gatgggagtt atagcacatg atggaagtat ttcatactat
180gcagactccg tgaagggccg attcaccttc tccagagaca attccaagaa
cacggtgtct 240ctgcaaatga acagcccgag acctgaggac acggctgtgt
attactgtgc gaaaggggag 300tatgatagta gtggttacaa tgcttttgat
atctggggca agggcaccct ggtcaccgtc 360tcgagtggtg gaggcggttc
aggcggaggt ggcagcggcg gtggcggatc gcagtctgtg 420ttgacgcagc
cgccctcagt gtctgcggcc ccaggacaga aggtcaccgt ttcctgctct
480ggaagcacct ccaacattgg gaataattat gtctcctggt accaacagca
cccaggcaaa 540gcccccaaac tcatgattta tgatgtcagt aagcggccct
caggggtccc tgaccgattc 600tctggctcca agtctggcaa ctcagcctcc
ctggacatca gtgggctcca gtctgaggat 660gaggctgatt attactgtgc
agcatgggat gacagcctga gtgaatttct cttcggaact 720gggaccaagc
tgaccgtcct aggt 74421726DNAArtificial SequenceDNA encoding N015D10
scFv 21caggtgcagc tggtgcagtc tggggctgaa gtgaagaagc ctgggtcctc
ggtgaggatc 60tcctgcaagg cttctggggg cagcttcagg acttatgttg tcagctgggt
gcgacaggcc 120cctggacaag ggcttgagtg gatgggaggg atcattcctg
tctatggcac accaaactac 180gcacagaagt tccagggcag agtcacgatt
accgcggacg aacctacgag aacaacctac 240atggagctga gcagcctgag
atcagaggac acgggcgtgt attattgtgc gagaaatggt 300gggggccttg
attactgggg ccaagggaca atggtcaccg tctcgagtgg tggaggcggt
360tcaggcggag gtggcagcgg cggtggcgga tcgcagtctg tgttgacgca
gccgccctca 420gtgtctgcgg ccccaggaca gaaggtcacc atttcctgct
ctggaagcac ctccaacatt 480gggaataatt atgtctcctg gtaccaacag
cacccaggca aagcccccaa actcatgatt 540tatgatgtca gtaagcggcc
ctcaggggtc cctgaccgat tctctggctc caagtctggc 600aactcagcct
ccctggacat cagtgggctc cagtctgagg atgaggccga ttattactgt
660gcagcatggg atgacagcct gagtgaattt ctcttcggaa ctgggaccaa
gctgaccgtc 720ctaggt 72622250PRTArtificial sequenceN024C01 scFv
22Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Asn Pro Gly Ser1
5 10 15Ser Val Lys Val Ser Cys Lys Pro Ser Arg Asp Thr Leu Ser Gly
Asp 20 25 30Asn Phe Ser Ser Ser Val Phe Ser Trp Val Arg Gln Ala Pro
Gly Gln 35 40 45Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly
Val Ala Asn 50 55 60Tyr Ala Gln Lys Phe Gln Pro Arg Val Thr Ile Ser
Ala Asp Met Ser65 70 75 80Thr Asn Thr Ala Tyr Met Glu Leu Ser Ser
Leu Arg Ser Glu Asp Thr 85 90 95Ala Val Tyr Tyr Cys Ala Ser Thr Trp
Glu Leu Arg Asn Ala Phe Asp 100 105 110Ile Trp Gly Lys Gly Thr Leu
Val Thr Val Ser Ser Gly Gly Gly Gly 115 120 125Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gln Ser Val Leu Thr 130 135 140Gln Pro Pro
Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser145 150 155
160Cys Ser Gly Ser Thr Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr
165 170 175Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp
Val Ser 180 185 190Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly
Ser Lys Ser Gly 195 200 205Asn Ser Ala Ser Leu Asp Ile Ser Gly Leu
Gln Ser Glu Asp Glu Ala 210 215 220Asp Tyr Tyr Cys Ala Ala Trp Asp
Asp Ser Leu Ser Glu Phe Leu Phe225 230 235 240Gly Thr Gly Thr Lys
Leu Thr Val Leu Gly 245 25023251PRTArtificial sequenceN025B07 scFv
23Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1
5 10 15Ser Val Arg Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asn
Phe 20 25 30Tyr Met His Trp Leu Arg Gln Ala Pro Gly Arg Gly Pro Glu
Trp Met 35 40 45Gly Ile Ile Asp Pro Ser Asn Asn Tyr Thr Tyr Tyr Ala
Gln Lys Arg 50 55 60Val Thr Val Thr Arg Asp Thr Ser Thr Ser Thr Val
Tyr Met Glu Leu65 70 75 80Ser Ser Leu Arg Ser Glu Asp Thr Ala Ile
Tyr Tyr Cys Ala Arg Pro 85 90 95Val Tyr Tyr Tyr Asp Ser Ser Gly Tyr
Tyr Tyr Gly Leu Asn Ala Phe 100 105 110Asp Ile Ser Trp Gly Arg Gly
Thr Met Val Thr Val Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gln Ser Val Leu 130 135 140Thr Gln Pro
Pro Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile145 150 155
160Ser Cys Ser Gly Ser Thr Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp
165 170 175Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr
Asp Val 180 185 190Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
Gly Ser Lys Ser 195 200 205Gly Asn Ser Ala Ser Leu Asp Ile Ser Gly
Leu Gln Ser Glu Asp Glu 210 215 220Ala Asp Tyr Tyr Cys Ala Ala Trp
Asp Asp Ser Leu Ser Glu Phe Leu225 230 235 240Phe Gly Thr Gly Thr
Lys Leu Thr Val Leu Gly 245 25024242PRTArtificial sequenceN015E08
scFv 24Gln Met Gln Leu Gln Glu Ser Gly Ala Glu Val Lys Lys Pro Gly
Ser1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Asp Thr Phe Arg
Ser Tyr 20 25 30Ile Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
Glu Trp Met 35 40 45Gly Gly Ile Ile Pro Met Phe Gly Thr Thr Asn Tyr
Ala Gln Gln Phe 50 55 60Gln Gly Lys Val Thr Ile Thr Ala Asp Asp Ser
Thr Ser Thr Ser Tyr65 70 75 80Met Glu Leu Arg Ser Leu Arg Ser Asp
Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Thr Asn Tyr Met Asp
Val Trp Gly Gln Gly Thr Thr Val 100 105 110Thr Val Ser Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 115 120 125Gly Gly Ser Gln
Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala 130 135 140Pro Gly
Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Thr Ser Asn Ile145 150 155
160Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro
165 170 175Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val
Pro Asp 180 185 190Arg Phe Ser Gly Ser Lys Ser Gly Asn Ser Ala Ser
Leu Asp Ile Ser 195 200 205Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr
Tyr Cys Ala Ala Trp Asp 210 215 220Asp Ser Leu Ser Glu Phe Leu Phe
Gly Thr Gly Thr Lys Leu Thr Val225 230 235 240Leu
Gly25248PRTArtificial sequenceN015F10 scFv 25Gln Val Gln Leu Gln
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val
Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr 20 25 30Ala Ile Ser
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Gly
Ser Ile Pro Lys Phe Arg Thr Ala Asn Tyr Ala Lys Lys Phe 50 55 60Gln
Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr65 70 75
80Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg Gly Ser Ala Tyr Asn Leu Arg Asn Ala Phe Asp Ile Trp
Gly 100 105 110Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly
Ser Gly Gly 115 120 125Gly Gly Ser Gly Gly Gly Gly Ser Ala Gln Ser
Val Val Thr Gln Pro 130 135 140Pro Ser Val Ser Ala Ala Pro Gly Gln
Arg Val Thr Ile Ser Cys Ser145 150 155 160Gly Ser Ser Ser Asn Ile
Ala Asn Asn Tyr Val Ser Trp Tyr Gln Gln 165 170 175Leu Pro Gly Thr
Ala Pro Lys Leu Leu Ile Tyr Asp Asn Asn Lys Arg 180 185 190Pro Ser
Gly Ile Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser 195 200
205Ala Thr Leu Gly Ile Thr Gly Leu Gln Thr Gly Asp Glu Ala Asp Tyr
210 215 220Tyr Cys Gly Thr Trp Asp Ser Ser Leu Ser Ala Tyr Val Phe
Gly Thr225 230 235 240Gly Thr Lys Val Thr Val Leu Gly
24526244PRTArtificial sequenceN024D01 scFv 26Gln Val Gln Leu Gln
Gln Ser Gly Gly Gly Val Val Gln Pro Gly Arg1 5 10 15Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30Ala Met His
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly
Ile Ser Trp Asn Ser Gly Ser Ile Gly Tyr Ala Asp Ser Val 50 55 60Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr65 70 75
80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95Ala Lys Thr Gly Gly Gly Asn Ser Leu Asp Tyr Trp Gly Arg Gly
Thr 100 105 110Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser 115 120 125Gly Gly Gly Gly Ser Gln Ser Val Leu Thr Gln
Pro Pro Ser Val Ser 130 135 140Ala Ala Pro Gly Gln Lys Val Thr Ile
Ser Cys Ser Gly Ser Thr Ser145 150 155 160Asn Ile Gly Asn Asn Tyr
Val Ser Trp Tyr Gln Gln His Pro Gly Lys 165 170 175Ala Pro Lys Leu
Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val 180 185 190Pro Asp
Arg Phe Ser Gly Ser Lys Ser Gly Asn Ser Ala Ser Leu Asp 195 200
205Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala
210 215 220Trp Asp Asp Ser Leu Ser Glu Phe Leu Phe Gly Thr Gly Thr
Lys Leu225 230 235 240Thr Val Leu Gly27247PRTArtificial
sequenceN015D08 scFv 27Gln Val Gln Leu Leu Gln Ser Ala Pro Glu Val
Lys Lys Pro Gly Ser1 5 10 15Ser Val Arg Val Ser Cys Lys Thr Ser Gly
Gly Thr Phe Ser Ser Gln 20 25 30Leu Ile Asn Trp Val Arg Gln Pro Pro
Gly Gln Gly Pro Glu Trp Met 35 40 45Gly Gly Ile Ile Pro Ile Phe Gly
Thr Ala Asn Tyr Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Ile Thr
Ala Asp Glu Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu Leu Ser Ser
Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asp Leu
Thr Ala Gly Arg Phe Asp Ala Phe His Ile Trp Gly 100 105 110Arg Gly
Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120
125Gly Gly Ser Gly Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Pro
130 135 140Ser Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys
Ser Gly145 150 155 160Ser Thr Ser Asn Ile Gly Asn Asn Tyr Val Ser
Trp Tyr Gln Gln His 165 170 175Pro Gly Lys Ala Pro Lys Leu Met Ile
Tyr Asp Val Ser Lys Arg Pro 180 185 190Ser Gly Val Pro Asp Arg Phe
Ser Gly Ser Lys Ser Gly Asn Ser Ala 195 200 205Ser Leu Asp Ile Ser
Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr 210 215 220Cys Ala Ala
Trp Asp Asp Ser Leu Ser Glu Phe Leu Phe Gly Thr Gly225 230 235
240Thr Lys Leu Thr Val Leu Gly 24528248PRTArtificial
sequenceN024B07 scFv 28Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val
Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly
Gly Thr Phe Ser Ser Tyr 20 25 30Ala Ile Ser Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Gly Ser Ile Pro Lys Phe Arg
Thr Ala Asn Tyr Ala Lys Lys Phe 50 55 60Gln Gly Arg Val Thr Ile Thr
Ala Asp Glu Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu Leu Ser Ser
Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Ser
Thr Tyr Asn Leu Arg Asn Ala Phe Asp Ile Trp Gly 100 105 110Lys Gly
Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120
125Gly Gly Ser Gly Gly Gly Gly Ser Ala Gln Ser Val Val Thr Gln Pro
130 135 140Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser
Cys Ser145 150 155 160Gly Gly Ser Ser Asn Ile Gly Arg Asn Thr Val
Asn Trp Tyr Gln Gln 165 170 175Val Pro Gly Thr Ala Pro Lys Leu Leu
Ile Tyr Thr Asn Asn Gln Arg 180 185 190Pro Ser Gly Val Pro Asp Arg
Phe Ser Gly Ser Lys Ser Gly Thr Ser 195 200 205Ala Ser Leu Ala Ile
Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr 210 215 220Tyr Cys Ala
Ala Trp Asp Asp Ser Leu Asn Asp Val Glu Phe Gly Gly225 230 235
240Gly Thr Lys Leu Thr Val Leu Gly 24529243PRTArtificial
sequenceN024E07 scFv 29Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu
Glu Gln Pro Gly Arg1 5 10 15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly
Phe Thr Phe Asp Asp Tyr 20 25 30Pro Met His Trp Val Arg Gln Ala Pro
Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile Ser Gly Asn Ser Asp
Arg Ile Ala Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser
Arg Asp Asn Ser Lys Asn Thr Leu Trp65 70 75 80Leu Gln Met Asn Ser
Leu Arg Ala Glu Asp Thr Ala Ile Tyr Tyr Cys 85 90 95Ala Arg Ala Ala
Arg Asn Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu 100 105 110Val Thr
Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 115 120
125Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala
130 135
140Ala Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Thr Ser
Asn145 150 155 160Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln His
Pro Gly Lys Ala 165 170 175Pro Lys Leu Met Ile Tyr Asp Val Ser Lys
Arg Pro Ser Gly Val Pro 180 185 190Asp Arg Phe Ser Gly Ser Lys Ser
Gly Asn Ser Ala Ser Leu Asp Ile 195 200 205Ser Gly Leu Gln Ser Glu
Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp 210 215 220Asp Asp Ser Leu
Ser Glu Phe Leu Phe Gly Thr Gly Thr Lys Leu Thr225 230 235 240Val
Leu Gly30255PRTArtificial sequenceN023F05 scFv 30Gln Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Phe1 5 10 15Ser Val Lys
Val Ser Cys Lys Ala Ser Gly Gly Ser Phe Ser Asn Tyr 20 25 30Val Ile
Ser Trp Leu Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly
Gly Ile Met Pro Ile Phe Gly Asn Ala Asn Tyr Ala Gln Lys Phe 50 55
60Gln Asp Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr65
70 75 80Met Glu Leu Ser Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr
Cys 85 90 95Ala Arg Asp Gln Ile Val Val Asp Pro Val Thr Lys Gly Ala
Tyr Tyr 100 105 110Ser Gly Leu Asp Val Trp Gly Arg Gly Thr Met Val
Thr Val Ser Ser 115 120 125Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Ala 130 135 140Gln Ser Val Leu Thr Gln Pro Pro
Ser Ala Ser Gly Thr Pro Gly Gln145 150 155 160Arg Val Thr Ile Ser
Cys Ser Gly Gly Ser Ser Asn Ile Gly Ala Asn 165 170 175Ala Ile Thr
Trp Phe Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu 180 185 190Ile
Tyr His Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser 195 200
205Gly Ser Lys Ser Gly Thr Ser Gly Ser Leu Ala Ile Ser Gly Leu Gln
210 215 220Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Val Trp Asp Asn
Ser Leu225 230 235 240Asn Ala Met Leu Phe Gly Gly Gly Thr Lys Leu
Thr Val Leu Gly 245 250 25531245PRTArtificial sequenceN024D08 scFv
31Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Arg Pro Gly Ala1
5 10 15Ser Val Lys Ile Ser Cys Arg Thr Ser Gly Tyr Thr Phe Thr Ser
Tyr 20 25 30Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu
Trp Leu 35 40 45Ala Ile Ile Asn Pro Thr Ala Gly Asn Thr Tyr Tyr Thr
Gln Asp Phe 50 55 60Gln Asp Arg Val Thr Val Thr Arg Asp Thr Ser Thr
Ser Thr Val Tyr65 70 75 80Met Glu Leu Arg Gly Leu Asn Ser Glu Asp
Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ser Pro Tyr Gly Val Arg Asn Ala
Phe Asp Val Trp Gly Gln Gly 100 105 110Thr Met Val Thr Val Ser Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly 115 120 125Ser Gly Gly Gly Gly
Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Val 130 135 140Ser Ala Ala
Pro Gly Gln Lys Val Thr Ile Ser Cys Ser Gly Ser Thr145 150 155
160Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly
165 170 175Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg Pro
Ser Gly 180 185 190Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn
Ser Ala Ser Leu 195 200 205Asp Ile Ser Gly Leu Gln Ser Glu Asp Glu
Ala Asp Tyr Tyr Cys Ala 210 215 220Ala Trp Asp Asp Ser Leu Ser Glu
Phe Leu Phe Gly Thr Gly Thr Lys225 230 235 240Leu Thr Val Leu Gly
24532248PRTArtificial sequenceN023B03 scFv 32Glu Val Gln Leu Leu
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30Ala Met Ser
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Ala
Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75
80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg Gln Gly Ser Gly Ser Tyr Pro Pro Pro Ala Phe Asp Ser
Trp 100 105 110Gly Arg Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly
Gly Ser Gly 115 120 125Gly Gly Gly Ser Gly Gly Gly Gly Ser Ala Gln
Ala Val Val Ile Gln 130 135 140Glu Pro Ser Leu Thr Val Ser Pro Gly
Gly Thr Val Thr Leu Thr Cys145 150 155 160Ala Phe Asn Ser Gly Gln
Val Thr Ser Gly Phe Tyr Pro Asn Trp Phe 165 170 175Gln Gln Lys Pro
Gly Gln Pro Pro Arg Ser Leu Ile Tyr Asn Thr Asp 180 185 190Asn Lys
His Ser Trp Thr Pro Ala Arg Phe Ser Gly Ser Leu Leu Gly 195 200
205Gly Lys Ala Ala Leu Thr Leu Ser Gly Val Gln Pro Asp Asp Glu Ala
210 215 220Asp Tyr Tyr Cys Leu Leu Tyr Tyr Asp Arg Ser Leu Val Phe
Gly Gly225 230 235 240Gly Thr Lys Leu Thr Val Leu Gly
24533243PRTArtificial sequenceN023E01 scFv 33Gln Val Gln Leu Val
Gln Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1 5 10 15Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30Ala Met His
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly
Ile Ser Trp Asn Ser Ala Ser Ile Gly Tyr Ala Asp Ser Val 50 55 60Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr65 70 75
80Leu Gln Met Asn Ser Leu Arg Gly Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95Ala Lys Gly Ala Arg Asp Ala Leu Asp Ile Trp Gly Lys Gly Thr
Leu 100 105 110Leu Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly 115 120 125Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro
Pro Ser Val Ser Ala 130 135 140Ala Pro Gly Gln Lys Val Thr Ile Ser
Cys Ser Gly Ser Thr Ser Asn145 150 155 160Ile Gly Asn Asn Tyr Val
Ser Trp Tyr Gln Gln His Pro Gly Lys Ala 165 170 175Pro Lys Leu Met
Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro 180 185 190Asp Arg
Phe Ser Gly Ser Lys Ser Gly Asn Ser Ala Ser Leu Asp Ile 195 200
205Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp
210 215 220Asp Asp Ser Leu Ser Glu Phe Leu Phe Gly Thr Gly Thr Lys
Leu Thr225 230 235 240Val Leu Gly34251PRTArtificial sequenceN024C05
scFv 34Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser
Gln1 5 10 15Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser
Ser Asn 20 25 30Thr Ala Ala Trp Ser Trp Ile Arg Gln Ser Pro Ser Arg
Gly Leu Glu 35 40 45Trp Leu Gly Arg Thr Tyr Tyr Ser Arg Ser Lys Trp
Tyr Lys Asp Tyr 50 55 60Ala Val Ser Val Lys Ser Arg Ile Thr Ile Asn
Pro Asp Thr Ser Lys65 70 75 80Asn Gln Phe Ser Leu Gln Leu Asp Ser
Val Thr Pro Glu Asp Thr Ala 85 90 95Val Tyr Tyr Cys Thr Arg Glu Gly
Tyr Tyr Asp Tyr Ser Gly Val Val 100 105 110Asp Tyr Trp Gly Gln Gly
Thr Thr Val Ile Val Ser Ser Gly Gly Gly 115 120 125Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gln Ser Val Leu 130 135 140Thr Gln
Pro Pro Ser Ala Ser Gly Ser Pro Gly Gln Ser Val Thr Ile145 150 155
160Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser
165 170 175Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Phe Met Ile
Tyr Asp 180 185 190Val Ser Lys Arg Pro Ser Gly Val Ser Asn Arg Phe
Ser Gly Ser Lys 195 200 205Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser
Gly Val Gln Ala Glu Asp 210 215 220Glu Ala Asp Tyr Tyr Cys Ser Ser
Tyr Thr Ser Ala Ser Thr Val Ile225 230 235 240Phe Gly Gly Gly Thr
Lys Leu Thr Val Leu Gly 245 25035245PRTArtificial sequenceN025E05
scFv 35Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly
Ser1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Asp Thr Phe Ser
Ser Asn 20 25 30Thr Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu
Glu Trp Met 35 40 45Gly Gly Ile Ile Pro Ile Ile Gly Thr Pro His Tyr
Ala Gln Lys Phe 50 55 60Gln Gly Arg Val Thr Ile Thr Ala Asp Arg Ser
Thr Ser Thr Ala Tyr65 70 75 80Met Glu Leu Thr Asn Leu Arg Ser Glu
Asp Thr Ala Val Tyr Phe Cys 85 90 95Ala Arg Asn Arg Val Gly Thr Ser
Ser Phe Asp Phe Trp Gly Gln Gly 100 105 110Thr Met Val Thr Val Ser
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 115 120 125Ser Gly Gly Gly
Gly Ser Ala Leu Pro Val Leu Thr Gln Pro Pro Ser 130 135 140Ala Ser
Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser Gly Ser145 150 155
160Ser Ser Asn Ile Gly Ser Asn Thr Val Asn Trp Tyr Gln Gln Leu Pro
165 170 175Gly Thr Ala Pro Lys Leu Phe Ile Tyr Ser Asn Asn Gln Arg
Pro Ser 180 185 190Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly
Thr Ser Ala Ser 195 200 205Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp
Glu Ala Asp Tyr Tyr Cys 210 215 220Ser Ser Trp Asp Asp Ser Leu Asn
Leu Ile Phe Gly Gly Gly Thr Lys225 230 235 240Val Thr Val Leu Gly
24536245PRTArtificial sequenceN025C01 scFv 36Gln Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Thr1 5 10 15Ser Val Lys Val
Ser Cys Lys Ala Ala Gly Asp Thr Phe Arg Ser Tyr 20 25 30Ile Ile Ser
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Val 35 40 45Gly Gly
Ile Ile Pro Met Phe Gly Thr Ser Asn Tyr Ala Gln Lys Phe 50 55 60Gln
Gly Arg Val Thr Ile Thr Ala Asp Asp Ser Thr Ser Thr Ala Tyr65 70 75
80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg Thr Ala Gln Gly Gly Ser Tyr Tyr Asn Tyr Trp Gly Gln
Gly 100 105 110Thr Pro Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly 115 120 125Ser Gly Gly Gly Gly Ser Gln Ser Val Leu Thr
Gln Pro Pro Ser Val 130 135 140Ser Ala Ala Pro Gly Gln Lys Val Thr
Ile Ser Cys Ser Gly Ser Thr145 150 155 160Ser Asn Ile Gly Asn Asn
Tyr Val Ser Trp Tyr Gln Gln His Pro Gly 165 170 175Lys Ala Pro Lys
Leu Met Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly 180 185 190Val Pro
Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Ser Ala Ser Leu 195 200
205Asp Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala
210 215 220Ala Trp Asp Asp Gly Leu Ser Glu Phe Leu Phe Gly Thr Gly
Thr Lys225 230 235 240Leu Thr Val Leu Gly 24537247PRTArtificial
sequenceN024F09 scFv 37Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val
Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly
Tyr Thr Phe Thr Gly Tyr 20 25 30Tyr Met His Trp Val Arg Gln Ala Pro
Gly Gln Arg Leu Glu Trp Met 35 40 45Gly Gly Ile Leu Pro Phe Phe Gly
Thr Thr Ser Tyr Ala Gln Asn Phe 50 55 60His Gly Arg Leu Thr Ile Thr
Ala Asp Glu Ser Thr Arg Thr Ala Tyr65 70 75 80Met Glu Leu Ser Ser
Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asp Glu
Ser Ala Asp Pro Lys Asn Ala Phe Asp Ile Trp Gly 100 105 110Arg Gly
Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly 115 120
125Gly Gly Ser Gly Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Pro
130 135 140Pro Val Ser Ala Ala Pro Gly Gln Lys Val Thr Ile Ser Cys
Ser Gly145 150 155 160Ser Thr Ser Asn Ile Gly Asn Asn Tyr Val Ser
Trp Tyr Gln Gln Arg 165 170 175Pro Gly Lys Ala Pro Lys Leu Met Ile
Tyr Asp Val Ser Lys Arg Pro 180 185 190Ser Gly Val Pro Asp Arg Phe
Ser Gly Ser Lys Ser Gly Asn Ser Ala 195 200 205Ser Leu Asp Ile Ser
Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr 210 215 220Cys Ala Ala
Trp Asp Asp Ser Leu Ser Glu Phe Leu Phe Gly Thr Gly225 230 235
240Thr Lys Leu Thr Val Leu Gly 24538246PRTArtificial
sequenceN024B01 scFv 38Gln Val Gln Leu Gln Gln Ser Gly Asn Glu Val
Lys Lys Pro Gly Ser1 5 10 15Ser Val Lys Ile Ser Cys Lys Ala Ser Gly
Ala Pro Phe Asn Ser Tyr 20 25 30Val Ile Ser Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu Glu Trp Val 35 40 45Gly Gly Val Val Pro Ile Phe Gly
Thr Ala His Tyr Ala His Gln Phe 50 55 60Gln Gly Arg Val Thr Ile Ile
Ala Asp Lys Ser Thr Ser Thr Val Tyr65 70 75 80Met Glu Leu Arg Gly
Leu Thr Ser Asp Asp Thr Ala Glu Tyr Phe Cys 85 90 95Ala Arg Gln Gly
Pro Tyr Gly Lys Leu Asp Asp Trp Gly Gln Gly Thr 100 105 110Met Val
Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 115 120
125Gly Gly Gly Gly Ser Ala Leu Ser Tyr Glu Leu Thr Gln Pro Pro Ser
130 135 140Ala Ser Gly Thr Pro Gly Gln Arg Val Thr Ile Ser Cys Ser
Gly Ser145 150 155 160Ser Ser Asn Ile Gly Ser Asn Tyr Val Tyr Trp
Tyr Gln Gln Phe Pro 165 170 175Gly Thr Ala Pro Lys Leu Leu Met Tyr
Arg Asn Asn Gln Arg Pro Ser 180 185 190Gly Val Pro Asp Arg Phe Ser
Gly Ser Lys Phe Gly Thr Ser Ala Ser 195 200 205Leu Ala Ile Ser Gly
Leu Arg Ser Glu Asp Glu Ala Asp Tyr Tyr Cys 210 215 220Ala Ala Trp
Asp Asp Ser Leu Thr Gly Arg Val Phe Gly Gly Gly Thr225 230 235
240Lys Val Thr Val Leu Gly 24539248PRTArtificial sequenceN024F07
scFv 39Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys Pro Gly
Ser1 5 10 15Ser Val Asn Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Asp
Thr Phe 20 25 30Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
Glu Trp Met 35 40 45Gly Val Ile Ala His Asp Gly Ser Ile Ser Tyr Tyr
Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Phe Ser Arg Asp Asn Ser
Lys Asn Thr Val Ser65 70 75 80Leu Gln Met Asn Ser Pro Arg Pro Glu
Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Gly Glu Tyr Asp Ser Ser
Gly Tyr Asn
Ala Phe Asp Ile Trp 100 105 110Gly Lys Gly Thr Leu Val Thr Val Ser
Ser Gly Gly Gly Gly Ser Gly 115 120 125Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gln Ser Val Leu Thr Gln Pro 130 135 140Pro Ser Val Ser Ala
Ala Pro Gly Gln Lys Val Thr Val Ser Cys Ser145 150 155 160Gly Ser
Thr Ser Asn Ile Gly Asn Asn Tyr Val Ser Trp Tyr Gln Gln 165 170
175His Pro Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser Lys Arg
180 185 190Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly
Asn Ser 195 200 205Ala Ser Leu Asp Ile Ser Gly Leu Gln Ser Glu Asp
Glu Ala Asp Tyr 210 215 220Tyr Cys Ala Ala Trp Asp Asp Ser Leu Ser
Glu Phe Leu Phe Gly Thr225 230 235 240Gly Thr Lys Leu Thr Val Leu
Gly 24540242PRTArtificial sequenceN015D10 scFv 40Gln Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser1 5 10 15Ser Val Arg
Ile Ser Cys Lys Ala Ser Gly Gly Ser Phe Arg Thr Tyr 20 25 30Val Val
Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly
Gly Ile Ile Pro Val Tyr Gly Thr Pro Asn Tyr Ala Gln Lys Phe 50 55
60Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Pro Thr Arg Thr Thr Tyr65
70 75 80Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Gly Val Tyr Tyr
Cys 85 90 95Ala Arg Asn Gly Gly Gly Leu Asp Tyr Trp Gly Gln Gly Thr
Met Val 100 105 110Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly 115 120 125Gly Gly Ser Gln Ser Val Leu Thr Gln Pro
Pro Ser Val Ser Ala Ala 130 135 140Pro Gly Gln Lys Val Thr Ile Ser
Cys Ser Gly Ser Thr Ser Asn Ile145 150 155 160Gly Asn Asn Tyr Val
Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro 165 170 175Lys Leu Met
Ile Tyr Asp Val Ser Lys Arg Pro Ser Gly Val Pro Asp 180 185 190Arg
Phe Ser Gly Ser Lys Ser Gly Asn Ser Ala Ser Leu Asp Ile Ser 195 200
205Gly Leu Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp
210 215 220Asp Ser Leu Ser Glu Phe Leu Phe Gly Thr Gly Thr Lys Leu
Thr Val225 230 235 240Leu Gly4123DNAArtificial sequencePCR primer
useful for amplifying VH and VL domains 41caggtgcagc tggtgcagtc tgg
234223DNAArtificial sequencePCR primer useful for amplifying VH and
VL domains 42caggtcaact taagggagtc tgg 234323DNAArtificial
sequencePCR primer useful for amplifying VH and VL domains
43gaggtgcagc tggtggagtc tgg 234423DNAArtificial sequencePCR primer
useful for amplifying VH and VL domains 44caggtgcagc tgcaggagtc ggg
234523DNAArtificial sequencePCR primer useful for amplifying VH and
VL domains 45gaggtgcagc tgttgcagtc tgc 234623DNAArtificial
sequencePCR primer useful for amplifying VH and VL domains
46caggtacagc tgcagcagtc agg 234724DNAArtificial sequencePCR primer
useful for amplifying VH and VL domains 47tgaggagacg gtgaccaggg
tgcc 244824DNAArtificial sequencePCR primer useful for amplifying
VH and VL domains 48tgaagagacg gtgaccattg tccc 244924DNAArtificial
sequencePCR primer useful for amplifying VH and VL domains
49tgaggagacg gtgaccaggg ttcc 245024DNAArtificial sequencePCR primer
useful for amplifying VH and VL domains 50tgaggagacg gtgaccgtgg
tccc 245123DNAArtificial sequencePCR primer useful for amplifying
VH and VL domains 51gacatccaga tgacccagtc tcc 235223DNAArtificial
sequencePCR primer useful for amplifying VH and VL domains
52gatgttgtga tgactcagtc tcc 235323DNAArtificial sequencePCR primer
useful for amplifying VH and VL domains 53gatattgtga tgactcagtc tcc
235423DNAArtificial sequencePCR primer useful for amplifying VH and
VL domains 54gaaattgtgt tgacgcagtc tcc 235523DNAArtificial
sequencePCR primer useful for amplifying VH and VL domains
55gacatcgtga tgacccagtc tcc 235623DNAArtificial sequencePCR primer
useful for amplifying VH and VL domains 56gaaacgacac tcacgcagtc tcc
235723DNAArtificial sequencePCR primer useful for amplifying VH and
VL domains 57gaaattgtgc tgactcagtc tcc 235823DNAArtificial
sequencePCR primer useful for amplifying VH and VL domains
58cagtctgtgt tgacgcagcc gcc 235923DNAArtificial sequencePCR primer
useful for amplifying VH and VL domains 59cagtctgccc tgactcagcc tgc
236023DNAArtificial sequencePCR primer useful for amplifying VH and
VL domains 60tcctatgtgc tgactcagcc acc 236123DNAArtificial
sequencePCR primer useful for amplifying VH and VL domains
61tcttctgagc tgactcagga ccc 236223DNAArtificial sequencePCR primer
useful for amplifying VH and VL domains 62cacgttatac tgactcaacc gcc
236323DNAArtificial sequencePCR primer useful for amplifying VH and
VL domains 63caggctgtgc tcactcagcc gtc 236423DNAArtificial
sequencePCR primer useful for amplifying VH and VL domains
64aattttatgc tgactcagcc cca 236524DNAArtificial sequencePCR primer
useful for amplifying VH and VL domains 65acgtttgatt tccaccttgg
tccc 246624DNAArtificial sequencePCR primer useful for amplifying
VH and VL domains 66acgtttgatc tccagcttgg tccc 246724DNAArtificial
sequencePCR primer useful for amplifying VH and VL domains
67acgtttgata tccactttgg tccc 246824DNAArtificial sequencePCR primer
useful for amplifying VH and VL domains 68acgtttgatc tccaccttgg
tccc 246924DNAArtificial sequencePCR primer useful for amplifying
VH and VL domains 69acgtttaatc tccagtcgtg tccc 247023DNAArtificial
sequencePCR primer useful for amplifying VH and VL domains
70cagtctgtgt tgacgcagcc gcc 237123DNAArtificial sequencePCR primer
useful for amplifying VH and VL domains 71cagtctgccc tgactcagcc tgc
237223DNAArtificial sequencePCR primer useful for amplifying VH and
VL domains 72tcctatgtgc tgactcagcc acc 237323DNAArtificial
sequencePCR primer useful for amplifying VH and VL domains
73tcttctgagc tgactcagga ccc 237423DNAArtificial sequencePCR primer
useful for amplifying VH and VL domains 74cacgttatac tgactcaacc gcc
237523DNAArtificial sequencePCR primer useful for amplifying VH and
VL domains 75caggctgtgc tcactcagcc gtc 237623DNAArtificial
sequencePCR primer useful for amplifying VH and VL domains
76aattttatgc tgactcagcc cca 23
* * * * *